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Melanoma is the most aggressive type of skin cancer and various treatments have been 
investigated to treat this disease. However, an intrinsic issue in the clinical setting is the 
development of multidrug resistance. So far no single approach has emerged that may overcome 
such drug resistance by drug delivery. Alongside this, inflammation is an important marker of 
melanoma relating both to the incidence and progression of the disease, with upregulation in 
COX-2 and iNOS reported as playing a role in melanoma progression.  
The work embodied in this thesis describes the development, optimisation, and characterisation 
of alginate, chitosan, and pullulan nano-emulsions as a delivery platform to target melanoma. 
In this study, a novel nano-emulsion delivery system was designed and optimised using a series 
of experimental steps including, in vitro drug release, cell viability (MTT), Cellular apoptosis 
ELISA, confocal and fluorescent microscopy, PCR, and Western blot to address melanoma 
chemo-resistance, and COX-2 and iNOS expression. 
Chitosan-pullulan, pullulan-alginate, and alginate-chitosan polymer blends were prepared as 
nano-emulsions. A comparative analysis of their effect on melanoma (A375) and keratinocyte 
(HaCaT) cells was conducted. The “pullulan-chitosan” formulation was taken forward with 
folate-modification and used to target A375 cells. Subsequently, the melanocortin type 1 and 3 
receptor agonists BMS-470539-dihydrochloride and [DTrp8]-γ-MSH were delivered to A375 
cells using folate-modified pullulan-chitosan nano-emulsion, to target regulation of iNOS and 






Folate-modified pullulan-chitosan nano-emulsion enabled the delivery of doxorubicin and 
dacarbazine to A375 cells and diminished cell viability to 14 and 48% for doxorubicin and 
dacarbazine loaded nano-emulsions, respectively. Furthermore, BMS470539-dihydrochloride 
[DTrp8]-γ-MSH loaded nano-emulsions were able to decrease the regulation of iNOS and 
COX-2 to zero, after 72 hours.  
Optimal delivery of therapeutics has been successfully applied to address chemo-resistance and 
enhanced apoptosis induction to melanoma cells. A novel optimal pullulan-chitosan nano-
emulsion delivery system was developed for malignant melanoma. The nano-emulsion 
provided a controlled delivery of the chemotherapeutics to defeat chemo-resistance. 
Furthermore, the anti-inflammatory compound loaded pullulan-chitosan nano-emulsion 
decreased the iNOS and COX-2 expression in the A375 cell. This indicates that the compounds 
are more effective while delivered intracellularly, as opposed to the attachment to surface 
melanocortin receptors. This novel approach can be a promising tool to be used alongside 
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1.1 Cancer and its challenges 
Increased cancer-related incidents and mortality rates in recent years have raised a challenge 
towards cancer diagnosis tools and treatments. Cancer is amongst the most common cause of 
mortality across the globe (Bray et al., 2018). The number of patients diagnosed with various 
types of it is increasing worldwide and it is estimated that the numbers will rise further in the 
next 20 years (Bray et al., 2018, Siegel et al., 2019, Ferlay et al., 2019). Cancer mortality and 
incidents were studied in the UK. According to the cancer mapping incidents in the UK, half 
of the people in the UK will develop cancer in their lifetime (Oke et al., 2018). Until 2018, 
cancer incidents and mortality rates were reported to raise in western Europe by 34.9% and 
27.7% incidents for men and women respectively. While the mortality was reported as 13.3% 
and 8.8% for men and women respectively (Rawla et al., 2019).   
So far, researchers have undertaken extensive investigations on the diagnosis, prevention, 
causes, and cancer therapies (Arruebo et al., 2011). However, no particular cause or therapy for 
cancer has been reported so far. This is mainly due to the highly heterogeneous nature of 
tumours (Siegel et al., 2020).  In simple terms, cancer is the irregular growth of the cells in any 
part of the body which leads to the development of a tumour (Sudhakar, 2009).  
The function of the cell is based on the expression of proteins that regulate cell growth, division, 
and programmed cell death. However, this regularity is entirely altered in cancer cells 
(Guimarães and Linden, 2004). This also means that inherited or recently generated gene 
mutations may lead to changed signalling pathways and dysregulation of protein expression 






of dysfunction of cellular apoptosis, caused in the result of dysregulated programmed cell death 
(Ruddon, 2007, Kim, Duesberg and McCormack, 2013). There are many factors involved in 
the process of cellular transformation of normal cells to “cancer cells”; these factors arise from 
the genetic mutation in cells (Xu et al., 2018). When the normal cell is transformed into a so-
called “cancerous” cell, it will act autonomously; a cancer cell is completely independent of 
normal healthy cells in terms of growth and proliferation (Alibert et al., 2017). Cancerous 
tumours can be either benign or malignant (Weinberg, 2013) and can result from a variety of 
genetic or environmental factors.  
The cell proliferation cycle plays a crucial role in controlling cell proliferation and apoptosis, 
in the body (Pucci et al., 2000). Cell apoptosis is a programmed cell death which is a 
combination of organised biochemical processes leading to cell destruction (Elmore, 2007). 
There are two main pathways for apoptosis, the mitochondrial pathway, and the death receptor 
pathway (intrinsic and extrinsic) (Figure 1.1). The mitochondrial pathway is triggered by any 
DNA damage in the cells (Jan and Chaudhry, 2019). The death receptor pathway is activated 
by external death ligands activating tumour necrosis factor receptor (TNFr). Activation of both 
pathways leads to activation of apoptosis initiator caspases (Li and Yuan, 2008). 
While apoptosis is a crucial biological process for repair, healing, and regeneration, 
dysregulation in apoptotic pathways can lead to over-proliferation of the cells (Ryoo and 
Bergmann, 2012). Subsequently, irregular cell proliferation as the result of the absence of 
apoptotic factors will lead to the formation of tumours (Lee et al., 2018). Hence, resistance to 







Figure 1.1 Intrinsic and extrinsic apoptosis pathways 
Created in Biorender.com 
 
Carcinogenesis happens in multiple steps that involve genetic and epigenetic (external factors 
which can cause damage or affect human genes) factors. Genetic instability is another important 
factor for carcinogenesis. Inherited or acquired DNA mutations will turn a healthy cell into a 








Figure 1.2 Irregular proliferation of cancerous cells leading to tumour formation 
Created in BioRender.com 
 
Malignant tumours are characterised by their invasiveness and ability to metastasise. The 
process of the growth of a tumour happens in a series of steps. The progression pace can be fast 
or slow, depending on the cancer type and/or the patient’s general health and immune system 
(van Zijl et al., 2011). Initially, a tumour consists of over proliferated cell clusters (Figure 1.2), 
called hyperplasia. This “overgrowth” starts to change appearance, a status called dysplasia. In 
the dysplasia phase, cells have the potential to spread over the healthy tissue, although, they 
have not done (invaded) so yet. With further progression, the cells lose their initial functions 
and this phase is called anaplastic. The cells in the anaplastic phase have the potential to invade 
the surrounding tissues and organs (Ruddon, 2007).  
Cancer cells produce enzymes such as metalloproteinases that break down extracellular matrix 






the tissue and infiltrate the blood vessels and lymphatics and travel through the vasculature to 
reach other sites in the body (Walker et al., 2018). Tumours formed from migrated cells in 
distant organs are called “secondary tumours”. The process of secondary tumour formation is 
metastasis and it is the main cause of mortality after cancer (Agliano et al., 2017).  
1.2 Cancer treatment  
Cancer has been recognised throughout the millennia and early reports of cancer diagnosis date 
back to 1600 BC (Falzone et al., 2018b). Since then, investigators and physicians were in the 
quest for a cure to treat the disease. At that time, the most feasible treatment seemed to be 
surgery and removing the tumour mass (Samiee et al., 2012). Nevertheless, the mortality rate 
kept increasing (Jeffe et al., 2016). 
The very first cancer treatments started in the early 1820s using surgery to remove solid tumours 
(Kuflik and Gage, 1990). However, this technique could only be used in the excision of 
accessible solid tumours with a specific border and did not have a significant effect on the long-
term survival of cancer patients. During the late 1860s, a French doctor, Claudius Regaud, who 
is now known as the “father of radiation therapy” started treating cancer by X-ray radiations 
(Sgantzos et al., 2014). Afterward, X-ray treatment started to be used for breast cancer and a 
few types of skin cancer such as basal cell carcinoma (Silverman et al., 1992). In the 1920s, 
immune-stimulation by the injection of complex mixtures from tumours, was attempted as a 
complementary therapy to radiotherapy for cancer treatments (McCarthy, 2006a). This was 






2006b). Although the method was controversial at that time, it is now shown to have had some 
validity but the overall risk of this treatment was high (Wang, 2017). Chemotherapy remains 
the most common systemic cancer treatment with many chemotherapeutics synthesised, 
particularly by chemists commencing in the 1960s and beyond (DeVita and Chu, 2008). The 
chemicals for cancer treatments were partially successful. This means that although the survival 
rate of the patients increased, the mortality rate remained high (Huang et al., 2017). Moreover, 
the chemicals were severely toxic to the patients resulting in a significant decline in their 
general health conditions. Furthermore, most of the chemotherapeutics had poor bioavailability 
and were not able to specifically target cancer cells (De Souza et al., 2010, Gerber, 2008, 
Nurgali et al., 2018).  
Most of the chemotherapeutics are cytotoxic reagents that can interfere with DNA and destroy 
the cells. Therefore, the presence of chemotherapeutics in the bloodstream can interact with 
healthy and crucially essential cells in the body, such as bone marrow cells (Dickens and 
Ahmed, 2018). Chemotherapy reagents are usually more effective when used in combination 
with surgery (Huang et al., 2017). Furthermore, depending on the biochemical nature of the 
drugs and/or their bioavailability, the therapy may fail to be efficiently delivered to cancer cells 
(Tharkar et al., 2019). Although chemotherapy in metastasised cancer is mostly considered as 
palliative care, which increases the patient’s lifetime (Dickens and Ahmed., 2018), ultimately 
it may not be successful in eliminating cancer (Alfarouk et al., 2015).  
Chemo-resistance is an important gap between initial cancer treatment and effective cure. This 
problem directly affects the patient’s life quality and survival (Jo et al., 2018). Various 






Nevertheless, effective and efficient delivery of chemotherapeutics to cancer cells and 
preventing chemo-resistance remain important factors in the therapy progress (Chatterjee and 
Bivona, 2019). 
All the mentioned therapy procedures which have been developed over time were successful in 
increasing the survival rate of cancer patients particularly during the last half-century (Joo et 
al., 2013). Nevertheless, cancer-related mortality is still high. Furthermore, the side effects 
caused by the conventional therapy procedures are quite significant to the patient’s overall 
health, their quality of life (QoL), and the cost is also notable (Love et al., 1989, Pearce et al., 
2017).  
Emerging novel targeted therapy procedures have had a great impact on cancer treatments and 
consequently have enhanced patients’ QoL. The combination of chemotherapy and targeted 
drug delivery systems is called targeted drug delivery in cancer (Bayat Mokhtari et al., 2017). 
The main purpose of targeted therapy is to increase the efficacy of cancer treatment and 
diminish adverse effects on healthy tissues (Senapati et al., 2018). In this regard, targeted 
therapy approaches are promising tools with regards to increasing the scope for the treatment 
of cancer (Sawyers, 2004). Targeted therapy is a vast area of research that consists of various 
branches. The approaches to treat different cancer types and the progression stages are also 






1.3 Cancer drug delivery  
A deeper understanding of cancer behaviour has driven researchers, particularly in the last 
decade, to seek improved delivery vehicles for chemotherapeutics (Falzone et al., 2018a). Due 
to the challenging nature of cancer and its treatments many investigations have been performed 
towards the effective delivery of therapeutics (Navya et al., 2019, Senapati et al., 2018b).  
Common obstacles faced by traditional chemotherapy include lack of targeting, enzymatic 
digestion of the drug and biodegradation, and chemo-resistance (Liang et al., 2010). Through 
designing pertinent carrier systems for specific or non-specific drugs, these problems are 
starting to be addressed (Iwamoto, 2013).  
1.3.1 How anti-cancer drugs work, general principles  
The most conventional treatments for cancer are surgery, chemotherapy, and radiotherapy, 
depending on the stage of progression (Miller et al., 1981). Conventional chemotherapy acts 
non-selectively on all the cells in the body (Senapati et al., 2018a) and has a cytotoxic effect on 
the cells. However, recently novel biopharmaceuticals such as monoclonal antibodies and 
immunomodulators have improved the concept of conventional therapies (Kesik-Brodacka, 
2018). Yet, cytotoxic drugs (chemotherapeutics) are principal components of cancer treatment 
along with surgery and radiotherapy (Schirrmacher, 2019). Cancer cells in a tumour exist in 
three states, dividing cells in active phases of the cell cycle, resting cells not dividing but 
potentially can, and cells that no longer have the capacity for cell division (Bertram, 2000). 






to be affected by cytotoxic drugs. The cells in the second state may not be affected by the 
cytotoxic drug, however, may start proliferating (Housman et al., 2014). 
Most of the cytotoxic anti-cancer drugs act only against one aspect of the cancer cell cycle. The 
cytotoxic drugs affect the cells in the dividing phase (S phase) and usually have an anti-
proliferative effect by damaging the cell DNA. However, along with cancer cells, most of the 
rapidly dividing healthy cells in the body can be affected by cytotoxic drugs. This may 
subsequently cause nausea, hair loss, vomiting, sterility, decreased resistance to infections, and 
growth suppression (mostly in children) (Mitchison, 2012).  
Anti-cancer drugs are divided into three general groups (Table 1.1) namely cytotoxic drugs, 
hormones, protein kinase inhibitors, and monoclonal antibodies. Cytotoxic drugs include 
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Chemotherapeutic drugs usually are used in combination but resistance to anticancer drugs can 
either happen in primary treatment or can be acquired during treatment mostly due to adaptation 
of the tumour cells or mutation (Bayat Mokhtari et al., 2017).  
Several mechanisms leading to resistance have been described. These include low accumulation 
or uptake of the cytotoxic drug in the cells, increase in drug inactivation, increased 
concentration of target enzyme, decreased substrate, activation of alternative metabolic 
pathways, rapid repair of DNA damage caused by the drug, alteration in target activity (in the 
cell), and mutation in various or multiple genes (Vaidya et al., 2020). Accordingly, recent 
advances in cancer therapy involve drug treatment with lower side effects, targeted therapies 
for increase treatment efficiency, and a decrease in the chance of resistance (Pucci et al., 2019).  
  
1.3.2 Cancer drug delivery and nano-medicine  
Emerging nano-medicine has the potential to have a huge impact on cancer drug delivery 
(Bertrand et al., 2014). The utilization of nano-sized particles as carriers for chemotherapeutics 
has become an important tool in cancer therapy (Cho et al., 2008). Nano-sized particles have a 
high tendency to enter cells by an enhanced permeation and retention (EPR) effect which is 
known as passive targeting. The transport of nano-sized particles via the leaky vasculature in 
the tumour microenvironment (Dadwal et al., 2018) is known as passive targeting of cancer 
cells. These carrier particles can be further modified to especially target the cancer cells; this is 






Besides the EPR effect, delivery via nano-particles has additional advantages. Therapeutics and 
drug conjugates entrapped in nano-particles tend to be more stable, particularly for drugs that, 
intrinsically do not have stability and long half-life (Parveen et al., 2012). The nano-particle 
shell can preserve the drug allowing for longer biological life (Nguyen, 2011). Also, the 
concentration of drug-containing particles will increase in the cancerous tissue site, due to the 
EPR effect (Senapati et al., 2018b). Furthermore, nano-particles can be used for entrapments of 
multiple drugs and they are suitable for multiple modes of delivery. The use of nano-particles 
can be advantageous for the delivery of drugs containing siRNA and protein as well since they 
can protect them from being degraded (Navya et al., 2019).  
Nano-particles are investigated as suitable tools for both targeting cancer cells and addressing 
chemo-resistance at the same time (Sutradhar and Amin, 2014). Encapsulating 
chemotherapeutics within nano-particles can provide controlled release over time. This will 
happen by the slow degradation of the nano-sized shell encapsulating the drug (Rizvi and Saleh, 
2018). The drug efflux delivered to the tumour will be limited and slower over time; this helps 
to prevent drug-efflux-dependent chemo-resistance (Navya et al., 2019, Da Silva et al., 2017). 
This feature of the delivery system can be manipulated to fit the final purpose.  
Nano drug delivery systems can be prepared using various materials and different procedures. 
Liposomes (Allen and Cullis, 2013), micelles (Rapoport, 2007), polymeric nano-particles 
(Kumari et al., 2010), dendrimers (Tomalia et al., 2007), and hydrogels (Sharma et al., 2016), 
are the most common structures of nano-sized particles which can be used as drug carriers.  
Micelles are among the very first novel drug delivery systems (Sutton et al., 2007). Micelles 






the properties for effective extravasation and there is the possibility of chronic liver toxicity in 
micellar drug delivery systems (Yokoyama, 2011).  
After the successful application of micelles in delivering chemotherapy drugs such as 
doxorubicin, improvements to similar delivery systems for enhanced therapy and quality has 
gained importance (Fromherz and Ruppel, 1985). Lipid nano-carriers which emerged about 
three decades ago (Müller et al., 1997) were introduced as nano-sized delivery systems for 
therapeutics. Although these carriers have advantages like increased drug-loading efficiency 
and enhanced stability, other groups of non-toxic nano-sized particles made of natural and 
synthetic lipids show superior properties and provide controlled release with enhanced stability 
(Niu et al., 2016).  
Another well-known nano-delivery vehicle is the dendrimer-based nano-particle composed of 
repetitively branched molecules, recognised for its very small size (1.5 to 10 nm), (Wolinsky 
and Grinstaff, 2008, Guo and Shi, 2012). Dendrimer’s properties can be easily controlled by 
modifications and it can be used in a range of applications in nano-medicine and drug delivery 
(Bahrami and Arabi, 2016). Polymeric nano-structures made of various natural or synthetic 
polymers acting as nano-carriers for drugs or targeted therapies have very flexible preparation 
methods and controllable properties especially in cancer drug delivery (Wiradharma et al., 
2009). Other than polymers, gold particles (Singh et al., 2017), magnetic nano-carriers (Tietze 
et al., 2015), albumin nano-carriers (Khandelia et al., 2015), viral particles 
(Biabanikhankahdani et al., 2016) and carbon-based carriers (Karimi et al., 2015) are alternative 
nano-carrier materials used for targeted and specific cancer drug delivery. Although nano-sized 






challenges and sometimes disadvantages with each system. These include stability and 
cytotoxicity and particle accumulation in the body (Jong et al., 2008); however, these 
limitations can be addressed with further alterations, such as surface modification for active 
targeting, using peptides (Pang et al., 2019).  
As mentioned above, the simplest tumour drug delivery mechanism using nano-particles is the 
EPR effect. It is capable of delivering chemotherapeutics to a cancer cell in a controlled fashion 
to overcome chemo-resistance and provide higher efficiency of chemotherapy. All of the nano-
sized delivery systems mentioned above, have their pros and cons. The most important factor 
in choosing a delivery system for cancer is the nature of the tumour and its stage of progression 
(Patra et al., 2018). However, the fate of the nano-particles after entering the cell cytosol needs 
to be considered. Therefore, a cancer-specific drug delivery system should be designed based 
on both kinetic and histologic parameters, to meet the criteria for ultimate use (Blanco et al., 
2015). 
1.3.3 Intracellular delivery of the drugs 
One of the major concerns of chemotherapeutics is the drug’s action-site and its fate in the body 
and even its interactions with the cancer cell (Alfarouk et al., 2015). Since organelles are located 
within the cell walls, the drug carrier must first penetrate the cell, to be effective. Hence 
successful uptake of drug or drug-carrying particles is crucial. There is a basic mechanism for 







1.3.3.1 Cellular uptake of drug particles in cancer cells  
Cells take up nano-particles and most chemotherapy therapeutics by endocytosis. However, due 
to endosomal entrapment, often they are degraded by the lysosome (Pei and Buyanova, 2019). 
Delivering drugs to cancer cells in a targeted manner requires surface functionalisation of the 
carrier particles, with specific ligands that will bind to cell surface receptors. The uptake of 
such functionalised particles is termed “receptor-mediated endocytosis” (Vácha et al., 2011, 
Devarajan et al., 2019), the aim is successful uptake of the drug carriers by the cells, however, 
this may not affect the ultimate treatment efficacy (Mo and Gu, 2016).  Drug particle size and 
penetration mechanism are significant factors and other important considerations are that the 
therapeutic reaches and activates the cellular organelle(s) effectively (Barua and Mitragotri, 
2014). As an instance, for doxorubicin to activate in the nucleus (Wang et al., 2017b), the drug 
delivery vehicle should be designed to penetrate the cytosol and reach the nucleus for ultimate 
effectiveness (Wei et al., 2018).  
A drug delivery system requires energy to enter the cancer cells and remain in the cytoplasm 
rather than being degraded in lysosomes (Dong et al., 2018). So far, various tools have been 
developed to address this issue. For example, the modification of therapeutic carriers for 
enhanced cellular uptake (Dissanayake et al., 2017). Surface modification using cell-
penetrating peptides is among the options for providing enhanced cellular uptake. As an 
instance, tat-peptide (a cell-penetrating peptide) was used in various targeted delivery systems 
and applications. Tat-modified drug-carrying nano-particles have demonstrated enhanced 






delivery systems and have shown an increased tendency to enter the cell without dependency 
on any external force. For example, this mechanism was used for doxorubicin which is a 
nucleus-specific drug (Hodoniczky et al., 2008). Cell-penetrating peptides are also used to 
address the drug-resistance issues, such as Acta-arginine (R8) delivering paclitaxel with high 
efficiency (Borrelli et al., 2018, Singh et al., 2018). Overexpressed in cancer cell lines, folate 
receptor is another option for surface modification of the drugs or drug carrier to provide 
increased uptake in cancer cells (Cheung et al., 2016).  Vitamin B-9 occurs as folate in the body, 
which is an essential component for rapidly proliferating cells in the body (Curtis et al., 2017).  
Transferrin proteins (Daniels et al., 2006) and antigens such as CD19 and CD20 (Yu et al., 
2010) which have been widely used in cancer drug delivery, are also alternatives for cancer 
targeting and providing enhanced uptake in cancer cells.  
1.3.3.2 Intracellular release and fate of the drug 
Reaching delivery target and controlling drug release pace can be achieved via manipulation of 
carriers to become stimuli-responsive as well, depending on the target and its specifications. 
The enzyme-redox potential, temperature, and pH-triggered releases are the most common 
elements for controlling drug release (Sheng et al., 2019). However, the fate of the drug particle 
may not be predictable even using these triggering factors. Hence, alternative triggering factors 
are being investigated. For example, nano-carriers can be triggered by ultrasound as they have 
been used for Paclitaxel delivery, and nano-emulsions can be activated by ultrasound (Cochran 






once exposed to a light source such as UV light. However, there are concerns about this process 
due to polymerisation and in vivo degradation of polymer coatings (Viger et al., 2013).  
Every single cellular organelle in cancer has a specific role. An efficient drug delivery system 
should be able to enter the cell and deliver the drug to the related organelle. Hence knowledge 
of the subcellular organelles specifications is important (Biswas and Torchilin, 2014).  
Most of the cancer-targeting drugs can pass through the cell membrane and reach the cytosol 
(Yang and Hinner, 2015). However, a very negligible amount of them can reach into the 
subcellular organelles, such as the nucleus, where they exert their inhibitory effect on specific 
gene expression pathways. Subsequently, the cancer cell’s fate is controlled (Kumar et al., 
2020).  
The nucleus is the main and most important part of a cell and it hosts the human DNA, the 
genetic material of the cell. Any upregulation or downregulation of genes may lead to lethal 
diseases like cancer (Mazzone et al., 2019). In cancer cell lines, the nucleus is the target for the 
delivery of most of the chemotherapy drugs (Vasir and Labhasetwar, 2005). For drugs to get to 
nuclei they should be able to pass the nuclear pore complex (NPC) passively or actively 
(Yasuhara et al., 2004). Nano-sized drug delivery systems have been developed to be 
compatible with cancer drug delivery applications but not all of them successfully deliver the 
drug to the nucleus for subsequent cell death induction. This means that more specific 
modifications to nano-particles are needed (Parta et al., 2018). As an instance, Tat-peptide-
modified nano-particles have been developed to deliver doxorubicin more efficiently to the 






nuclear-delivery by drug-loaded nano-particles. This method was simply used to deliver poly(ε-
caprolactone)-block-polyethyleneimine nano-particle directly to the nucleus (Xu et al., 2007).  
Mitochondria are known as the powerhouse of the cells. They regulate cell cycle and 
proliferation and have an important role in cell apoptosis. Apoptosis messenger agents in the 
cytosol induce mitochondrial membrane permeabilisation leading to initiation of the apoptosis 
process (Costantini et al., 2000, D'Souza et al., 2011). An alteration with an inhibitory effect on 
mitochondrial membrane permeabilisation functions can consequently inhibit apoptosis. This 
process may ultimately end up as cancer. Considering the importance of mitochondria in cancer, 
the possibility of inducing apoptosis to cancer cells by targeting the mitochondria can be an 
option. So far various delivery systems have been designed, including nano-particle delivery 
systems, which can be functionalised to have mitochondrial selective delivery (Murphy, 1997, 
Chan et al., 2017).  
Lysosomes have the most important role in endocytosis. They have a highly acidic environment 
and their role is to degrade the unwanted particles, recycle molecules, and receptors back to the 
cell. Cancer drug delivery systems need to escape this cycle (Piao and Amaravadi, 2016, 
Dielschneider et al., 2017) to be functional. On the other hand, failure of lysosomal function 
will lead to the accumulation of toxic materials in the cytosol which may end up in crucial 
diseases. However, this aspect can be taken for granted in a cancer cell drug delivery (Piao and 
Amaravadi, 2016). Accordingly, a major challenge for intracellular drug delivery is to find 
ways to prevent the drugs from entering the endocytosis cycle and keep the therapeutics in the 






Another cellular organelle, the Golgi apparatus, bears great importance in the drug delivery 
process. Any disorder in the Golgi apparatus may lead to serious disease, due to its role in 
processing macromolecules. It is known as an important target for cancer drug delivery (Vasir 
and Labhasetwar, 2005). Delivery systems that were targeted to the Golgi apparatus have 
appeared to be more functional and efficient (Tarragó-Trani and Storrie, 2007). Various 
pathways have been used to deliver the drugs to the Endoplasmic reticulum (ER) and then to 
the Golgi apparatus using specific receptors (Tarragó-Trani and Storrie, 2007). There are 
instances such as inhibition of breast cancer cell invasion by application of signaling proteins 
to target the Golgi (McKinnon and Mellor, 2017) and ADP-ribosylating bacterial toxin 
targeting cancer cell’s Golgi and ER. 
As mentioned above, many attempts have been tried to eliminate cancer cells efficiently and 
completely. Thus, the combination of the right delivery system and the right receptors to target 
the cell, and the organelle are crucially important. This requires a careful design of the delivery 
carrier to reach the appropriate target efficiently.  
1.4 Challenges in cancer drug delivery 
A multitude of factors has to be considered in the process of developing a novel delivery system. 
Type and stage of cancer, age of the patient, and immune response are among key factors 
influencing drug design and delivery (Hassanzadeh et al., 2019). Furthermore, the design 
should be based on essential therapeutics needed for specific target cells and must overcome 






(Li et al., 2018b). So far various systems have been developed to achieve efficient delivery of 
chemotherapy drugs to cancer cells, a few of them address specific delivery along with 
overcoming resistance in cancer cells. A delivery system needs to address both to have a highly 
efficient therapy procedure.  
Other than cancer type, the tumour microenvironment is an important factor in cancer drug 
delivery system design (Khawar et al., 2015). Heterogeneous cancer cells are surrounded by 
immune cells, growth factors, blood vessels, signalling molecules, and extracellular matrix 
(ECM) (Anderson et al., 2020).  For a drug delivery system to be successful, the particles must 
cross the extracellular matrix, fibroblasts, and other cells of the tumour microenvironment to 
reach the cancer cells (Roma-Rodrigues et al., 2019). Thus, it is important to understand the 
tumour microenvironment structure to avoid drug resistance and provide more efficient 
delivery (Figure 1.3).  
Stromal cells, one of the tumour microenvironment components, secrete connective tissue 
proteins including collagen, this can lead to fibrosis. When this happens, it may prevent the 
delivery of therapeutic agents from reaching cancer cells (Ria and Vacca, 2020). Hence, an 
active tumour microenvironment will lead the cancer cells to metastasise and invade the lymph 
nodes initially and ultimately to other organs. Additionally, the pressure-induced by stromal 
cells will affect the therapy adversely (Trédan et al., 2007). This will also happen through the 
entrapment of the drugs and lowered drug efflux due to the same mechanism, which inhibits 
the effect of therapy. This process may also lead to drug resistance in cancer (Yang and Gao, 







Figure 1.3 Understanding tumour microenvironment and how it limits drug delivery 
Created with Biorender.com 
 
Hence, the drug delivery system should be able to cross the tumour microenvironment and 
reach the cancer cells. Given the importance of tumour microenvironment, a drug delivery 
vehicle must be able to overcome these barriers (Stylianopoulos et al., 2018). Nano-particle-
based delivery systems have demonstrated their ability to increase the yield and the quality of 
drug delivery and subsequently increases the therapy outcome. This will help to defeat tumour 






1.5 Skin structure and function 
 Skin is the largest organ in our body and has the crucial protection role acting as a shield against 
pathogens and is responsible for synthesising vitamin D3 (cholecalciferol) in presence of UVB 
(Mostafa and Hegazy, 2015). Three main layers are located in the skin, epidermis, dermis, and 
hypodermis (Agarwal and Krishnamurthy, 2019).  
The epidermis is the outermost layer of the skin which consists of four layers, namely Stratum 
corneum, Stratum lucidum, Stratum granulosum, Stratum spinosum, and Stratum Basale. 
Stratum Basale is home to keratinocytes and melanocytes (Baroni et al., 2012). Melanocytes 
are responsible for producing granules of melanin in melanosomes (Cichorek et al., 2013). 
While keratinocytes divide and grow, they travel towards the surface of the skin.  
The dermis is located below the epidermis and its thickness varies all over the body depending 
on the underlying tissue (Carroll, 2007). Fibroblasts are located in the dermis, it also contains 
blood vessels, lymphatics, hair follicles, sebaceous gland, and sweat gland.  
The hypodermis, the most innermost layer of the skin, contains connective and adipocyte tissues 
and its thickness can change depending on its anatomical locations (Lee, 1953).  
1.5.1 Skin cancer  
Skin cancer is one of the most frequently diagnosed cancer types. The incidence is higher in 
people with fair and white skin types (Roider and Fisher, 2016). So far an increasing rate of 
skin cancer incidence and related mortality has been reported (Queen, 2017). According to the 






cancers, which its 5-year mortality rate has increased by 0.7% until 2018 (Bray et al., 2018). 
Hence early detection, diagnosis, and treatment are vital in any kind of skin cancer type – 
aggressive or benign-(Diepgen and Mahler, 2002, Esteva et al., 2017).  
Among the reasons for the increased rates of skin cancer diagnosis, environmental factors could 
be mentioned (Masoumi et al., 2018). Yet, various factors may be involved as an initiation point 
for skin cancer incidents, including inherited gene mutations or lifestyle. The genetic factor 
gains importance when the patient has a family history of skin cancer or a less pigmented skin 
type. The most important risk factor for skin cancer is increased exposure to UV light which 
increases the risk of skin cancer incidents which is most common in people aged 20-35 
(O’Sullivan et al., 2019).  
UV light is a primary reason for sunburn and skin cancers. It has three categories, UVA (320-
400 nm), UVB (290-320 nm), and UVC (200-280 nm) (Harrison and Bergfeld, 2009). Only 5% 
of sun radiations are UV light, and about 0.3% of it reaches the earth after absorption by the 
ozone layer. However, even this amount can cause sunburns and skin defects (Gonzaga et al., 
2009). UV light is known as an important reason for skin aging, benign skin defects, and rashes. 
It is known that UVB and UVA radiations are more responsible for skin cancer than UVC (Rass 
and Reichrath, 2008). 
There are three most common skin cancer subtypes (Figure 1.4) squamous cell carcinoma, basal 
cell carcinoma, and malignant melanoma (Deinlein et al., 2016). Squamous cells are located on 
the outer layer of the skin. This type of skin cancer is also called non-melanoma skin cancer. It 
occurs most commonly on sun-exposed areas of the body. These cells grow slowly, and they 






cell carcinoma. Basal cell carcinoma is another non-melanoma skin cancer. About 80 percent 
of skin cancer cases are basal cell carcinoma (Rubin et al., 2005). This kind of skin cancer 
develops from UV exposure, in the lowest layer of the skin epidermis. Basal cell carcinoma is 
rarely lethal but it may be when left untreated (Helfand et al., 2001). On the other hand, 
melanoma which initiates from melanocytes is an aggressive type of skin cancer that has the 
potential to invade and spread in the body (Ioannides, 2017).  
 
 
Figure 1.4 Skin cancer types 
 Basal cell carcinoma (left), Squamous cell carcinoma (middle), and malignant melanoma 








1.5.2 Drug resistance in skin cancer  
Surgery, chemotherapy, laser therapy, immunotherapy, and radiotherapy are the main treatment 
procedures for cancer, still, chemotherapy plays the main role in the treatment (Price and 
Sikora, 2020). However, about 90% of chemotherapy procedures will end up in failure due to 
drug resistance during the invasion and metastasis (Longley and Johnston, 2005). Hence, drug 
resistance is a serious problem in cancer treatments.  
Various mechanisms are responsible for drug resistance. Multidrug resistance happens while 
cancer cells continue to survive despite the use of multiple anti-cancer drugs (Wu et al., 2014). 
This can happen due to the increased release of drugs outside of the cancer cells and reduced 
absorption of the drugs. ABC transporters including P-glycoproteins (P-gp), multidrug 
resistance-associated protein 1 (MRP1), and breast cancer resistance protein (BCRP/ABCG2), 
are a family of ATP-dependant transporters, are responsible for these phenomena (Leslie et al., 
2005, Choi and Yu, 2014). Blocked pathways of apoptosis are another mechanism for drug 
resistance (Fernald and Kurokawa, 2013).  
As mentioned in section 1.1, cellular apoptosis regulation plays a crucial role in cancer initiation 
and treatment. Cell death happens in three apoptosis, necrosis, and autophagy, and apoptosis 
happens through internal and external pathways (Chen et al., 2018). Cell death receptors such 
as TFN-R, FAS, linker proteins, caspases-3, -6, -7, -8 are involved in external pathways leading 
to apoptosis (Figure 1.1) (Elmore, 2007). As internal mitochondrial apoptosis pathway, 






of pro-apoptotic genes (Bax, Bclxl, etc) in tumour cells will lead to the emergence of resistance 
(Campbell and Tait, 2018).  
Alteration in drug metabolism is another factor leading to drug resistance (Lopes-Rodrigues et 
al., 2017). Enzyme reactions in the cells limit the drug resistance via reducing the activation of 
prodrug (reduced activity of some enzymes) (Ahmed et al., 2016) and increasing the drug 
activation (increased activity of some enzymes) (Hientz et al., 2017). Hence, alterations in 
enzyme activities associated with drugs and receptors may lead to drug resistance.  
In some cases of skin cancer especially in melanoma, resistance happens with the alteration of 
chemotherapy drug targets (Kozar et al., 2019). In most of the melanoma cases bearing 
BRAFV600 mutation, resistance happens through the inactivation of MAPK/ERK pathways 
(Czarnecka et al., 2020). While the target of the chemotherapy drug, such as mutations and 
expression levels changes, the drugs will not be effective on that target (Wang et al., 2019b).  
So, the cell will continue proliferating without any damage. For instance, cancer cells having 
mutations of topoisomerase II will be resistant to the drug targeting topoisomerase II (Nitiss, 
2009).  
Imposing DNA damage (directly or indirectly) is one of the mechanisms of chemotherapy drugs 
(Woods and Turchi, 2013). Some mechanisms lead to the repair of the damaged DNA. These 
include the nucleotide excision repair system (NER) (Shuck et al., 2008) and homologous 
recombination repair mechanism (RRM), which can repair the DNA damage thus will trigger 






Amplification of drug target genes is also a reason for the cancer cells to be drug-resistant. 
Some epigenetic factors such as DNA methylation and histone alterations will take a part in 
resistance as well (Lu et al., 2020).  
There are also other factors at a cellular level, leading to resistance development. Namely 
tumour heterogeneity, drug efflux, tumour microenvironment, and cancer stem cells. Intra-
tumoural pressure induces by stromal cells, hypoxia and paracrine signalling often lead to block 
the drug passage and inefficient delivery leading to drug resistance in tumour cells (Prasetyanti 
and Medema, 2017).  Extracellular matrix (ECM) in tumour microenvironment also positively 
contributes to resistance emergence due to being home to cytokines and growth factors 
(Nallanthighal et al., 2019). Accordingly, to reach an efficient cancer therapy, the problem of 
drug resistance should be resolved. 
1.6 Melanoma  
Among the skin cancer categories, melanoma is the most aggressive and lethal type of skin 
cancer (Carreau and Pavlick, 2018). Similar to many other diseases, there are external factors 
that may be the initiation point for melanoma (Belter et al., 2017). UV radiation exposure is 
one of the critical environmental factors responsible for melanoma initiation and progression. 
Also, genetic and lifestyle factors should not be neglected, a weak immune system is likewise 







Melanoma initiates from melanocytes (Figure 1.5), melanocytes are responsible for skin 
pigmentation.  They produce melanin which changes skin colour when exposed to UV light. 
Melanocytes are located in the skin epidermis and have a protective effect on the skin from UV 
light. However, under triggering factors such as increased exposure to UV light, melanocytes 
start to proliferate irregularly and abnormally, which leads to malignant melanoma formation 
(Kozovska et al., 2016, Brenner and Hearing, 2008). Melanoma growth and progression have 
various types depending on the tumour cells spreading direction. Melanoma has 4 main 
subtypes Figure 1.6 superficial spreading melanoma, nodular melanoma, lentigo melanoma, 








Figure 1.5 Skin layers showing the location of melanocytes in the skin  
Melanoma initiates from the irregular proliferation of melanocytes, which are located in the 
epidermis. Created with BioRender.com. 
 
 
The most common subtype of melanoma is superficial spreading melanoma (Forman et al., 
2008). This type of melanoma has uneven borders and it is mostly on the surface of the skin 
and grows horizontally. It can also grow vertically penetrating the epidermis but the larger 
portion of the tumour is on the surface of the skin.  
The second most common melanoma, nodular melanoma, grows deep into the skin layer (Erkurt 
et al., 2009). It grows fast and spreads very promptly. It is the worst type of melanoma. It is 







The third subtype of melanoma that is more common in old people is lentigo melanoma 
(DeWane et al., 2019). Lentigo melanoma is usually dark brown and grows in the epidermis. It 
can also grow within the skin layers after a long time of growth on the skin surface. The final 
subtype of melanoma is common in people with darker skin. Unlike other types of melanoma, 
Acral lentiginous melanoma is not so dependent on high UV exposure. This type of melanoma 








Figure 1.6 Various melanoma separated in terms of physical shape 
Nodular melanoma, (b) Acral lentiginous melanoma, (c) Lentigo malignant 
melanoma and, (d) superficial spreading melanoma are four subtypes of 




Melanoma progression happens after a few evolutionary stages, to reach its malignant form. 
The initial sign of a melanoma is the development of a mole (Nevi), which on its own, is a 
benign skin lesion (Michael et al., 2017). However, most of the melanoma cases initiate from 






start differentiating irregularly and turn into dysplastic nevi, which is stage two. In the third 
stage, dysplastic nevi start growing and turns into a tumour (Zaidi et al., 2008). It may grow 
vertically or horizontally, depending on the type of melanoma as mentioned above, until it 
reaches the epidermis but does not invade the dermis. In stage four, melanoma can invade the 
dermis. At this stage, melanoma has the potential to invade and differentiate faster. Following 
this stage, the tumour grows faster and metastatic lesions appear, which can invade other organs 
(Elder, 2016).  
The mortality rate of melanoma patients is among the highest compared to other skin cancer 
types (Schadendorf et al., 2018). According to epidemiology studies in the United States, over 
the past 30 years, the population of patients diagnosed with melanoma has been increased (Erdei 
and Torres, 2010). Until 2017, 87,100 new patients were diagnosed with a progressed stage of 
melanoma in the United States. The mortality rate of patients was 11.15%; the majority of them 
being men (Matthews et al., 2017). In the UK, melanoma incidents had a sharp rise of 55% over 
9 years until 2009 (Arnold et al., 2014). Since 2011, melanoma is the 5th most common cancer 
in the UK (Robertson and Fitzgerald, 2017). It is predicted that incidents will rise by 7% until 
2035 in the UK (Mayers, 2018). 
In the early stages, the melanoma lesion can be removed with surgery (Testori et al., 2009). The 
survival rate for early-stage patients is about 98% (Mohammadpour et al., 2019). However, the 
more developed it becomes, the treatment process becomes a challenge and the survival rate 
drops to 17% in the metastatic stage (Ugurel et al., 2017). Hence, early detection and highly 






The treatment process for melanoma is a challenge. Due to difficulties of early diagnosis 
melanoma is hard to be diagnosed in the early stages and often presents a poor prognosis 
(Weyers, 2018). In most cases, it can be detected only when it is progressed to late stages and 
already invaded other organs, which makes the treatment process hard and lowers the patient’s 
survival chance. More importantly, melanoma is highly drug-resistant which makes the 
treatment process a challenge (Nikolaou et al., 2018). Hence, conventional therapeutics used 
for cancer treatments are less effective.  
Melanoma cells can develop alternative pathways to avoid apoptosis and resist therapeutics and 
can continue proliferating and spreading even after severe conditions of treatment. The 
malignancy of melanoma also depends on the stage of its progression (Winder and Virós, 2017). 
Melanoma may travel, initially, to the closest lymph nodes forming loco-regional deposits. 
These may seed out further metastases which may travel to distant organs, the wider the 
melanoma is disseminated, and the greater number of organs involved, so the poorer outlook 
and prognosis (Damsky et al., 2010).   
However, the development of metastasis can be very fast, but only it forms after certain 
evolutionary stages, as mentioned above (Maddox, 2017). There are many factors and 
hypotheses which can be the initiating points of tumour metastasis, but the exact reason behind 
it is still a mystery. Distant metastasis to multiple organs is the most problematic stage of 
melanoma to treat and more efficient therapy procedures are desirable for advanced melanoma 
stages (Hua et al., 2016). 
Depending on the stage of disease progression, common treatment procedures for a person 






radiation therapy, and chemotherapy (Tran et al., 2009). Specifying the best treatment depends 
on how developed the melanoma is. Usually, four stages of its progression need to be 
considered. Surgery applies to melanoma in stages zero and one, in which the cancer cells are 
very superficial or have not grown deeply. Wide excision surgery is applied for the patients 
diagnosed with stage II melanoma in which lymph nodes are also involved, adjuvant therapy 
can also be advised (Koster et al., 2017). Adjuvant and radiation therapy are recommended for 
stage III melanoma patients, after surgery of the affected area, followed by chemo and targeted 
therapy (Blank et al., 2018). For stage IV of melanoma, the treatment will be the combination 
of radiotherapy, chemotherapy, and targeted therapy depending on how wide metastasis has 
been spread (Brossart et al., 1993, Garbe et al., 2010). 
So far there are only a few therapy options that are approved by the FDA to treat metastatic 
melanoma, nevertheless, the overall chance of survival is still the same despite the high toxicity 
of the chemotherapeutics (Jacquelot et al., 2017). Later on, many of the therapeutics containing 
highly toxic components were removed from formulations in the markets (Bonifacio et al., 
2014). As mentioned, there remain many challenges to have malignant melanoma treated 
without possible side effects, with enhanced efficiency and decreased multidrug resistance 
using conventional therapy systems. However, novel targeted therapy approaches can have 
promising effects on reducing the progression of melanoma.  
The most important obstacle towards melanoma treatment is chemo-resistance (Kalal et al., 
2017). There are various reasons behind the resistance mechanism in melanoma (Erdmann et 
al., 2019). Melanoma cells can develop various signalling pathways to regulate cell 






the development of the tumour or on the other hand, apoptosis induction to the tumour cells. 
The fundamental reason for resistance can be apoptosis dysregulation (Helmbach et al., 2001). 
More specifically, resistance in melanoma happens via altered DNA repair, altered enzymatic 
activation, dysregulation of apoptosis pathways, and drug transport efflux (Kalal et al., 2017).  
Recently, investigators have been focused on alternative resistance factors influencing 
melanoma treatment such as the physical environment of the tumours. There are possibilities 
that tumour microenvironment can be an escalating factor for resistance (Parkin et al., 2019). 
High intra-tumoural pressure induced by stromal cells, poor perfusion of drugs in the tumour 
microenvironment, drug efflux, and intracellular entrapment of therapeutics are the most 
important related factors (Somasundaram et al., 2016).  
 
1.6.1 Anti-cancer treatments for melanoma alleviation 
Dacarbazine (DTIC) was the first drug approved by the FDA for melanoma treatment (Velho, 
2012). It was used as the main chemotherapy agent for treating melanoma. However, the 5-year 
mortality rate was still 96-98%. Hence, despite its high toxicity which is thought to be in result 
of photo-degradation (Koreich et al., 1981), the utilisation of dacarbazine continued to be used 
in combined chemotherapies (Wu et al., 2015). The most important side effects of dacarbazine 
are decreasing white blood cells and severe hepatotoxicity (Ma et al., 2013). Among 
chemotherapy drugs, doxorubicin (classified as anthracycline antibiotic) has been routinely 
used for multiple types of cancer treatments including melanoma (Licarete et al., 2020). 






among the drugs to which melanoma develops resistance (Fukunaga kalabis et al., 2012, 
Licarete et al., 2020). Furthermore, doxorubicin is severely cardiotoxic due to its reaction with 
free iron in the body, which can be prevented by combined therapy using iron chelators such as 
dexrazoxane (Thorn et al., 2012).  
Improvements in melanoma treatment continued by using Temozolomide (TMZ), a prodrug 
derived from dacarbazine (Shah et al., 2010a). Although the development of Temozolomide 
was an important step, the survival rate of melanoma patients did not improve. According to 
the investigations, no significant difference in side effects of Temozolomide was detected 
compared to DTIC (Teimouri et al., 2013), hence the use of DTIC was recommended. 
Electrochemotherapy (ECT) was later developed for treating melanoma. This system was 
designed for use of two cytotoxic drugs bleomycin and cisplatin (Fiorentzis et al., 2018). The 
base of treatment was facilitating the delivery of the drugs to cells by high-intensity electric 
pulses. This method was effective for treating subcutaneous melanoma nodules, however, it 
was highly toxic to the lymphatic system. Another treatment procedure for melanoma was 
introduced as photodynamic therapy (PDT), a light-based minimally invasive therapy for stage 
III/IV cutaneous melanoma (Naidoo et al., 2018). Although this method was non-toxic, it 
helped reactive oxygen species (ROS) to release. Hence the effect of PDT on melanoma was 
limited. However, it was suggested to be used in combination with chemotherapy drugs.   
Cancer and the immune system are closely related, due to the presence of immune cells in 
tumour sites at the chronic inflammation site. Hence Immunotherapy was suggested for cancer 
treatment in the 19th century (Drake et al., 2014, Domingues et al., 2018). This procedure was 






used in combination with chemotherapy. Interferons are important cytokines in 
immunotherapy. They have important immunomodulatory, antiangiogenic, antitumor, and 
antiproliferative. FDA approved the use of Interferon α-2b in 1995 for melanoma stage III/IIB. 
Approved in 2011 by FDA, Peg-interferon (Peg-INF α-2b) was used in stage III, melanoma 
treatment as a supplementary therapy (Medrano et al., 2017). Peg-INF was developed by 
combining Interferon α-2b with polyethylene glycol to prolong the stability of the Interferon α-
2b (Shiffman, 2001). Hence its therapeutic effect was improved. IL-2 was another cytokine 
known for its antitumor effect and approved by the FDA in 1998 for metastatic melanoma 
treatment (Jiang et al., 2016). Another treatment approved by the FDA in 1999 for antitumor 
immune response suppression, were Treg inhibitors (Han et al., 2019). FDA also approved the 
use of Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade in 2011, PD-I ligand 
blockade in 2014, oncolytic virus therapy in 2015, Toll-like receptor agonists, and adoptive T-
cell therapy, as immune therapy approaches for cancer (Wang et al., 2011). However, all these 
approaches were more efficient while used in combination with other therapies such as 
chemotherapy.  
Targeted therapy procedures significantly contributed to melanoma therapy. Approved in 2011, 
BRAF inhibitors were used in the treatment of melanomas harbouring BRAF mutations (Shah 
et al., 2019). Vemurafenib and Debrafenib two BRAF inhibitor drugs used for metastatic 
melanoma patients were reported to show tumour regression in 90% of patients (Croce et al., 
2019). Furthermore, Trametinib (MEK inhibitor) (Lugowska et al., 2015), Imatinib (CKIT 
inhibitor) (McLean et al., 2005), Bevacizumab (VEGF inhibitor) (Ferrara et al., 2005), 






inhibitor) (Spring et al., 2019), and lapatinib (ErbB4 inhibitor) (Qiu et al., 2008), demonstrated 
increased efficacy in melanoma targeted therapy. 
1.6.2 Melanoma drug delivery 
As mentioned in previous sections, the most important obstacle towards reaching efficient 
melanoma treatment is chemo-resistance (Xue and Liang, 2012). Furthermore, the drug release 
efflux delivered to the cell and its release from the drug carrier have to be controlled to prevent 
drug-efflux dependant resistance in melanoma. Due to the high potential of chemo-resistance 
in melanoma, drug delivery system design is even more challenging (Helmbach et al., 2001). 
Among the delivery systems, polymer-drug conjugates, and encapsulation of 
chemotherapeutics in nano-particles have shown a worthy performance regarding melanoma 
treatment (Li et al., 2015).  








Table 1.2 Drug delivery systems used for melanoma 
Delivery 
system 
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Paclitaxel PEG based pH-redox sensitive B16F1 In vivo (Lv et al., 
2014) 
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Nanoparticle Docetaxel – cellax Carboxymethyl cellulose -PEG - B16F10 In vivo  (Hoang et 
al., 2015) 
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5FU Chitosan- PCL - B16F10 In vitro (Zhu et al., 
2019) 
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al., 2018) 
Solid in oil 
peptide nano-
carrier 
Vaccine - - B16F10 In vivo  (Wakabayas
hi et al., 
2018) 










Paclitaxel Hyaluronic acid – Tocopherol 
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Self-assembly B16F10 In vivo (Xia et al., 
2018) 
Nano-particles Curcumin Bovine serum albumin - Murine 
melanoma 









Doxorubicin Polysaccharide - A375 In vivo (Li et al., 
2018a) 




Pluronic F127 - B16F10 In vivo  (Zhang et 
al., 2018a) 
Nano-particles siRNA Gold - B16-BL6 In vitro  (Zhang et 
al., 2018b) 




(Sahu et al., 
2019a) 











The summary information provided in the table above indicates the variability of drug delivery 
systems used to combat melanoma in vitro and in vivo. Polymeric drug carriers seem to be more 
utilized as drug carriers for melanoma. Furthermore, among them, nano-sized delivery systems 
have acted more efficiently against melanoma (Table 1.2). 
Chitosan is among the most utilized biopolymers for melanoma treatment, as indicated in 
Table 1.2. This can be due to chitosan’s improved ability to permeate through skin cells (He et 
al., 2009). As mentioned, using the EPR effect, nano-particles can accumulate in the tumour 
via the leaky tumour vasculatures which have larger pore sizes (Maeda et al., 2009). Molecules 
having a range of nano-sized particles up to a few hundred nano-meters can penetrate tumour 
vasculatures easily (Zununi Vahed et al., 2019). On the other hand, these nano-sized particles 
cannot penetrate healthy tissues since the vasculature conditions are normal and this range of 
nano-sized particles is unable to extravasate. Hence the accumulation of nano-particles will be 
in the tumour environment. Consequently, they can provide targeted delivery to melanoma 
(Blanco et al., 2015). 
In another perspective, the nano-particle shell protects the low molecular weight drugs from 
enzymatic digestion in the cell cytosol. The small molecules such as drugs can be lysed in the 
cell cytosol before affecting the cancer cell. Enzymatic digestion is one of the reasons that 
chemotherapy cannot be effective enough in the treatment of melanoma (Pfannenstiel et al., 
2019).  
Delivery of therapeutics using nano-particles is also important in terms of delivery dose and 
delivery flux of the drugs. A nano-sized delivery shell, rather than protecting the drugs 






prevent increased drug accumulation in the cell and consequent resistance development 
(Yoncheva et al., 2019).  
Among nano-sized delivery systems, polymeric nano-particles are the most common ones 
(Khalid and El-Sawy, 2017). A range of synthetic and natural, biodegradable, and 
biocompatible polymers have been used in the development of various drug delivery systems 
against melanoma treatment (Naves et al., 2017).  
So far, Polymeric nanoparticles have been investigated as appropriate options to be used as 
melanoma delivery systems and to decrease chemo-resistance by adjusting drug release (Liu et 
al., 2018). Using careful design and optimisations, polymeric nano-particles can be designed to 
reach the appropriate initial burst followed by controlled release of the drugs. They can also be 
modified to increase or decrease the delivery rate. Surface modifications of the nano-particles 
can further increase the quality of delivery (Pathak et al., 2019).  
1.6.3 Polysaccharides in melanoma drug delivery 
Due to their unique characteristics and wide availability, polysaccharides have gained 
importance specially in the cancer drug delivery field (Coviello et al., 2007, Debele et al., 2016). 
Furthermore, their low cost has made them a good option for medical and pharmaceutical 
applications (Debele et al., 2016). Additionally, polysaccharides have an increased tendency 
for cell membrane permeation and adherence. These features have made them a suitable choice 
for targeted cancer drug delivery (Dheer et al., 2017).  
Polysaccharides are long-chain monosaccharides linked with glycosidic bonds. Based on their 






non-toxicity, low immunogenicity, bioactivity, muco-adhesion, are environmentally safe, and 
have the potential for targeting specific tissues (Gopinath et al., 2018). Various polymers 
include alginate, pectin, guar gum, dextran, xanthan gum, chitosan, chondroitin, hyaluronic 
acid, heparin, cyclodextrin, pullulan, and amylose are included in the polysaccharides family 
(abedini et al. 2018). Each of these polysaccharide-based polymers has a unique characteristic 
that can be used in a wide range of applications. Polysaccharide molecules have several reactive 
groups (depending on the polymer) which are accessible to various modifications. Based on 
their functional groups, they can be hydrophobic, hydrophilic, or neutral. Polymers from this 
category usually have a more extracellular matrix (ECM)-like backbone which is considered as 
a positive point for a delivery system (Liu et al., 2008). Hence, they are not considered as 
foreign material in the body consequently they will not be lysed readily and they are not 
immunogenic (Diekjürgen and Grainger, 2017). The most advantageous characteristics for 
polysaccharides nano-particles are their selective attachment to the target cancer site and 
successful uptake by the cells (Wang et al., 2006).  








Table 1.3 Characteristics of selected polysaccharides 
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Table 1.3 shows the potential capability of polysaccharides  for drug delivery and their unique 
characteristics. A few polysaccharides show enhanced activity to permeate skin cells making 
them suitable for skin cancer targeted delivery alternatives (Franze, 2015). Depending on their 
characteristics and the ultimate aim of application, each can perform different behaviours.  
Chitosan, α(1-4)2-amino 2-deoxy β-D glucan, one of the most abundantly available 
biopolymers is derived from chitin. Chitosan is a de-acetylated form of chitin and is a well-
known polysaccharide that has been widely investigated for various applications (Mohammed 
et al., 2017). Positively charged chitosan can make a strong bonding through electrostatic 
interactions with negatively charged molecules, surfaces, and particles. Chitosan is soluble in 
acidic environments and hydrophilic in a neutral environment (Ali and Ahmed, 2018, Ghaz-
Jahanian et al., 2015). This unique characteristic makes it a promising choice for cancer drug 
delivery, mostly due to the acidic environment of the tumours. A few of the chitosan properties 
depend on its deacetylation degree (DD), and others on molecular weight (Kumar et al., 2020). 
The lower the deacetylation degree, the more soluble the chitosan in increased pH and vice 
versa. Also, lower concentrations of chitosan usually have lower encapsulation efficiency(Ding 
et al., 2019). However, due to its functional groups, it is capable of various modifications to 
enhance its biological and biochemical properties. (Chellappan et al., 2019). Chitosan emerged 
in many investigations for various applications including skin tissue engineering and drug 
delivery due to its unique permeation ability (Liang et al., 2019).  
Alginate is another linear well-known polyanionic polysaccharide, and it is initially sourced 
from algae. Its chemical structure is 1,4-linked -α-L-guluronic acid and β-D-mannuronic acid. 






alginate can act as a mildly pH-sensitive polymer and has been used in drug delivery systems 
(Bhunchu and Rojsitthisak, 2014, De Souza et al., 2010). 
Pullulan is a highly water-soluble neutral polysaccharide derived from the fungi Aureobasidium 
pullulans and it is composed of α-1,6-linked maltotriose units (Tabasum et al., 2018). It is 
known to have promising characteristics and has been used in various medical, biological, and 
drug delivery applications. Pullulan is capable of adhering to cell surfaces and facilitates 
intracellular uptake and provides a time-based release (Ganeshkumar et al., 2014) of 
encapsulated molecules.  
These three polymers separately have been used for skin and skin cancer delivery systems. 
However, the potential for improved drug delivery quality using mixing polysaccharides has 
not been greatly investigated. 
1.6.4 Nano-emulsion delivery system for melanoma treatment 
Nano-emulsion is a homogenized form of mixed immiscible reagents (oil/water) stabilized 
using an emulsifier (Jaiswal et al., 2015). Recently nano-emulsions have been increasingly used 
in the pharmaceutical fields (Rai et al., 2018a). This is potentially due to advantages such as 
increased drug loading efficiency, stability, decreased size of particles, and increased 
bioavailability. The use of nano-emulsions has also increased topical delivery systems such as 
cream and spray forms (Pathak et al., 2018). Simple preparation and functionalization abilities 
have also made nano-emulsions suitable for cancer drug delivery and specifically melanoma 
(Severino et al., 2013, Bagde et al., 2018). The table below lists some nano-emulsions used for 







Table 1.4 Nano-emulsions used in cancer research 




In vivo degradation Reference  
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Hydrophobic Hydrolysis of ester linkage (Wan et al., 
2015) 
PEG Polyether Non ionic NA Hydrophilic In vitro degradation using 
proteinase K 
(Constantinides 
et al., 2008) 





Through physical and 
chemical cross-linking 
Hydrophilic In vivo degradation in 
physiological conditions 
(Date et al., 
2010) 
Pectin Polysaccharide Polyanionic 
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Alginate Polysaccharide Anionic Covalent and Ionic 
cross-linking, thermo 
gelation 
Hydrophilic In vitro degradation using 
alginase. 
But Slightly oxidized alginate 
can degrade in aqueous media 
(Li et al., 2013, 
Liu et al., 2008) 
Pullulan Polysaccharide Neutral, high 
water solubility, 
adhesive 
Crosslinking ability Hydrophilic In vitro degradation via 
pullulanase, and in vivo 
degdarable 







As the table shows, a range of materials has been used for the preparation of nano-emulsions 
for skin cancer and melanoma drug delivery. The nano-emulsions can be prepared using various 
approaches depending on the ultimate application (Fofaria et al., 2016b). However, most of the 
nano-emulsion delivery systems lack stability and high drug loading capacity (Patel et al., 
2017). Nano-emulsions were investigated to provide a potential solution for the flux-dependant 
melanoma drug resistance and a tool to increase therapy efficiency (Vecchione et al., 2017). 
This can happen through the nano-emulsion particles which can cross the tumour 
microenvironment barrier, and overcome intra-tumoural pressure. Hence they can reduce the 
resistance caused by alterations in drug efflux, due to their ability to provide a controlled release 
and increase the stability of the drug. Although to reach this, specific modifications may be 
needed (Patel et al., 2019).  
 
1.6.5 Classification of nano-emulsions for melanoma treatment 
based on the rout of administration 
 
As melanoma has a poor response to existing treatment modalities and is highly resistant to 
conventional therapies, the development of a novel system to defeat it, is crucial (Mishra et al., 
2018). Nano-emulsions are considered attractive drug delivery tools especially for skin diseases 
(McDonald et al., 2015). They are also well-known drug delivery systems for dermal and 
transdermal disorders (Shakeel et al., 2012). Increasing bioavailability of the drugs, nano-






the size of nano-emulsion particles and the target disease, it can be designed to be used for 
particular administration routes.  
Nano-emulsions have been successfully used in topical delivery of hydrophobic and toxic drugs 
such as Dacarbazine for melanoma, and facilitated use of the delivery system was consequently 
reported as an important point (Hafeez and Kazmi, 2017, Lasoń, 2020).  Researchers also 
investigated the delivery of drug-loaded nano-emulsion by intramuscular injection, which 
decreased melanoma by 61% compared to untreated control (Tagne et al., 2008). Other 
administration routes of drug-loaded nano-emulsions for melanoma were also investigated, 
such as oral (Lin, 2018) and intravenous injection (Sánchez-López et al., 2019).  However, 
topical delivery of nano-emulsion for skin cancer has been reported among the most common 
and effective routes of delivery (Giacone et al., 2020, Kaplan et al., 2019).  
1.7 Effect of inflammation on melanoma 
Inflammation is the body’s response to damage caused in the body following exposure to 
pathogens, damaged cells, injury, and toxins. This process involves immune cells (Leukocytes), 
blood vasculatures, and some molecular mediators. The mediators including chemokines, 
cytokines, histamine, proteases, prostaglandin, leukotrienes, and serglycin proteoglycans are 
released during the host response (Chen et al., 2017).  
When a tissue or part of the body is injured due to internal (autoimmune disorder) or external 
factors (bacteria, toxins, heat, and trauma), Histamine is released from mast cells immediately 






of the host inflammatory response), is completed, inflammation subsides (Prockop, 2016). The 
physical signs of inflammation are usually redness (rubor), swelling (tumour), pain (dolor), and 
fever (calor) and correspond with acute inflammatory changes seen within the first 48 hours of 
an inflammatory response (Zetoune et al., 2014). 
There are two types of inflammation, acute and chronic. Acute inflammation will stop after the 
injured part of the body is completely healed due to the body’s prompt response to any trauma 
or injury (Coussens and Werb, 2002). It is characterised by the migration of neutrophils to the 
site of injury or infection via a repair process involving these stages. Initially, capillaries will 
expand to increase the blood flow following the release of histamine from mast cells causing a 
constriction in the endothelial cells, secondly, the microvascular structure will change with 
protein plasma exudation and finally, leukocytes migrate through the endothelium and 
accumulate at the damaged part (Hunter, 2012). This occurs by leukocytes passing from the 
bloodstream, adhering to the endothelium via upregulation of β2 integrins (CD11a/CD18b) on 
the leukocyte cell surface and upregulation of adhesion molecules on the endothelium e.g. 
intracellular adhesion molecule 1 (ICAM1). This leads to a strong interaction of the leukocyte 
to the endothelium, subsequent flattering of the cell, and finally emigration through adjacent 
endothelial cells via upregulation of molecule CD31 (PECAM1) (Golias et al., 2007). 
Afterward, the foreign bodies will be removed by phagocytosis and the tissue will start to repair 
with subsequent scar formation. 
Chronic inflammation is the failure of the inflammation to resolve due to a continued 
inflammatory response and may take weeks, months, or years to diminish as seen in diseases 






inflammation (Abudukelimu et al., 2018) and occurs due to various reasons such as prolonged 
exposure to mycobacterium, fungi, or protozoa which the body’s immune system is unable to 
eliminate (Fulford and Stankiewicz, 2020, Bellamy et al., 2020), or chemical irritants (Bains 
and Fonacier, 2019). Alternatively, existing autoimmune disorders such as seen in Rheumatoid 
Arthritis or mitochondrial dysfunction can also lead to chronic inflammatory changes (Pahwa 
and Jialal, 2018) or via physical injury (Hughes, 2018), all these can lead to the 5th cardinal sign 
of inflammation, loss of function (function laesa). 
Prolonged chronic inflammation may cause severe DNA damages and genomic changes which 
may be an initiation point for various diseases (Crusz and Balkwill, 2015) including 
cardiovascular diseases (Ferrucci and Fabbri, 2018), various cancer types, and diabetes (Chang 
and Yang, 2016).  
There are two types of chronic inflammation, one is nonspecific proliferative inflammation, 
and the other granulomatous inflammation. The first type forms as a non-specific granulation 
in the presence of lymphocytes, macrophages, and plasma cells, and it continues proliferating 
in fibroblasts and connective tissue (Snape and Collins, 2020). Simple forms of this kind of 
inflammation are polyps and abscess, whilst the second types usually form as nodular lesions 
or granulomas. This type of inflammation can be due to a chronic infection such as tuberculosis 
or leprosy or in the presence of a foreign body or immune response (Billero et al., 2017). Some 
of these can be attributed to risk factors such as age, overweight, diet, smoking, and stress 






1.7.1 Mediators that drive the host inflammatory response 
For initiation of an inflammatory response, a message is delivered by inflammatory mediators 
which are released by injured or activated cells. These mediators are chemicals responsible as 
messengers. There are two types of mediators, plasma-derived mediators, and cell-derived 
mediators. Vasoactive amines (such as histamine and serotonin), arachidonic acid metabolites 
(Cyclooxygenase and Lipoxygenase pathways), liposomal components, platelet-activating 
factors, cytokines (IL-1, TNF-α, TNF-β, IFγ, and chemokines), and nitric oxide and nitrogen 
metabolites are cell-derived mediators of inflammation. On the other hand, plasma-derived 
mediators are derived from the kinin system, the clotting system, the fibrinolytic system, and 
the complement system (Abdulkhaleq et al., 2018). Each mediator has a particular role in the 
inflammation process and these responses such as pain, fever, and irritation. For instance, iNOS 
is the inducible form of Nitric Oxide synthetases (NOS), (Nakazawa et al., 2017), and 
cyclooxygenase-2 (COX-2), are enzymes that mediate inflammatory responses in the body 
(Gandhi et al., 2017) and are overexpressed in cancerous tissues (Murakami and Ohigashi, 
2007, Singh et al., 2019).  
1.7.2 Inflammation and cancer 
Chronic inflammation has been proved to be an important hallmark in cancer occurrence and 
progression. The very first hypothesis of cancer initiation in chronic inflammation sites was 
mentioned in 1863 (Weber et al., 2010). The triggering factor is the proliferation of the cells in 






2017a) with persistent inflammation potentially leading to cancer cell formation (Korniluk et 
al., 2017). Persistent inflammation could be due to immune deficiency problems, prolonged 
injury or infection, and long-term exposure to toxic chemicals and irritants (Mosenthal, 2018).  
There are two types of inflammatory mediators, pro-inflammatory ones (e.g. TNF-α, IL-1β), 
and anti-inflammatory mediators (e.g. IL-10, Heme-oxygenase 1) (Coras et al., 2019). The 
presence of increased pro-inflammatory chemokines and an uneven balance between catabolic 
pro-inflammatory vs anabolic anti-inflammatory chemokines are in part due to prolonged 
inflammatory response (Coussens and Werb, 2002). Consequently, due to long-lasting chronic 
inflammation phagocytic cells, Leukocytes and other inflammatory mediators will damage the 
DNA of the host cells, resulting in alterations in the proliferation cycle of the cells and 
subsequent abnormalities occurring (Kawanishi et al., 2017).  
Studies have highlighted that cancer initiated from inflammation is responsible for 15-20% of 
cancer-related death worldwide (Okada, 2014). Rather than cancer initiation, inflammation can 
have a critical role in all stages of cancer and will positively affect cancer cell proliferation, 
migration, and invasion (Sui et al., 2017). Since inflammatory cells are known to be an 
abundant source of growth factors and cytokines prerequisites for cell survival and 
proliferation, this can affect the whole cancer therapy process including the response to the 
chemotherapeutics (Rajput and Wilber, 2010, Coussens and Werb, 2002). Several 
inflammatory mediators and chemokines are known to be directly related to cancer initiation 
and tumorigenesis. These include the pro-inflammatory, TNF-α, IL-6, TGF-β, NF-κB, and 






and COX-2 expression increase during the inflammatory process (Liu et al., 2003), with 
overexpression causing tumorigenesis and metastasis (Janakiram and Rao, 2012). 
The cytokine IL-10 is anti-inflammatory which is associated with suppression of cancer-
associated inflammatory changes with inhibition of pro-inflammatory genes including TNF-α, 
IL-1β via inhibition of NF-κB(Landskron et al., 2014).  
Inflammation is also known as one of the important risk factors for skin cancer initiation and 
malignancy. As mentioned in previous sections, UV light has an important impact on skin 
cancer by inducing DNA damage (Prasad and Katiyar, 2017). When skin is inflamed by the 
action of UV light, inflammatory mediators, and cytokines such as IL-6 are released (Quist et 
al., 2016). Long-term accumulation of them in the skin will lead to the initiation of melanoma. 
The cytokines such as IL-1β released from UV triggered keratinocytes, and melanocytes along 
with dendritic cells and Langerhans cells, during the melanoma inflammation process, promote 
aggressive tumour cell behaviour (Bou-Dargham et al., 2017).  
Recent studies have shown a strong link between chronic inflammation and melanoma 
progression and metastasis (Maru et al., 2014, Tang and Wang, 2016). Non-melanoma skin 
cancers (Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)) are directly linked 
to inflammation (Voiculescu et al., 2018). Melanoma development is also strongly linked to 
inflammation due to the increased release of various cytokines such as IL-4, IL-10, and IL-13 
by melanocytes (Neagu et al., 2019), due to paracrine signalling with the tumour 
microenvironment of the inflamed part. Hence the inflammation prevention and treatment gain 






1.7.3 Current treatments for inflammatory pathologies 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to relieve pain, inflammation, 
and fever. These include aspirin, ibuprofen, and naproxen. NSAIDs have two categories, non-
selective ones such as aspirin, ibuprofen, and diclofenac which inhibit the COX-1, and 2 
pathways leading to a reduction in prostaglandins and COX-2 selective (Coxibs) such as 
celecoxib which decrease the pain and inflammation-mediated from COX-2 (Cairns, 2007). 
However, although NSAIDs decrease the symptoms of inflammation, they may cause other 
side effects such as gastrointestinal diseases/bleeding via inhibition of the cytoprotective 
enzyme COX-1 (Matsui et al., 2011). On the other hand, specific COX-2 inhibitors (Coxibs) 
can inhibit inflammation by inhibiting PGE2. However, the most important problem with 
Coxibs is substantial cardiotoxicity. This may lead to myocardial infarction through inhibition 
of prostacyclin tipping the balance in favour of thromboxane a prothrombiotic eicosanoid 
(Zarghi and Arfaei, 2011).  
1.7.4 Novel therapeutics for treating inflammatory pathologies 
Melanocortin peptides are short amino acid sequences including alpha-melanocyte-stimulating 
hormone which corresponds to the first 13 amino acids of the parent hormone ACTH1-39, a 
hormone derived from the larger precursor molecule the Proopiomelanocortin (POMC) gene 
(Getting et al., 2009). 
Melanocortin peptides exert their biological effect by binding to a family of G-protein coupled 






MC5. Their activation leads to an increase in adenylate cyclase and a subsequent increase in 
cAMP (Wang et al., 2019a, Can et al., 2020). Studies have highlighted that melanocortin 
receptors can be expressed in various tissues in the body such as the brain and skin (Lisak and 
Benjamins, 2017). They have a notable effect on a few of the body functions including 
inflammation (Maaser et al., 2006). Activation of MC1 and MC3 has been shown to modulate 
the host inflammatory response and lead to an anti-inflammatory phenotype resulting in 
resolution of inflammation (Kaneva et al., 2012). To date, the most characterised peptide is an 
α-melanocyte stimulating hormone (αMSH) which is a naturally occurring melanocortin 
peptide. αMSH has a high affinity for the MC receptors and is involved in inflammation. 
Melanocortin peptides are expressed on immune cells such as neutrophils, macrophages, and 
also melanocytes responsible for skin pigmentation and melanoma metastasis and progression 
(Bulman et al., 2013). BMS-470539 dihydrochloride and [DTrp8]-γ-MSH are two 
commercially available melanocortin receptor agonists targeting the MC1 and MC3 receptor 
respectively and have been shown to modulate the host inflammatory response in in vitro 
models of osteoarthritis and in vivo models of stroke and ischaemic reperfusion injury (Can et 
al., 2020; Holloway et al., 2015; Leoni et al., 2010). These compounds inhibit leukocyte 
trafficking in models of stroke and ischaemic reperfusion injury in mice (Holloway et al., 2015; 
Leoni et al., 2010), modulate inflammatory markers including IL-6, IL-8 (Can et al., 2020), and 
induce an anti-inflammatory protein in in vitro models of osteoarthritis (Can et al., 2020; 
Kaneva et al., 2012).  
As mentioned previously, chronic inflammatory markers are important factors influencing 






2019). Malignant melanoma expresses high levels of MC1 (Baumann et al., 1997, Park et al., 
2019), which plays a crucial role in melanogenesis. Hence this can be utilized as a positive 





















1.8 Research approach  
The growing number of patients diagnosed with cancer, today is a global issue. The acquisition 
of genetic mutations due to environmental and lifestyle factors is increasingly important in 
influencing the incidence of melanoma. Cancer research is a vast field of study, so there are 
various factors to be considered in cancer therapy. Prevention, diagnosis, treatment, and 
palliative care are four major tasks in cancer research. In this project, the major focus is on 
treatment. To this end, an experimental approach was followed for this research.  
The design of experiments was based on choosing appropriate polymers and cell lines for the 
particular aim of melanoma drug delivery and design a nano-emulsion for topical drug delivery. 
Initially, series of optimisation steps were carried out to reach a nano-emulsion providing a 
controlled release and lowest initial burst. Followed by reaching the optimal nano-emulsion, 
the nano-emulsion particles were surface modified.  
The optimal drug-loaded nano-emulsion was further assessed using in vitro cellular assays. The 
related experimental assays were performed using A375, human malignant melanoma primary 
cell line, and HaCaT, keratinocyte cell line as control.  
Furthermore, the downregulation of two important inflammation markers in melanoma was 
investigated. Current research contains a novel approach used for downregulation of iNOS and 






1.9 Research aim and objectives 
This research aimed to develop a strategy to improve the drug delivery to A375 malignant 
melanoma human cell line. The intended drug delivery aims for successful apoptosis induction 
and decrease flux-dependant drug resistance. 
To achieve the aim of this research a careful design and optimisation of the nano-emulsion were 
implemented to provide enhance uptake of the drug in A375 cells. Furthermore, the nano-
emulsion was designed to be used as a topical delivery system in early-stage melanoma. Hence, 
the experimental part of the thesis was conducted using a comparison study between A375 and 
HaCaT cells as control healthy cells. Ultimately knockdown of two inflammation markers was 
tried to control melanoma progression.  
To address the aim, the following objectives were implemented. 
1. Development of chitosan/pullulan/alginate nano-emulsion to provide a slow and controlled 
release and optimisation of the nano-emulsions.   
2. Tracking nano-emulsion particles in cell culture via encapsulation of coumarin-6 (C6, a 
fluorescent model drug) and comparing to the doxorubicin-loaded nano-emulsions. 
3. Comparing the toxicity of doxorubicin/dacarbazine loaded nano-emulsions to naïve drugs in 
melanoma and keratinocytes. 
4. Surface modification of optimised nano-emulsion to increase the uptake specifically in 
melanoma cells.  






6. Encapsulation of BMS-470539 dihydrochloride and [DTrp8]-g-MSH in the surface modified-































2.1 Materials   
2.1.1 Chemicals and reagents 
Basic laboratory chemicals and reagents were purchased from Sigma, Thermo-Fischer 
Scientific, and Invitrogen. The list of materials and reagents, used in this research are outlined 
below in Table 2.1. 
Table 2.1 Materials and reagents 
Compound Supplier Catalog number  
3,3′,5,5′-Tetramethylbenzidine 
(TMB) Liquid Substrate System for ELISA 
Sigma Aldrich-Merck 0440 
Agarose (molecular biology grade) Fischer scientific UK 10366603 
Cell tracker green (CMFDA) Thermo-Fischer scientific-
Invitrogen 
C7025 
Cell tracker red (CMTPX) Thermo-Fischer scientific-
Invitrogen 
C34552 
Chitosan medium molecular weight 
(deacetylation ≥ 75%) 
Sigma Aldrich-Merck. UK 9012-76-4 
Chloroform  Sigma Aldrich-Merck 67-66-3 
Coumarin-6 (≥99%) Sigma Aldrich-Merck UK 38215-36-0 
Dacarbazine (DTIC) Sigma Aldrich-UK 4342-03-4 
DAPI (4',6-Diamidino-2-Phenylindole, 
Dihydrochloride) 
Thermo-Fischer scientific D1306 
Dimethyl Sulfoxide  Sigma Aldrich-Merck. UK D2650 






DNA free, DNA removal kit Thermo–Fischer scientific AM1906 
Doxorubicin hydrochloride Sigma Aldrich-UK 25316-40-9 
Ethanol absolute  VWR chemicals-UK 20821.310P 
Fetal bovine serum Sigma Aldrich-UK MFCD00132239 
Folic acid Sigma Aldrich-Merck F7876 
Formaldehyde Sigma Aldrich-Merck F8775 
Gene Ruler 1 kb DNA Ladder Thermo-Fischer scientific SM0311 
Genipin Sigma Aldrich-Merck 4796 
Glacial acetic acid Fischer scientific UK 15541152 
Glycerol (molecular biology grade) Sigma Aldrich-UK 56-81-5 
Guanidine chloride Sigma Aldrich-Merck 50-01-1 
Isopropanol VWR chemicals-UK 470301-456 
Methanol Fischer scientific 10365710 





PCR master mix 2X Thermo-Fischer scientific K0171 
Phosphate buffered saline (DPBS) Sigma Aldrich-UK MFCD00131855 
Ponceau S Solution Sigma Alrich-Merck UK 7170 
Pre-stained protein molecular weight marker  Thermo-Fischer scientific 26612 
Pullulan (aureobasidium pullulans) Sigma Aldrich-Merck UK 9057-02-7 
Sodium alginate Sigma Aldrich-Merck UK 9005-38-3 
Sodium dodecyl sulfate Sigma Aldrich-Merck 151-21-3 
SYBR™ Safe DNA Gel Stain 
 






TBE (tris-borate-EDTA) Thermo-Fischer scientific-
Invitrogen 
LC6675 
Thiazolyl Blue Tetrazolium Bromide Sigma Aldrich-Merck M2128 
Tri reagent  Sigma Aldrich-Merck 93289 
Tris-Acetate-EDTA 10x Sigma Aldrich-UK  9650 
Tris-HCl Invitrogen 15-568-025 
Trypan blue  Thermo-Fischer scientific T10282 
Trypan blue solution  Sigma Aldrich-Merck T8154 
Trypsin-EDTA 10X Sigma Aldrich-UK 9002-07-7 
Twin 20 Fischer scientific 9005-64-5 

















The list of cytotoxic drugs used for drug delivery and their physicochemical characteristics are 
listed in the table below Table 2.2. 





Toxicity LogP pKa Stability  Pharmacological 
classification 












Dacarbazine  182.18 
g/mol 







The list of cell lines used in this research is outlined below in Table 2.3. 
Table 2.3 Cell lines 
Cell 
line 
Supplier Order number Mutations  














The list of oligonucleotide sequences, used in this research are outlined below in the Table 2.4 
Table 2.4 Primer sequences used for PCR (Si et al, 2018) 





















1513 IDT Integrated DNA 
Technologies, BVBA 
 
The list of ELISA kits, used in this research is outlined below in Table 2.5 
Table 2.5 ELISA kits 
Kit Supplier Catalog number 
Human folate binding protein ELISA Abcam-UK ab213781 
DNA fragmentation ELISA Sigma Aldrich-Roche 11585045001 
 
The list of antibodies, used in this research is outlined below in Table 2.6 
Table 2.6 antibodies 
Antibody Supplier Catalog number  
Human polyclonal Anti-COX-2 anti-body Abcam-UK ab15191 
Human polyclonal Anti-iNOS anti-body Abcam-UK  ab3523 









The list of buffers, used in this research are outlined below in Table 2.7 
Table 2.7 Buffers used in the experiments 
Buffer  Preparation 
1% SDS 1 gr SDS 100 ml H2O 
Lameali sample 
buffer 
4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 0.004% bromophenol 
blue, 0.125 M Tris-HCl, pH 6.8.  
SDS page running 
buffer 
25 mM Tris, 190 mM glycine,  0.1% SDS  
TAE 1X 100 ml 10xTAE buffer, 900 ml milli Q water. 
TBST 1x 
10 ml 1M Tris-HCL, pH 8.0, 30 ml 5M NaCl, 500 µl Tween 20, ddH2O 
up to 1L. 
Western blot transfer 
buffer 
25 mM Tris, 190 mM glycine, 20% methanol  
 
The list of equipment, used in this research is outlined below in Table 2.8 
Table 2.8 Equipment 
Equipment  Model/Supplier Serial number  
Balance  Sartorius  M-Power SAR AZ64 
C18 HPLC column (4.6 mm x 
10.0 mm) 3PK 
Thermo-Scientific  071973 
Centrifuge  Eppendorf 5418 R, 05-401-201 
Confocal microscope Leica TCS SP2 NA 





Countess™ II FL 





Bio-rad Wide Mini sub-cell 
GT  
170–4405 











Nano sight NS300 







Nano-drop  Thermo-Fischer Scientific ND-One-W 
Scanning electron 
microscopy  
FEI Quanta 650 FEG-ESEM 
 
NA 
Sonicator Phillip Harris Scientific  599006006 
Sonicator probe-MS73 
micro-tip, titanium alloy, 3 
mm diameter 






Spectra/Por™ 5 12-14 kD 
MWCO Dialysis tubing 
Fischer scientific 15340782 





UV gel imaging system  
BioDoc-It UVP 3-Door 




Western blot tank 
Thermo-Fischer Scientific 
XCell SureLock™ Mini-Cell 
EI0001 
















The list of software, used in this research are outlined below in Table 2.9. 
Table 2.9 Software 
Software  Version  
Biochem draw Pro V.16.0.1 
Biorender online drawing software NA 
Chromeleon  7 
Endnote  X9 
Graph pad Prism  8-win64bit 
Image J 
1.52d 
Java 1.7.0 – 60 (64 bit) 
Microsoft office  Microsoft version 2013 
NTA software version 3.4 built 3.4.003 
















2.2 Methods  
2.2.1 Preparation of drug-loaded polysaccharide-based nano-
emulsion  
Nano-emulsions were prepared using a high-energy sonication method (Fofaria et al., 2016a). 
Chitosan, pullulan, and alginate were used as main biopolymers. A range of nano-emulsions 
was prepared using different w/w ratios of the three polymers for coumarin-6 (Smith and Purr, 
2019) or doxorubicin encapsulation to reach the formulation with an optimised and controlled 
release rate. 
Starting with chitosan, the polymer powder was dissolved in ultrapure water containing the 
same ratio of acetic acid to chitosan Table 2.10. The solution was stir-mixed for 24 hours to 
reach homogeneity. Coumarin-6 solution (1mg/ml concentration), was prepared before the 
nano-emulsion preparations. Separately tween-80 was added to glycerol and then mixed for 2 
hours. Fifty microliters of coumarin-6 solution were added to tween-80 and glycerol mixture 
and then left mixing for another hour. After preparing the oil phase (glycerol-tween-80), the 
chitosan solution was added to the oil mixture and was left for mixing for 2 hours to reach the 
oil in the water mixture. The mixture was sonicated using a high-energy sonicator for 20 
minutes in an ice bucket to obtain coumarin-6 loaded nano-emulsion particles. The pH of 
prepared samples was adjusted to 7.4 using 1M sodium hydroxide. The ratios used for the 




















NEC1 0.2 0.2 1 20 50 
NEC2 0.4 0.4 2 20 50 
NEC3 0.6 0.6 3 20 50 
NEC4 0.8 0.8 4 20 50 
NEC5 1 1 5 20 50 
NEC6 1.2 1.2 6 20 50 
NEC7 1.4 1.4 7 20 50 
 
Similarly, alginate powder was dissolved in ultrapure water. The solution was stir-mixed for 
24 hours to obtain a homogenous mixture. Separately tween-80 with the ratio of 5:1 to alginate 
was added to glycerol and mixed for 2 hours. Fifty microliters of coumarin-6 solution were 
then added to tween-80 and glycerol mixture followed by another hour of stir-mixing. Alginate 
solution was added to the oil and tween-80 mixture then left for mixing for 2 hours to obtain 
oil/water mixture. The mixture was sonicated for 20 minutes to prepare nano-emulsion 
particles. The ratios of all prepared samples are shown in Table 2.11. the same preparation 
procedure as alginate was repeated to develop pullulan nano-emulsion and the ratios are 






















NEAl1 0.2 20 1 20 50 
NEAl2 0.4 20 2 20 50 
NEAl3 0.6 20 3 20 50 
NEAl4 0.8 20 4 20 50 
NEAl5 1 20 5 20 50 
NEAl6 1.2 20 6 20 50 
NEAl7 1.4 20 7 20 50 
 












NEPl1 0.2 20 1 20 50 
NEPl2 0.4 20 2 20 50 
NEPl3 0.6 20 3 20 50 
NEPl4 0.8 20 4 20 50 
NEPl5 1 20 5 20 50 
NEPl6 1.2 20 6 20 50 
NEPl7 1.4 20 7 20 50 
 
Each of the mentioned nano-emulsions was examined in the in vitro release test. Following the 
selection of one best sample from each polymer group, based on coumarin-6 and doxorubicin 
release, selected polymer samples were cross-linked. Accordingly, chitosan-pullulan, pullulan-
alginate, and chitosan-alginate blended nano-emulsions were prepared using different w/w 






concentration of 1mg/ml and 500 microliters of genipin solution (1% v/v) were added to each 
polymer blend and stir mixed continuously for 72 hours to complete the cross-linking process. 
The cross-linking procedure was also applied to previously selected three non-composite 
formulations, chitosan, pullulan, and alginate. All the prepared blends were loaded with 
coumarin-6 and doxorubicin separately. Fifteen nano-emulsions were prepared with the same 
procedure. UV sterilisation was applied over two 20-minute cycles before uptake experiments. 
Coumarin-6 and doxorubicin release tests were also conducted for these samples under the 
same conditions as stated above. The same preparation and drug loading procedure were 
applied to prepare doxorubicin-loaded nano-emulsions. Blank coumarin-6 and doxorubicin 
were used as positive controls in the treatments and calculations.  




























NEC1-Al (2:1) 2 4 - 
NEC1-Al (1:1) 2 2 - 
NEC1-Al (1:2) 4 2 - 
NEAl2-Cs (2:1) 8 4 - 
NEAl2-Cs (1:1) 4 4 - 
NEAl2-Cs (1:2) 4 8 - 
NEPl2-Cs (1:1) - 4 4 
NEPl2-Cs (2:1) - 4 8 
NEPl2-Cs (1:2) - 8 4 
NEC1-Pl (1:1) - 2 2 
NEC1-Pl (2:1) - 4 2 
NEC1-Pl (1:2) - 2 4 
NEPl2-Al (1:2) 8 - 4 
NEPl2-Al (2:1) 4 - 8 
NEPl2-Al (1:1) 4 - 4 
NEC1 - 2 - 
NEPl2 - - 4 









2.2.2 Measurement of the drug encapsulation efficiency of 
optimised nano-emulsion 
To quantify the drug encapsulated within nano-emulsion particles dialysis methodology was 
used. All prepared coumarin-6, and doxorubicin-loaded nano-emulsions were dialyzed against 
phosphate-buffered saline (PBS). The buffer pH was adjusted to 7.4 using hydrochloric acid 
(HCl). To obtain the drug encapsulation efficiency, 1 ml of each sample was placed in a dialysis 
bag (10-12 KD molecular weight cut off (MWCO)) and then located in PBS buffer. The amount 
of free coumarin-6 in PBS was quantified by a spectrophotometer (JENWAY 6300, 83054-05) 
at 450 nm, and encapsulation efficiency was calculated using the following equation: 
 
"#$%&'()%*+,#	.//+$+.#$0 = 2,*%)	34(5	),%3.3 − 74..	34(52,*%)	34(5	),%3.3 ∗ 100		
 
The amount of free doxorubicin was quantified using high-performance liquid chromatography 
(HPLC) according to (Dharmalingam et al., 2014) with slight modifications. Briefly, UHPLC 
(Ultimate 3000 Thermo-scientific) was performed using a C18 column (4.6 mm x 100 mm, 2.7 
µm, Thermo-Scientific 071973). UV detection for doxorubicin was done at 233 nm. The mobile 
phase contained water and acetonitrile (25:75 v/v, adjusted to pH 3.0 using 85% w/v phosphoric 
acid) using the flow-rate of 1.0 ml per minute. The mobile phase was run using a gradient 
method as follows: acetonitrile gradient of 10% at 0 minutes, 20% at 3 minutes, 35% at 6 






was identified, and the retention time of doxorubicin was detected at 2 minutes. Accordingly, 
the quantity of the doxorubicin released was measured (Appendix A). 
2.2.3 Coumarin-6 and doxorubicin in vitro release tests 
To identify the drug release profile for each prepared nano-emulsion, in vitro coumarin-6 
release experiment was conducted. The experiment was carried out for all the prepared 
coumarin-6 and doxorubicin-loaded chitosan, alginate and pullulan, and blended nano-
emulsion samples. A dialysis method was used to screen the in vitro release (Hua, 2014), 1 ml 
of each nano-emulsion was added to separate dialysis bags and placed into flasks containing 
PBS. The flasks moved into a shaker incubator, at 25°C and 55 rpm with continuous stirring. 
Liquid samples from the flasks analysed using UV-spectrophotometer at 450 nm wavelength 
for coumarin-6 and 479 nm for doxorubicin. The measurements were conducted for 21 days. 
The amount of liquid taken out was replaced each time. This protocol was applied to all the 
nano-emulsion samples in this experiment under the same conditions. Naïve coumarin-6 and 
doxorubicin solutions were used as control.  
2.2.4 Nano-emulsion characterisation  
To identify the particle size, size distribution, morphology, and stability of a nano-emulsion, it 
needs to be characterised. To characterise the size and concentration of nano-emulsion particles, 
a nanoparticle tracking analyser (NTA, Nano sight NS300, Malvern, UK) was used. To confirm 






optimisation was done by diluting the nano-emulsion sample in multiple steps (Grillo et al., 
2019).  
The experiment started by cleaning the lens over the flow cell. Initially, 1 ml of PBS was 
pumped into the system using a syringe to clean any previously remaining particles. The diluted 
nano-emulsion (1:200 PBS) was then syringe-pumped into the system. Images were captured 
using the following settings: laser type on blue 488, camera level set at 11, slider gain 146, 
syringe pump speed 50, detect threshold 2, and blur on auto. All the experiments were carried 
out at 25 °C and were performed in triplicates. The raw data was analysed by the software. The 
size, the mean concentration of particles, and the finite track length adjustment (FTLA) were 
collected during the total time of recording.  
To identify the morphology of the nano-emulsion particles, scanning electron microscopy 
(SEM) was performed using FEI Quanta FEGSEM operating at 5.00 kV, 63k magnification, 
50 pa pressure, dwelling 10 µseconds.  
Zeta potential was determined at room temperature using Zetasizer nano (Malvern 
instrumentals, UK) in triplicates. The dilutions were made using PBS (1:100 v/v).  
 
2.2.5 Preparation of drug-loaded Folic Acid surface-modified 
nano-emulsion  
Modification of nano-emulsion was carried out in order to increase the uptake of particles in 
A375 cells. Hence, the previously, prepared drug-loaded nano-emulsions (section 2.2.1) were 






Folic acid coating of the polymer was conducted via electrostatic interactions according to Song 
et al (Song et al., 2013) with slight modifications. Briefly, folic acid solution (20 w%) was 
prepared by dissolving folic acid in 1 M NaOH. The folic acid solution was added dropwise to 
the drug-loaded nano-emulsion while stirring for 12 hours. The solution was washed with PBS 
3 to 4 times and centrifuged for 30 minutes at 16000 rpm to remove the unbound folic acid.  
2.2.6 Encapsulation of anti-inflammatory compound in optimised 
nano-emulsion 
According to the aims of the current research, to target iNOS and COX-2 expression in A375 
cells anti-inflammatory compounds were used. The compounds aimed to target iNOS and 
COX-2 expression by means of the developed nano-emulsion. Hence, encapsulation of the anti-
inflammatory compounds in nano-emulsion was conducted using the same procedure as 
mentioned above (section 2.2.2). However, due to the short half-life of the peptides (6 hours), 
the whole encapsulation procedure was done on ice. The compounds BMS-470539 
dihydrochloride and [DTrp8]-γ-MSH (Can et al., 2020) were used to target human melanocortin 
receptors on melanoma (MC1 and MC3) (Zhang et al., 2017, Zhou, 2019). In this research, they 









2.2.7 Cell culture 
As the skin comprises fibroblasts, melanocytes, and keratinocytes. The HaCaT cell line was 
used as a highly proliferative epidermis in-vitro model in cell culture and viability (Souto et al., 
2020, Bácskay et al., 2018) studies due to facilitated proliferation, propagation, and its 
phenotype (Lehmann, 1997, López-García et al., 2014). Similarly, the A375 metastatic 
melanoma human-derived primary cell line was chosen for in-vitro studies of drug optimisation 
and viability screening (Couto et al., 2019). A375 cells are chosen to study the features of the 
drug delivery system for early-stage melanoma. Hence, the HaCaT cell line was used as a 
control healthy cell to malignant A375 cell line in this study to investigate the effect of drug-
loaded nano-emulsion as a topical delivery system (Bittkau et al., 2019).    
A375 (malignant melanoma) and HaCaT (human immortalized keratinocyte) cell lines were 
cultured in T-75 flasks using Dulbecco’s Modified Eagle Medium (DMEM) high glucose (4500 
mg/L, no sodium pyruvate and containing L-Glutamin) and 10% (v/v) fetal bovine serum 
(FBS). The cell-containing flask was incubated at 37°C and 5% CO2. After confluency of 80%, 
the cells were collected for seeding.  
To seed the cells in multi-well plates, the medium was removed from the flask, and cells were 
washed with PBS. Trypsin-EDTA was added to the volume of 2 ml to the flask to detach the 
cells and left for incubation at 37 °C and 5% CO2, 2 minutes for melanoma cells, and 4 minutes 
for keratinocytes. After the cells were detached, 6 ml of DMEM was added to the flask, and 
cells were suspended and collected. The media containing trypsin-ETDA was centrifuged for 






suspended in fresh DMEM and added to a new T-75 flask containing 10 ml of fresh DMEM. 
Passage numbers 13-17 were used for cell experiments.   
To seed the cells in multi-well plates, the pellet was re-suspended in 1 ml DMEM and was 
transferred to an Eppendorf tube. To count the cells, 10 µl of the cell suspension was mixed 
with 10 µl Trypan Blue dye and incubated for 2 minutes. Then 10 µl of the dyed cell suspension 
was pipetted into cell counting chamber slides and the cells were counted using Countess™ II 
FL Automated Cell Counter (Thermo-Fischer Scientific, A27974).  
Subsequently, the cells were seeded in suitable multi-well plates with a density of 106 cells per 
well in 6 well plates, and 105 cells per well in 96 well plates. Plates were incubated under the 
same conditions. Cell treatments were done after 8 hours while the cells were attached to the 
plates. The cell culture condition remained unchanged for all the cell-culture-based experiments 
and for all the time points.  
2.2.8 Mitochondrial activity (MTT) cytotoxicity assay 
To explore the viability of cells treated with drug-loaded and non-loaded nano-emulsions, MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was conducted. Cells 
(A375 and/or keratinocyte) were collected from T-75 flasks and seeded in 96 well plates with 
a density of 105 cells per well, then they all were incubated with 1-18 nano-emulsion 
preparation using three doses of 10, 20, and 30 µl/ml of culture medium during 72 hours. After 
the treatments, MTT dye (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide)) 
(Figure 2.1) (5 m g/ml) equivalent to 1/10 of culture medium was added to each well. The plate 






medium was removed. DMSO to the volume of 200 µl was added to the wells and incubated 
overnight at room temperature (25°C) in dark. The optical density (OD) of the wells was 
obtained at 570nm by an ELISA reader. The results were obtained as the percentage of control 
(untreated cells).  
 
 
Figure 2.1 Mitochondrial reduction happening during MTT assay 
 
2.2.9 Cellular uptake test using confocal microscopy 
To screen the uptake of the nano-emulsion particles in A375 and HaCaT confocal microscopy 
was used. As nano-emulsions were loaded with doxorubicin and coumarine-6 separately, after 
the treatment the cells were imaged. The fluorescent intensity of both doxorubicin and 
coumarine-6 was used as to observe the nano-emulsion particle’s uptake in the cells. To conduct 
cellular uptake experiments, cells were seeded into 6 well plates with a density of 5x106 cells 






of the coumarin-6 and doxorubicin-loaded nano-emulsions was measured for both HaCaT and 
A375 cells after specific treatment periods (4 hours, 24 hours, 48 hours, and 72 hours). After 
the treatments, the medium was removed from the wells, and all wells were washed with PBS 
twice. The cells were fixed using 4% (v/v) formaldehyde. For this, formaldehyde (50 µl) was 
added to the media into each well and left for 5 minutes, then the media were removed and 250 
µl of formaldehyde was added to each well to cover all the cell surface and incubated for 20 
minutes for cells to fix. Cells were washed with PBS twice and 2 ml of PBS were added to the 
wells for confocal microscopy (Leica TCS SP2).  
To obtain images for coumarin-6, FITC filter was used (λmax 488nm). Images were obtained 
along Z-axis (Z wide) and Z position was set to 0.1 µm per turn (objective HCX APOLU-V-1 
63X0.9W, pixels 1024 X 1024, pinhole 1 airy unit, stack 0.5 µm thick). Images for doxorubicin 
(excitation 543 nm, emission long-pass filter 570 nm) were obtained under the same conditions. 
After the cells were observed using confocal microscopy, the fluorescence intensity was 
quantified using Image J, to identify the cellular uptake. 
2.2.10  Fluorescent microscopy  
For more investigation on the cell morphology after the treatments with drug loaded nano-
emulsion, fluorescent microscopy was conducted. The microscopy imaging of the cells was 
conducted using an EVOS fluorescent microscope. The cells were initially labelled with cell 
tracker red (CMTPX) and cell tracker green (CMFDA) florescent probes according to the 
manufacturer’s protocol (Zouani et al., 2013). For CMFDA labelling, 107 µl of DMSO was 






To make 10 µM working solution, 50 µl of the stock solution (1 mM) were diluted in 5 ml of 
serum-free DMEM. For CMTPX, 72 µl of DMSO was added to the CMTPX vial; again 50 µl 
of the stock solution was diluted in 5 ml serum-free DMEM to make 10 µM working solution. 
To label the cells, HaCaT and A375 cells were previously passaged and seeded in a T-75 flask. 
After the cells became confluent, the media was removed and the cells were washed with PBS 
twice. Five ml of CMFDA working solution was added to the A375 flask and 5 ml of CMTPX 
working solution was added to the HaCaT flask. The flasks were incubated for 30 minutes in 
an incubator. Afterward, media from both flasks were removed and the cells were washed with 
PBS twice. The labelled cells were detached using trypsin-EDTA and collected for subsequent 
seeding in the 6 well plates. After the attachment of the cells, nano-emulsion treatments were 
applied. Cells were imaged for durations of 24 hours, 48 hours, and 72 hours afterward. 
DAPI stain was used to image the cell nuclei. Deionized water (2 ml) was added to the entire 
content of the DAPI vial to make a 5 mg/ml stock solution. To make a 300 µM DAPI 
intermediate solution, 2.1 µl of DAPI stock solution, was added to 100 µl of PBS. The 
intermediate solution was diluted 1:1000 in PBS to make a 300 nM solution. To commence the 
staining, the cells were washed with PBS twice. A sufficient amount of 300 nM DAPI solutions 
(approximately 250 µl) was added to cells to cover their surface. The plates were incubated for 
15 minutes protected from light, at room temperature. After incubation, the stain was removed 
and the cells were washed with PBS twice. They were then imaged using the DAPI filter in an 
EVOS microscope (M5000 Thermo-Fischer Scientific). Cells that demonstrated decreased 







Images of CMFDA-probed cells were taken at excitation 492 nm and emission 517 nm and 
GFP filter on EVOS microscope. CMTPX was imaged at excitation 577 nm and emission 602 
nm using an RFP filter.  
2.2.11   DNA fragmentation ELISA 
The apoptosis process includes activation of endonucleases leading to fragmentation of 
chromatin to oligonucleosomal fragments (approximate sizes of 180 bp). These DNA 
fragments appear in the early stages of apoptosis. One of the approaches to detect these 
fragments is DNA fragmentation ELISA (Salgame et al., 1997). DNA fragmentation ELISA 
was used in this section to detect early apoptosis as it is a highly sensitive monoclonal-antibody-
based assay (Jablonski et al., 2017, George and Rupasinghe, 2017).   
Cellular apoptosis ELISA experiment was done to specify the doxorubicin-loaded nano-
emulsions apoptosis induction-ability on melanoma and keratinocyte cells. A cellular apoptosis 
experiment was conducted using cellular fragmentation ELISA kit, following the manufacturer 
protocol. After confluency of about 80%, cells were treated with trypsin-EDTA to detach from 
the flask. After 30 seconds, 5 ml of media was added to the flask and the cell suspension was 
centrifuged for 5 minutes at 15000 rpm. The supernatant was removed, and the cell pellet was 
re-suspended in a fresh medium. BrdU (Bromodeoxyuridine/ 5-bromo-2'-deoxyuridine) 
labelling solution was added to the medium to prepare the final concentration of 10 µM and the 
cell suspension was incubated overnight in the incubator. After incubation time, BrdU cell 
suspension was centrifuged for 10 minutes at 250×g. The supernatant was taken out and the 






triplicate wells of round bottom 96 well plates to a final concentration of 1×105 cells/ml. The 
cells were treated with 10 µl/ml of nano-emulsions (section 2.2.5) and incubated for 4, 24, 48, 
and 72 hours. After the incubation, plates were centrifuged for 10 minutes at 250×g, and 
supernatants were removed thoroughly. Incubation solution was added to the remaining cells 
to lyse them. For this, the plates were incubated for 30 minutes at room temperature and then 
centrifuged. Supernatants were collected from each well and then added to triplicate wells pre-
coated plates for ELISA photometric measurements using an ELISA reader (BMG, Labtech). 
Add the full protocol detail 
2.2.12   Folate binding protein ELISA 
Folate receptors are overexpressed in most cancer cell lines. However, to confirm and identify 
the folate receptor expression concentration on melanoma cells (A375) folate binding protein 
(FBP) ELISA was done (Ogbodu et al., 2015). Accordingly, cell supernatants from A375, 
HaCaT (negative control), and MDB MA-231 (positive control) cell lines were used for the 
assay. Preparation of all the reagents, samples, and standard stock solutions was based on the 
manufacturer’s protocol. Standard solution (100 µl) and sample solutions were added to the 
appropriate wells of the pre-coated ELISA plate. The plate was incubated at 37 °C for 90 
minutes. The content of the plate was tapped out after the incubation and 100 µl of biotinylated 
antibody was added to the wells and incubated for 60 minutes at 37 °C. The wells were washed 
with 300 µl of 0.01 M PBS three times. After the washing, 100 µl of Avidin-biotin-peroxidase 
complex (ABC) working solution was added and the plate was incubated at 37 °C for 30 






added to the wells and incubated at 37 °C in dark for 15-20 minutes. TMB stop solution with 
the volume of 100 µl was added to the wells afterward, and the OD of the wells was read at 450 
nm within 30 minutes.  
2.2.13   Co-culture of HaCaT and A375 cells  
To observe the effect of the drug-loaded nano-emulsions on both A375 and HaCaT cell lines, 
the treatments were conducted on the co-culture of both cells. The co-culture of HaCaT and 
A275 was also a primary monolayer model to study the effect of drug-loaded nano-emulsion 
as a topical delivery system for melanoma.  Previously fluorescent labelled A375 and HaCaT 
cells 2.2.10)were seeded in 6 well plates with a ratio of 1:5 respectively and grown in DMEM. 
Plates were incubated at 37°C and 5% CO2. After 12 hours, the seeded and labelled cells were 
treated with 10 µl/ml of drug-loaded nano-emulsions in duplicate wells, incubated for 72 hours, 
and imaged using fluorescent microscopy. 
 
2.2.14  Polymerase chain reaction 
Polymerase chain reaction (PCR) was performed to screen the apoptosis-associated proteins 
caspase-3 (Duan et al., 2020), and caspase-9 (Chen et al., 2019). Bax (Pan et al., 2019) a pro-
apoptotic gene, and Bcl2 (Pan et al., 2019) an anti-apoptotic gene expression were also screened 
using a PCR methodology. This methodology was used as a qualitative method screening of 






2.2.14.1   RNA extraction using TRIzol method 
Total RNA was extracted directly from the treated cells in 6 well plates (cell density of 5x106) 
using TRIzol reagent. Initially, the media was removed and cells were washed with PBS. Using 
1ml of TRIzol, the content of 3 wells was pooled together and mixed well. The lysate was then 
transferred to 1.5 ml Eppendorf microcentrifuge tubes containing 1.5 µl Glycoblue co-
precipitant. Chloroform at 200 µl/ml of TRIzol was added to each tube. The content of each 
tube was mixed by inversion for 10 seconds and left for incubation for 5 minutes at room 
temperature. The mixture was then centrifuged at 12,000 × g for 15 minutes at 4 °C.  
 
Figure 2.2 Organic, interface, and aqueous phases after treating with TRIzol. 
 
After centrifugation, the upper phase was removed fully and accurately added to a new tube. 
Isopropanol at half of the original TRIzol was added to each tube and gently mixed by inversion 
three times followed by centrifugation at 12,000 × g for 10 minutes at 4°C. The supernatant 
was removed leaving a blue pellet behind. The pellet was washed using 500 µl of 75% ethanol 






The pellet was then air-dried and RNA was re-suspended in 44 µl of nuclease-free water. The 
RNA quality was measured and quantified using nano-drop in the table below (Table 2.14) 
(Thermosientific UK). 
 
Table 2.14 RNA quantification and quality by nano-drop 















810.08 351.1 2.12 2.08 
Doxorubicin-loaded 
nano-emulsion 
697.0 1084.5 2.10 2.10 
Dacarbazine-loaded 
nano-emulsion 
659.9 264.3 2.11 2.10 
Naïve doxorubicin 332.3 313.3 2.25 2.07 
Naïve dacarbazine 983.3 396.6 2.11 2.05 










2.2.14.2  RNA purification and DNase treatment 
The extracted RNA samples were DNase treated using the DNA purification kit according to 
the manufacturer’s recommendations. The volumes used are shown in the table below 
Table 2.15. 
 
Table 2.15 RNA purification and reagents 
RNA 17 µl 
DNase (buffer) 2 µl 
DNase enzyme 1 µl 
 
The mixtures were incubated for 15 minutes at 25 °C in a thermocycler. EDTA was then added 
to all samples to the volume of 1 µl and incubated for 10 minutes at 65 °C. All the samples 
were run on the gels to detect the total, DNA-free RNA. 
2.2.14.3  Preparation of cDNA  
The extracted and purified RNA was used for complementary DNA synthesis. The RNA was 
converted to cDNA using a superscript II reverse transcriptase kit (Invitrogen). The total 
extracted and purified RNA (500 ng) was used for cDNA synthesis. To commence, Oligo 
(dT)12-18 and dNTP mix was added to nuclease-free microcentrifuge tubes (1 µl each). Nuclease-
free sterile water was added to each sample to the total volume of 12 µl. Finally, 4 µl of purified 
RNA was added to the tubes. The mixture was heated to 65°C for 5 minutes. Subsequently, the 






RNAse OUT to the volumes of 4, 2, and 1 µl respectively, were added to the tube. The mixture 
was gently mixed and 1µl of superscript II was added to the tube. The mixture was incubated 
at 42 °C for 50 minutes followed by reaction inactivation for 15 minutes at 70 °C.  
2.2.14.4    Thermo-cycling, an agarose gel electrophoresis analysis 
PCR was done using 5 µl of PCR master mix (2X), 0.5 µl forward and reverse primers, 1 µl of 
cDNA template, and Nuclease free water up to 12 µl (Si et al., 2018). 
The mixtures were gently vortexed and spun down. The samples were put in a thermal cycler 
with the conditions as follows: 
Table 2.16 PCR cycles and conditions 
Step Temperature °C Time Number of cycles 
Initial denaturation 95 2 minutes 1 
Denaturation 95 30 seconds  
Annealing 55 30 seconds 30 
Extension 72 2 minutes  
Final extension 72 15 minutes 1 
 
To visualise the amplified DNA, agarose gel electrophoresis was used. Agarose gel (1% w/v) 
was prepared before the experiment. The agarose powder (1 gr), was added to 100 ml of TAE 
(Tris-acetate-EDTA) buffer and heated in a microwave until the solution was clear and the 
agarose was dissolved. The agarose solution was cooled down at room temperature, and a 2% 






agarose solution was then poured into the gel electrophoresis tray and was left to set at room 
temperature. After solidifying, the gel was placed in the tank and TAE buffer was added. 
After the thermo-cycler step, the samples were collected and mixed with 3 µl of loading dye 
(Thermo-Scientific 6X DNA loading dye). The mixture was then loaded into the wells of 1% 
agarose gel in the tank.  
A molecular weight marker of 1Kb and 100 Kb were used alongside the cDNA samples. 
Electrophoresis was set to run for 60 minutes in the 100 V constant. After 60 minutes, the gel 
was imaged using the UV transilluminator at the wavelength of 200-280 nm and the DNA 
fragments were detected. 
2.2.15 Western blotting  
2.2.15.1    Protein extraction using TRIzol method 
The western blot experiment was carried out in order to screen and identify the iNOS and COX-
2 expression in A375 cells treated with anti-inflammatory compound-loaded nano-emulsion. 
Before performing Western blotting, the total protein content of the cells (5x106 cells per well) 
was extracted directly from the treated cells in 6 well plates, media was removed and cells 
washed with PBS once before the addition of, 1 ml of TRIzol, the content of 3 wells were 
pooled together and mixed well. The lysate was then transferred to 1.5 ml Eppendorf micro-
centrifuge tubes, chloroform, 200 µl per 1 ml of initial TRIzol was added to each tube. The 
content of tubes was mixed by inversion for 10 seconds and left for 5 minutes at room 






interface were discarded, and the organic phase was kept for protein extraction. Isopropanol 
was then added to each tube (0.8 ml per 1 ml of TRIzol). Samples were incubated for 10 minutes 
at 15-30 °C, and protein centrifuged at 7,500xg for 5 minutes at 2-8 °C. The supernatant was 
removed and the protein pellet washed three times using 0.3 M guanidine hydrochloride 
solution in 95% ethanol (2 ml of wash buffer was used per 1 ml of initially used TRIzol). During 
each wash step, the protein pellet was kept in the solution for 20 minutes at 15-30 °C, then 
centrifuged at 7,500xg for 5 minutes at 2-8 °C. Following the final wash step, the pellet was 
stored in ethanol for 20 minutes at 15-30 °C and then centrifuged at 7,500xg for 5 minutes at 
2-8 °C. The pellet was vacuum dried and dissolved in 1% SDS by continuous pipetting. The 
step was completed on a heat block at 50 °C. Final centrifugation at 10,000xg for 10 minutes 
at 2-8°C was done and the supernatant was removed to a fresh tube and stored at -80 °C for 
western blotting.  
2.2.15.2  SDS 10% polyacrylamide gel electrophoresis (SDS-PAGE) 
Extracted proteins were prepared and loaded onto SDS page gel; Subsequently, 25 µl of each 
protein extracted was mixed with 25 µl of 2x laemmli loading buffer (4% SDS, 10% 2-
mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, 0.125 M Tris-HCL, pH 6.8), and 
boiled at 95 °C water for 5 minutes. Samples were centrifuged down at 12,000 g for 1 minute 
and 20 µl of each sample was loaded into each well of precast SDS 10% polyacrylamide gels 
along with protein molecular markers (prestained protein MW marker). The tank was filled 
with running buffer (containing 25 mM tris, 190 mM glycine, and 20% methanol) and the gel 






2.2.15.3  Protein transfer 
Following running the gel, the gel cassette was placed in the Western blot running buffer for 
10-15 minutes and the gel was removed from the cassette to prepare the transfer sandwich. 
Nitrocellulose membrane(s), Western blot papers, and sponges were soaked in Western blot 
buffer for a few minutes and the gel was placed in a Western blot sandwich, with the gel on the 
anode side and the blot on the cathode side. The cassette was placed in the Western blot tank 
alongside an ice block (-20 °C) to keep the buffer cold using a magnetic stirrer. The transfer 
was run for 150 minutes at 30 mA.  
After the Western blotting step, the blot was removed and placed in TBST (Tris buffer saline 
containing tween 20). The blot was rinsed with dH2O and stained with 0.2% Ponceau S in 10% 
v/v acetic acid for 1 minute to assess transfer quality (Figure 2.3) The blot was then blocked 
with 5% non-fat milk in TBST for 2 hours and rinsed with TBST for 5 minutes 3-5 times.  
Following blocking, the blot was then incubated with primary antibodies against target proteins 
(anti-Cox-2 and anti iNOS antibodies (Abcam, ab15191 and ab 3523)). The antibody (dilution 
factor 1:200) was dissolved in TBST and then blot was incubated with the primary antibody at 
4 °C overnight. Following incubation, the blot was washed with TBST 3-5 times and incubated 
with the secondary antibody -mouse α-tubulin antibody- solutions for 1 hour at room 
temperature.  
The protein bands were visualized by incubating the blot in 3 ml of TMB solution for 10 








Figure 2.3 Western blot stained Ponceau S 
 
2.3 Statistical analysis 
The experiments conducted in this research were repeated at least three times (n=3) unless 
stated in the results. The acquired data were analysed using GraphPad software and ECXEL. 
Two-way ANOVA, Tukey’smultiple comparison test was performed to compare the significant 


































3.1 Synthesis and optimisation of nano-emulsion for enhanced 
drug delivery to melanoma  
3.1.1 Introduction 
One of the important factors causing an increase in drug-resistance in melanoma (at the 
cellular level) is the inefficient and uncontrolled (too low or too high) drug efflux (Xue 
and Liang, 2012) in delivering chemotherapeutics (Yuan et al., 2016). It has been 
reported that polysaccharides have unique potential in cancer drug delivery (Posocco et 
al., 2015), such as enhanced uptake in the cancer cells (Dheer et al., 2017). In this 
chapter, novel synergy of chitosan, pullulan and alginate were investigated with the 
intention of uptake enhancement and chemo-resistance defeat in melanoma (Gilani et 
al., 2018).  
The in vitro characteristics of chitosan-pullulan, pullulan-alginate, and alginate-
chitosan polymer blends as nano-emulsions, as described in this chapter. Based on 
release profiles, the nano-emulsion samples were narrowed down to top-nine.  
Subsequently, the toxicity to the A375 and HaCaT cell lines, release, and uptake of 
drug-loaded nano-emulsions were measured.  
Furthermore, apoptosis induction of doxorubicin delivery was evaluated by DNA 
fragmentation ELISA and based on the results, the optimal nano-emulsion was selected 
for further investigations. 



















3.1.2 Synthesis and evaluation of polymeric nano-emulsions 
characteristics 
3.1.2.1 Evaluation of in vitro release of coumarin-6 and doxorubicin 
from chitosan, pullulan, and alginate nano-emulsions 
A set of experiments were carried out to monitor the release of doxorubicin and coumarin-6 
from pullulan, alginate, and chitosan nano-emulsions. In the previous investigations, the three 
polymers individually presented unique characteristics in drug delivery systems, and they were 
subjected to various modifications and combinations in previous investigations (Ahmed and 
Aljaeid, 2016, Vora et al., 2020, Cheng et al., 2019a, Yu et al., 2017).  
However, in this research as a novel approach, the polymer combinations were compared to 
each other. Chitosan, alginate, and pullulan all have different surface charges. So the surface 
charge was considered as one of the factors influencing release profile and consequently the 
stability of the nano-emulsion.  
Each of the nano-emulsions was prepared with different amounts of polymers. The profile of 
coumarin-6 and doxorubicin release from nano-emulsion was measured by the dialysis method 
for 21 days. Initial burst (release in 0-24 hours) of coumarin-6 from chitosan nano-emulsions 
ranged between 0 to 30%, for pullulan nano-emulsions the range was 1 to 17.5%, and for 
alginate ranged between 1 to 5%. The initial burst of doxorubicin from chitosan nano-emulsions 
ranged between 0 to 9% for pullulan nano-emulsions the range was 1.7 to 14%, and for alginate 
ranged between 2.25 to 11.9%. Nano-emulsions that showed the steadiest release (fewer 






profiles were recorded for both coumarin-6 and doxorubicin-loaded nano-emulsions. In both 
cases, the data were collected from 3 independent experiments and calculated as percentages 
of naïve coumarin-6 and doxorubicin control values. Recorded profiles for doxorubicin release 










Figure 3.2 Coumarin-6 cumulative release from chitosan nano-emulsions 
The nano-emulsions were prepared (0.1, 0.2, 0.3, 0.4, 0.5, 0.6 and 0.7 w/v %), loaded with 
coumarin-6 and screened for 21 days. The release data was measured by spectrophotometer at 
7 different time points over 21 days. The experiment was conducted using the dialysis method 
at 25°C and 55 rpm with continuous stirring. Liquid samples from the flasks analysed using 
UV-spectrophotometer at 450 nm wavelength. The results were normalised to naïve coumarin-
6 release (control) and are demonstrated as the percentage of the control. The data were 






































Figure 3.3 Coumarin-6 cumulative release profile from pullulan nano-emulsions 
The nano-emulsions were prepared (0.1, 0.2, 0.3, 0.4, 0.5, 0.6 and 0.7 w/v %), loaded with 
coumarin-6 and screened for 21 days. The release data was measured by spectrophotometer at 
7 different time points over 21 days (n=3). The experiment was conducted by dialysis method 
at 25°C and 55 rpm with continuous stirring. Liquid samples from the flasks analysed using 
UV-spectrophotometer at 450 nm wavelength. The results were normalised to naïve coumarin-
6 release (control) and are demonstrated as the percentage of the control.  The data are obtained 





































Figure 3.4 Coumarin-6 cumulative release profile from alginate nano-emulsion  
The nano-emulsions were prepared (0.1, 0.2, 0.3, 0.4, 0.5, 0.6 and 0.7 w/v %), loaded with 
coumarin-6 and screened for 21 days. The release data was measured by spectrophotometer at 
7 different time points over 21 days (n=3). The experiment was conducted using a dialysis 
method at 25°C and 55 rpm with continuous stirring. Liquid samples from the flasks analysed 
using UV-spectrophotometer at 450 nm wavelength. The results were normalised to naïve 
coumarin-6 release (control) and are demonstrated as the percentage of the control. The data 





































Figure 3.5 Doxorubicin cumulative release profile from chitosan nano-emulsion 
The nano-emulsions were prepared (0.1, 0.2, 0.3, 0.4, 0.5, 0.6 and 0.7 w/v %), loaded with 
coumarin-6 and screened for 21 days. The release data was measured by spectrophotometer at 
7 different time points over 21 days (n=3). The experiment was conducted using a dialysis 
method at 25°C and 55 rpm with continuous stirring. Liquid samples from the flasks analysed 
using UV-spectrophotometer at 479 nm wavelength. The results were normalised to naïve 
doxorubicin release (control) and are demonstrated as the percentage of the control. The data 







Figure 3.6 Doxorubicin cumulative release profile from pullulan nano-emulsions 
The nano-emulsions were prepared (0.1, 0.2, 0.3, 0.4, 0.5, 0.6 and 0.7 w/v %), loaded with 
coumarin-6 and screened for 21 days. The release data was measured by spectrophotometer at 
7 different time points over 21 days (n=3). The experiment was conducted using a dialysis 
method at 25°C and 55 rpm with continuous stirring. Liquid samples from the flasks analysed 
using UV-spectrophotometer at 479 nm wavelength. The results were normalised to naïve 
doxorubicin release (control) and are demonstrated as the percentage of the control. The data 




































Figure 3.7 Doxorubicin cumulative release profile from alginate nano-emulsions 
The nano-emulsions were prepared (0.1, 0.2, 0.3, 0.4, 0.5, 0.6 and 0.7 w/v %), loaded with 
coumarin-6 and screened for 21 days. The release data was measure by spectrophotometer at 7 
different time points over 21 days (n=3). The experiment was conducted using a dialysis 
method at 25°C and 55 rpm with continuous stirring. Liquid samples from the flasks analysed 
using UV-spectrophotometer at 479 nm wavelength. The results were normalised to 
doxorubicin release (control) and are demonstrated as the percentage of the control.  The data 




































According to the Figure 3.2 to Figure 3.7 overall release pattern for all nano-emulsions for 21 
days increased over time. However, the cumulative release pattern of each nano-emulsion was 
different at each period.  
Through the release optimisation assessment, the selection of nano-emulsions was based on the 
controlled and slow release pattern over time. Additionally, the minimal initial burst of release 
pattern was considered for the nano-emulsion selection exercise.  
According to Figure 3.2 and Figure 3.5, the initial burst of chitosan nano-emulsions release 
profile was closest to zero for two of the samples. For pullulan nano-emulsions, three of the 
samples had initial bursts closest to zero. Among alginate nano-emulsions, four samples had 
initial bursts closest to zero. 
The main objective for this experiment was to identify which nano-emulsions could provide 
the lowest initial burst and a steady release profile. To this end, initial bursts and overall release 
patterns for each nano-emulsion were carefully analysed. Accordingly, NEC1, NEPl2, and 
NEAl2 were chosen due to their lowest initial burst and lowest fluctuations over time.  
3.1.2.2 Evaluation of in vitro release for blended chitosan, pullulan, 
and alginate nano-emulsions 
To improve the physical characteristics of nano-emulsions, the selected nano-emulsions from 
section 2.2.1 were blended. Nano-emulsions that showed the steadiest release and lowest initial 
burst during the 21 days were chosen for blending. In section 3.1.2.1 nano-emulsions presented 
a slow release profile over time. However, the patterns did not concur with the desired 






chitosan-pullulan, pullulan-alginate, and alginate-chitosan nano-emulsions were developed. 
Each of the blended nano-emulsions was prepared according to the method described in section 
2.2.1 and the release profile of encapsulated coumarin-6 and doxorubicin was measured by the 
dialysis method for 21 days. The results were obtained from three independent experiments and 
were calculated as percentages of naïve coumarin-6 and doxorubicin control values. In 
comparison to single polymer nano-emulsions, all the initial bursts were improved and were 
closer to zero.  
The initial burst of coumarin-6 loaded nano-emulsions ranged between 0 to 3.9%, and for 
doxorubicin-loaded nano-emulsions ranged between 0 to 2.7%. The release profile quality 
increased significantly. The initial burst reduced and the release profiles for the 21 days were 
steadier.  
The release trends for all the samples were observed and recorded (Figure 3.8 and Figure 3.9). 
The best release profile for both doxorubicin and coumarin-6 release fitting the criteria appeared 
to be pullulan-chitosan. This nano-emulsion consisted of 4 mg/ml pullulan and 8 mg/ml 
chitosan (Table 2.13). However, after the analysis, the samples narrowed down to 9 best 
according to controlled release and steadiness over 21 days, to investigate further. Based on the 
findings, nine nano-emulsion samples were marked out for their superior performance: NEC1-
Al 2:1, NEAl2-Cs 1:2, NEPl2-Cs 2:1, NEPl2-Cs 1:2, NEC-Pl 1:1, NEC1-Pl 2:1, NEPl2-Al 1:2, 
NEPl2-Al 2:1 and NEPl2-Al 1:1.  
The drug release showed an increasing pattern over 21 days, in all cases. The release profile 
was detected to be about 80% during the first 72 hours for a few samples. Hence, a good extent 







Figure 3.8 Coumarin-6 cumulative release profile from blended nano-emulsions 
The nano-emulsions were prepared with three different weight ratios (1:1, 1:2, 2:1 w/w%) 
loaded with coumarin-6 and screened for 21 days. The release data was measured by 
spectrophotometer at 7 different time points over 21 days (n=3). The experiment was conducted 
using a dialysis method at 25°C and 55 rpm with continuous stirring. Liquid samples from the 
flasks analysed using UV-spectrophotometer at 450 nm wavelength. The results were 
normalised to coumarin-6 release (control) and are demonstrated as the percentage of the 
control.  The data were obtained from 3 independent experiments and presented as mean ±SD 










Figure 3.9 Doxorubicin cumulative release profile from blended nano-emulsions 
The nano-emulsions were prepared with three different weight ratios (1:1, 1:2, 2:1 w/w%) 
loaded with doxorubicin and screened for 21 days. The release data was measured by 
spectrophotometer at 7 different time points over 21 days (n=3). The experiment was conducted 
using a dialysis method at 25°C and 55 rpm with continuous stirring. Liquid samples from the 
flasks analysed using UV-spectrophotometer at 479 nm wavelength. The results were 
normalised to doxorubicin release (control) and are demonstrated as the percentage of the 








3.1.2.3 Viability screening of non-loaded blended nano-emulsions at 
three different doses 
A375 and HaCaT cells were treated with 15 non-loaded blended nano-emulsions to screen the 
cell viability. The outcome was confirmed by MTT assay. The data were obtained from six 
independent experiments and outcomes are reported as a percentage of control.  
Cytotoxicity assay was conducted for 15 blended nano-emulsions plus three single polymer 
nano-emulsions chosen in section 3.1.2.1.  the cells were treated with three concentrations of 
10, 20, and 30 µl/ml of non-loaded nano-emulsions. 
The viability of HaCaT cells ranged from 75.5 to 106.06% (NEPl2-Al 1:2 and NEPl2-Cs 1:2), 
43.32 to 85% (NEAl2-Cs 2:1 and NEC1-Al 2:1) and 47.13 to 80% (NEAl2-Cs 2:1 and NEPl2-
Cs 1:1) for treatment concentrations of 10, 20, and 30 µl/ml respectively. A375 cell viabilities 
ranged from 70 to 107.48% (NEC1 and NEPl2-Cs 1:2), 56.14 to 87.71% (NEAl2-Cs 2:1 and 
NEC1-Al 2:1) and 28.16 to 96.99% (NEAl2-Cs 1:1 and NEPl2-Al 1:1) for treatment doses of 
10, 20 and 30 µl/ml respectively. This set of experiments aimed to choose the optimal 
concentration and find out the non-loaded nano-emulsions which do not decrease HaCaT 
viability but decrease the A375 viability. Nano-emulsion treatment concentration of 10 µl/ml 
was chosen accordingly. This was used to narrow down the samples to the ones inducing higher 
toxicity to A375 and lower toxicity to HaCaT. 
Increasing the dose to 20 and 30 µl/ml, significantly decreased the viability of both A375 and 






the lowest dose was chosen for treatments. However, the reason for decreased viability of both 
cell lines treated with increased concentration of the nano-emulsions can be further investigated 
with Annexin-V assay. A good example is sample NEPL2-Cs 1:2 which had a significant 


























Figure 3.10 Viability screening keratinocyte (HaCaT) cells treated with non-loaded nano-
emulsions 
The cells were treated at three nano-emulsion concentrations of 10, 20, and 30 µl/ml. Cells were 
treated with 15 nano-emulsion and incubated for 72 hours. The viability data were obtained 
using the MTT method, results were calculated based on untreated control cells, and reported 
as the percentage of control. Bars represent the mean value of 6 independent experiments ±SD 
error. The data were analysed with two-way ANOVA Tukey’s comparison test, **** is 











































































































































Figure 3.11 Viability screening melanoma (A375) cells treated with non-loaded nano-emulsions 
The cells were treated at three nano-emulsion concentrations of 10, 20, and 30 µl/ml. Cells were 
treated with 15 nano-emulsion and incubated for 72 hours. The viability data were obtained 
using the MTT method, results were calculated based on untreated control cells, and reported 
as the percentage of control. Bars represent the mean value of 6 independent experiments ±SD 
error. The data were analysed with two-way ANOVA Tukey’s comparison test, **** is 











































































































































3.1.2.4 Evaluation of the top-nine blended doxorubicin-loaded nano-
emulsions to induce toxicity to melanoma 
From the last three sections, based on MTT and release assays, the blended nano-emulsion 
samples were analysed and narrowed down to 9 top nano-emulsions as best fit designs for this 
project. The criteria for the top best were the highest possible viability for HaCaT compared to 
untreated HaCaT and decreased viability for A375 cells compared to untreated A375 cells. The 
data were obtained from 6 independent experiments and the values were calculated as a 
percentage of control. The results below, belong to the chosen 9 nano-emulsions.  
The toxicity of top-nine nano-emulsions was monitored and compared to doxorubicin-loaded 
nano-emulsions and naïve doxorubicin. 
The figure below (Figure 3.12) is a comparison of A375 cell viability treated with of non-
loaded, doxorubicin-loaded, and naïve doxorubicin. 
The viability of A375 cells treated with non-loaded nano-emulsions ranged from 35.82 to 
107.07% and 25.62 to 47.22% for doxorubicin-loaded nano-emulsions while the viability of 
cells treated with doxorubicin is 104.55% (All the viability data assessed as percentage of 
untreated control).  For the samples, NEC1-Al 2:1, NEPl2-Cs 2:1, NEC1-Pl 2:1, NEPL2-Al 










Figure 3.12 Viability of A375 cells treated with top-nine blended nano-emulsions 
The cells were treated with non-loaded and doxorubicin-loaded nano-emulsions and naïve 
doxorubicin. The cells were incubated for 72 hours following the treatment. The viability data 
were obtained using the MTT method, results were calculated based on untreated control cells, 
and reported as the percentage of control. Bars represent the mean value of 6 independent 
experiments ±SD error. The data were analysed with two-way ANOVA Tukey’s comparison 



















































































Doxorubicin loaded blended nano-
emulsions












According to Figure 3.12 viability of the cells treated with blank nano-emulsions was 
significantly higher than the cells treated with doxorubicin-loaded nano-emulsions.  
The results indicate that the encapsulation of doxorubicin is more effective to decrease the 
viability of A375 cells compared to blank blended nano-emulsions. Lower viability of cells 
treated with doxorubicin-loaded nano-emulsions may be the result of increased intracellular 
uptake of the drug-loaded nanoparticles and the subsequent effective action of the main drug 
(doxorubicin). Hence, while melanoma develops resistance to naïve doxorubicin (Xiao et al., 
2018), encapsulated doxorubicin can be effective in treating melanoma.    
3.1.2.5 Evaluation of the top-nine blended doxorubicin-loaded nano-
emulsion to induce toxicity to melanoma and keratinocytes at 4, 24, 48, and 
72 hours 
The experiment in section 3.1.2.4 was repeated, the repeat was to screen the viability of cells 
treated with blank and doxorubicin-loaded nano-emulsions over 72 hours. The viability test was 
conducted for both A375 and HaCaT cells treated with blank blended nano-emulsions. Six 
independent experiments were carried on to obtain the data and the results were calculated as a 
percentage of control. In each treatment, the effect of both treatments on cell viability was 
compared. A significant decrease of viability was observed in both cell lines treated with 
doxorubicin-loaded blended nano-emulsions compared to the viability of cells treated with non-










Figure 3.13 Viability of A375 cells in 4-hour treatment with non-loaded and doxorubicin-loaded 
blended nano-emulsion 
The cells were treated with non-loaded and doxorubicin-loaded nano-emulsions and incubated 
for 4 hours. The viability data were obtained using the MTT method, results were calculated 
based on untreated control cells, and reported as the percentage of control. The experiment was 
conducted in 6 independent experiments and bars are indicating the mean value ±SD error bars. 
The data were analysed with two-way ANOVA Tukey’s comparison test, **** is indicating 







Figure 3.14 Viability of A375 cells in 24-hour treatment with non-loaded and doxorubicin-loaded 
blended nano-emulsion 
The cells were treated with non-loaded and doxorubicin-loaded nano-emulsions and incubated 
for 24 hours. The experiment was conducted in 6 independent experiments and bars are 
indicating the mean value ±SD error bars. The viability data were obtained using the MTT 
method, results were calculated based on untreated control cells, and reported as the percentage 
of control. The data were analysed with two-way ANOVA Tukey’s comparison test, **** is 








Figure 3.15 Viability of A375 cells in 48-hour treatment with non-loaded and doxorubicin-loaded 
blended nano-emulsion 
The cells were treated with non-loaded and doxorubicin-loaded nano-emulsions and incubated 
for 48 hours. The experiment was conducted in 6 independent experiments and bars are 
indicating the mean value ±SD error bars. The viability data were obtained using the MTT 
method, results were calculated based on untreated control cells, and reported as the percentage 
of control. The data were analysed with two-way ANOVA Tukey’s comparison test, **** is 








Figure 3.16 Viability of A375 cells in 72-hour treatment with non-loaded and doxorubicin-loaded 
blended nano-emulsion 
The cells were treated with non-loaded and doxorubicin-loaded nano-emulsions and incubated 
for 72 hours. The experiment was conducted in 6 independent experiments and bars are 
indicating the mean value ±SD error bars. The viability data were obtained using the MTT 
method, results were calculated based on untreated control cells, and reported as the percentage 
of control. The data were analysed with two-way ANOVA Tukey’s comparison test, **** is 









Figure 3.17 Viability of HaCaT cells in 4-hour treatment with non-loaded and doxorubicin-loaded 
blended nano-emulsion 
The cells were treated with non-loaded and doxorubicin-loaded nano-emulsions and incubated 
for 4 hours. The experiment was conducted in 6 independent experiments and bars are 
indicating the mean value ±SD error bars. The viability data were obtained using the MTT 
method, results were calculated based on untreated control cells, and reported as the percentage 
of control. The data were analysed with two-way ANOVA Tukey’s comparison test, **** is 








Figure 3.18 Viability of HaCaT cells in 24-hour treatment with non-loaded and doxorubicin-
loaded blended nano-emulsion 
The cells were treated with non-loaded and doxorubicin-loaded nano-emulsions and incubated 
for 24 hours. The experiment was conducted in 6 independent experiments and bars are 
indicating the mean value ±SD error bars. The viability data were obtained using the MTT 
method, results were calculated based on untreated control cells, and reported as the percentage 
of control. The data were analysed with two-way ANOVA Tukey’s comparison test, **** is 









Figure 3.19 Viability of HaCaT cells in 48-hour treatment with non-loaded and doxorubicin-
loaded blended nano-emulsion 
The cells were treated with non-loaded and doxorubicin-loaded nano-emulsions and incubated 
for 48 hours. The experiment was conducted in 6 independent experiments and bars are 
indicating the mean value ±SD error bars. The viability data were obtained using the MTT 
method, results were calculated based on untreated control cells, and reported as the percentage 
of control. The data were analysed with two-way ANOVA Tukey’s comparison test, **** is 







Figure 3.20 Viability of HaCaT cells in 72-hour treatment with non-loaded and doxorubicin-
loaded blended nano-emulsion 
The cells were treated with non-loaded and doxorubicin-loaded nano-emulsions and incubated 
for 72 hours. The experiment was conducted in 6 independent experiments and bars are 
indicating the mean value ±SD error bars. The viability data were obtained using the MTT 
method, results were calculated based on untreated control cells, and reported as the percentage 
of control. The data were analysed with two-way ANOVA Tukey’s comparison test, **** is 










3.1.2.6 Quantification of in vitro coumarin-6 release in melanoma using 
confocal microscopy  
Confocal microscopy images were captured to screen the uptake of drug-loaded nano-
emulsions in A375 cells over 72 hours. Accordingly, the imaging was performed after 4, 24, 
28, and 72 hours.  In these experiments, the drug-loaded in the nano-emulsions was coumarin-
6. The data was obtained from quantification of images (using ImageJ) from 3 independent 
experiments and calculated as a percentage of control. Figure 3.21 indicates the intracellular 









Figure 3.21 Coumarin-6 intracellular release in A375 cells treated with top-nine C6 loaded nano-
emulsions 
The cells were treated with C6 loaded top-nine nano-emulsions. The experiment was repeated 
four times in the same conditions, and treated cells were incubated for 4, 24, 48, and 72 hours 
respectively. The fluorescent images were obtained by confocal microscopy (λmax 488nm) and 
quantified using Image-J. The results are normalised to naïve coumarin-6 uptake and presented 
as the percentage of control. The experiment was conducted in 3 independent experiments and 
mean data are reported ±SD error bars. The data were analysed with two-way ANOVA Tukey’s 








In Figure 3.21, based on coumarin-6 fluorescent intensity, the intracellular release of the drug 
from nano-emulsions can be estimated. Samples NEPl2-Al 1:1, NEPl2-Cs-1:2, NEC1-Al 2:1, 
and NEC1-Pl 2:1 demonstrated the increasing pattern of release over 72 hours. Other samples 
did not exhibit a certain pattern, but a sudden increase and decrease of fluorescent intensity 
were detected. Samples which can provide an increasing and steady pattern during the 72 hours, 
such as NEPl2-Cs 1:2, are most relevant to this project. The fluorescent intensity recorded for 
NEPl2-Cs 1:2 was increased from 9.28 to 58%. This could be an indication of the abrupt release 
of the drug due to possible degradation of the nano-particles and needs to be further investigated 
using alternative fluorescent drugs or NTA.  
Although there was a pattern for the release of coumarin-6 from the nano-emulsions, there was 
no significant difference in the release patterns. Samples NEPl2-Cs 2:1 and NEPl2-Al 1:2 have 
an abrupt decrease or increase in the fluorescent intensities which could be due to lysosomal 
degradation of coumarin-6 inside the cells.  
3.1.2.7 Visualisation of coumarin-6 and doxorubicin uptake and 
release in A375 and HaCaT cells 
To investigate the uptake of the nano-emulsions in the cell cytosol, both HaCaT and A375 cells 
were treated with coumarin-6 and doxorubicin-loaded nano-emulsions. Here the overall uptake 
after 72 hours were screened and the status for the two cell lines was compared.  
Confocal photos obtained from 72 hours’ treatments of doxorubicin-loaded nano-emulsions 
and coumarin-6 loaded nano-emulsions are demonstrated. The images were obtained from the 






The uptake of drug-loaded nano-emulsion particles in A375 cells and HaCaT is presented in 
Figure 3.22 and 3.23. Interestingly, it can be observed that a few nano-emulsions, namely 
NEPl2-Cs 1:2, NEC1-Al 2:1, NEPl2-Al 1:1, NEPl2-Al 1:2 and NEAl2-Cs 1:2 provided a good 
fluorescent intensity in A375 cells, yet the fluorescent intensity in the HaCaT for the same 
treatments was not considerable. On the other hand, some nano-emulsion samples provide good 
uptake both in A375 and HaCaT. The samples showing less uptake (low fluorescent intensity) 
in the HaCaT and high uptake in A375 cells (high fluorescent intensity) were selected for 
















Figure 3.22 Confocal images of A375 and HaCaT cells treated with C6 loaded nano-emulsions 
The A375 and HaCaT cells were treated with coumarin-6 loaded nano-emulsions for 72 hours. The cells 
were washed and fixed. PBS was added to the wells for confocal imaging. FITC filter was used (λmax 
488nm). Images were obtained along Z-axis (Z wide) and Z position was set to 0.1 µm per turn 
(objective HCX APOLU-V-1 63X0.9W, pixels 1024 X 1024, pinhole 1 airy unit, stack 0.5 µm 








































































Figure 3.23 Confocal images of A375 and HaCaT cells treated with doxorubicin-loaded nano-
emulsions 
The A375 and HaCaT cells were treated with doxorubicin loaded nano-emulsions for 72 hours. The 
cells were washed and fixed. PBS was added to the wells for confocal Imaging. Images were obtained 
along Z-axis (Z wide) and Z position was set to 0.1 µm per turn (objective HCX APOLU-V-1 










































































According to Figure 3.22 Figure 3.23, drug-loaded (Coumarin-6/Doxorubicin) nano-emulsions 
had successful uptake in melanoma cells, for most of the samples. Among the nano-emulsion 
samples, NEPl2-Cs 1:2 showed good uptake in A375, yet decreased uptake in HaCaT compared 
to A375 cells.  
3.1.2.8 DNA fragmentation ELISA measurement of apoptosis 
induction by the top-nine blended nano-emulsions delivering doxorubicin to 
A375 melanoma cells  
DNA fragmentation ELISA was performed to confirm and monitor the apoptosis induction 
ability of the doxorubicin-loaded nano-emulsions on the best nine nano-emulsions chosen from 
the previous sections (3.1.2.1 and 3.1.2.3). The data were obtained from three independent 
experiments and calculated as the percentage of control.  
The results from the ELISA indicate the apoptosis induction ability trend of nano-emulsions on 

















Figure 3.24 Induced apoptosis trend by doxorubicin-loaded nano-emulsions measured by DNA 
fragmentation ELISA 
Apoptosis induction ability of doxorubicin-loaded top nine nano-emulsion was measured by 
treating BrdU labeled A375 cells with doxorubicin-loaded nano-emulsions. After 4, 24, 48, and 
72 hours of incubations (in separate plates), The supernatant was tested with ELISA, and 
absorbance was measured (A370). The control values were assessed separately for each time 
point. The results are indicating the mean values from three independent experiments 
normalised to untreated A375 control value ±SD. 
 
 































Figure 3.24 indicates the cellular apoptosis trend for doxorubicin-loaded nano-emulsions 
treated A375 cells. Samples NEC1-Al 2:1, NEPl2-Cs 1:2, and NEAl2-Cs 1:2 show increasing 
apoptosis trends over 72 hours. Sample NEAl2-Cs 1:2 apoptosis trend indicated absorbance 
increase from 20 to 70.8 at 370 nm over 72 hours. For NEPl2-Cs 1:2 absorbance increases from 
55.52 to 91.67 at 370 nm, and from 2.67 to 59.79 for the nano-emulsion NEC1-Al 2:1.  
The overall trend of apoptosis induced to A375 cells by doxorubicin-loaded nano-emulsion 
demonstrates an increasing pattern. Looking at nano-emulsion NEC1-Pl 2:1, decreased 
apoptosis induction is observed. Yet, the best trends are the increasing ones with the highest 
yield (absorbance) for apoptosis induction (NEPl2-Cs 1:2, Figure 3.24).  
Based on the experiments done, NEPl2-Cs 1:2 was chosen as the optimised nano-emulsion for 
















3.2 Modification of optimised pullulan-chitosan nano-emulsion for 
enhanced uptake in A375 cells  
3.2.1 Introduction  
So far, preliminary experiments were conducted to find a nano-emulsion optimised in terms of 
release and toxicity. Pullulan-chitosan nano-emulsion was optimised in terms of physical 
characteristics. To have targeted uptake toward melanoma cells, the nano-emulsion was further 
modified. The modification was done using folic acid (folate). The procedure for nano-




















Figure 3.25 Flow-chart of nano-emulsion characterization and experiments for surface 









3.2.2 Characterisation of pullulan-chitosan nano-emulsion  
Based on the results of the previous experiments (section 3.1), the best sample optimised based 
on increased toxicity to melanoma cells, controlled release, and optimised apoptosis induction 
were NEPl2-Cs 1:2 (pullulan- chitosan nano-emulsion containing 4 mg/ml pullulan and 8 
mg/ml chitosan). 
The characteristics for optimised pullulan-chitosan nano-emulsion were investigated before 
surface modification.  
3.2.2.1 Drug encapsulation efficiency of pullulan-chitosan nano-
emulsion  
The encapsulation efficiency of the nano-emulsion was investigated using dialysis 
methodology. The nano-emulsion was investigated for encapsulation of doxorubicin and 
dacarbazine. The encapsulation efficiency of doxorubicin was detected as 87% and for 








Figure 3.26 Encapsulation efficiency of drug-loaded optimal nano-emulsion 
The experiment was conducted using the dialysis method at 25°C and 55 rpm with continuous 
stirring for 72 hours. Liquid samples from the flasks analysed using UV-spectrophotometer at 
479 nm and 331 nm for doxorubicin and dacarbazine respectively. The bars are indicating the 









The Figure 3.26 shows the encapsulation efficiency of pullulan-chitosan nano-emulsion loaded 
with dacarbazine and doxorubicin separately, they both indicate high encapsulation efficiency.  
3.2.2.2 Evaluation of particle size and size distribution of drug-loaded 
pullulan-chitosan nano-emulsion 
Defining the size of nano-emulsion plays an important role in its uptake and action in melanoma 
cells, hence the size was identified by a nano-particle tracking analyser. The method was 
optimised first and subsequently, the analysis was done for doxorubicin-loaded nano-emulsion 
and doxorubicin-loaded surface-modified nano-emulsion.  
Accordingly, the mean particle size for doxorubicin-loaded nano-emulsion (9F-dox) was 
detected as 174.2 +/- 3.8 nm, the zeta potential of +5, and peak concentration of particles at 115 
nm. The procedure was repeated with surface modified doxorubicin-loaded nano-emulsion and 
the mean particle size was measured as 238.7 +/- 10.7 nm, the zeta potential of +5.7, and peak 
concentration of particles was detected at 118 and 183 nm (Figure 3.27, Figure 3.28, and 
Table 3.1) (Appendix B).  











9F-dox 174.6 150.1 1.65e+10 +/- 1.67e+09 +5.0 








Figure 3.27 Nano-particle tracking analysis using NanoSight 
The analysis was performed for doxorubicin-loaded pullulan-chitosan nano-emulsion. 
The diluted nano-emulsion (1:200 PBS) was syringe-pumped into the NTA equipment. 
Images were captured using the following settings: laser type on blue 488, camera level 
set at 11, slider gain 146, syringe pump speed 50, detect threshold 2, and blur on auto. 









Figure 3.28 Nano-particle tracking analysis using NanoSight 
The analysis was performed for folate-modified doxorubicin-loaded pullulan-chitosan 
nano-emulsion. The diluted nano-emulsion (1:200 PBS) was syringe-pumped into the 
NTA equipment. Images were captured using the following settings: laser type on blue 
488, camera level set at 11, slider gain 146, syringe pump speed 50, detect threshold 
2, and blur on auto. The graphs are a single demonstration from 3 independent 







3.2.3  Cell viability screening of modified nano-emulsion 
3.2.3.1 Comparison of induced toxicity of modified and non-modified 
nano-emulsion on HaCaT and A375 cells  
The cytotoxicity test was conducted on both melanoma (A375) and keratinocyte (HaCaT) cells 
to compare the effect of folate-modified nano-emulsion on cell viability. Briefly, doxorubicin 
and dacarbazine-loaded folate-modified nano-emulsions and non-modified ones versus naïve 









Figure 3.29 Viability screening of A375 and HaCaT cells treated with drug-loaded nano-emulsion 
and naïve drugs  
The cells were treated with drug-loaded nano-emulsions and naïve drugs and the viability data 
were obtained using the MTT method. Results were calculated based on untreated control cells 
and reported as the percentage of control. The figure aims to exhibit the significant differences 
in HaCaT and A375 viability treated with modified and non-modified drug-loaded nano-
emulsions compared to Naïve drugs. Bars represent the mean value of 6 independent 
experiments ±SD error. The data were analysed with two-way ANOVA Tukey’s comparison 
test, to compare the effect of drug encapsulation on cell viability compared to untreated control 







The figure presents the viability of both cell lines screened with the MTT cytotoxicity test.  
The viability of A375 cells decreased by 17% and 14% for doxorubicin-loaded nano-emulsion 
and modified doxorubicin-loaded nano-emulsion treatments, compared to untreated A375 
viability, respectively. On the other hand, A375 treated with folate-modified dacarbazine-
loaded nano-emulsion detected as 48% viable, while the viability of A375 treated with naïve 
doxorubicin and dacarbazine detected as 92% and 53% respectively. 
HaCaT cell was observed as 47% viable while treated with doxorubicin-loaded nano-emulsion. 
However, modified doxorubicin and dacarbazine-loaded nano-emulsions increased the HaCaT 
cell viability by 112% compared to untreated HaCaT, and decreased its viability to 97% 
compared to untreated HaCaT viability, respectively. Yet, viability decreased by 22% for 
HaCaT cells treated with naïve dacarbazine compared to untreated HaCaT viability. For Naïve 
doxorubicin treatment, contrarily, the viability increased by 83% for HaCaT cells compared to 
the viability of HaCaT cells treated with doxorubicin-loaded optimal nano-emulsion treatment.  
A sharp decrease in melanoma viability by 14.8% was detected while treated with modified 
doxorubicin-loaded nano-emulsion. This decrease can be compared to the increase of 
keratinocytes viability by 112.37% while treated with the same treatment compared to untreated 
control. The obtained results provided a clear indication of increased uptake of modified nano-
emulsion in A375 rather than HaCaT. On the other hand, the low viability of both cell lines 
(17.3 and 47% for A375 and HaCaT respectively) treated with non-modified nano-emulsion 






3.2.4 Fluorescent microscopy  
3.2.4.1 Fluorescent imaging of modified and non-modified nano-
emulsion on co-culture of HaCaT and A375 cells 
To investigate a more realistic effect of the surface coated-nano-emulsion, the treatment was 
done on the co-culture of A375 and HaCaT, and the results were visually observed.  
The co-culture of the A375 and HaCaT cells was done successfully after labelling the cells 
using fluorescent cell trackers, fluorescent tracker green (CMFDA) for A375 cells, and 
fluorescent tracker red (CMTPX) for HaCaT cells (Figure 3.30). Followed by labelling the cells 
and seeding in 6 well plates for co-culture, the wells were treated with 5 treatments including, 
doxorubicin-loaded nano-emulsion, modified doxorubicin-loaded nano-emulsion, modified 
dacarbazine-loaded nano-emulsion, naïve doxorubicin, and dacarbazine. The results are 
obtained from fixed cells after 72 hours of treatment using EVOS microscopy.  The images are 
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Figure 3.30 Fluorescent microscopy of HaCaT and A375 in co-culture 
Fluorescent labelled HaCaT (CMTPX, red) and A375 (CMFDA, green) cells in co-culture. Two cell 
lines were seeded (1:5, A375: HaCaT) and incubated for 12 hours before the treatment, then incubated 
for 72 hours after the treatments. The cells were imaged on 72nd hour.  Apoptotic melanoma cells are 
marked by blue arrows and healthy melanoma cells are pointed by red arrows. The images are a single 
demonstration from three independent experiments. The red arrow in the untreated figure, however, 






According to images obtained from co-culture, the wells treated with modified drug-loaded 
nano-emulsion have more viable HaCaT (red) rather than A375 (green) cells compared to the 
ones treated with non-modified nano-emulsion or naïve doxorubicin and dacarbazine.  
3.2.4.2 Imaging co-culture of A375 and HaCaT cells over 72 hours 
treated with modified and non-modified nano-emulsions  
Treated keratinocyte and melanoma co-culture plates (containing DMEM) were screened 
consecutively, during 4, 24, 48, and 72 hours in a fluorescent microscope. The obtained images 
are single demonstrations from three independent experiments.  
According to the images obtained, a reduction of melanoma cells (green fluorescent labelled), 
can be detected with the treatment of doxorubicin/dacarbazine loaded modified nano-emulsion. 
Although in the same treatment, keratinocytes are remaining healthy and proliferating. The 


























Figure 3.31 Fluorescent microscopy of A375 and HaCaT in co-culture (dacarbazine-loaded 
nano-emulsion) 
Fluorescent labelled HaCaT (CMTPX, red) and A375 (CMFDA, green) cells in co-culture 
were treated with dacarbazine-loaded pullulan-chitosan nano-emulsion. Two cell lines 
were seeded (1:5, A375: HaCaT) in wells of a 6 well plate incubated for 12 hours before 
the treatment, then incubated and imaged on 24th, 48th, and 72nd hours after the treatments. 
The wells contained DMEM during the imaging. The Images are a single demonstration 


















Figure 3.32 Fluorescent microscopy of A375 and HaCaT in co-culture (doxorubicin-
loaded nano-emulsion) 
Fluorescent labelled HaCaT (CMTPX, red) and A375 (CMFDA, green) cells in co-
culture were treated with doxorubicin-loaded pullulan-chitosan nano-emulsion. Two 
cell lines were seeded (1:5, A375: HaCaT) in wells of a 6 well plate incubated for 12 
hours before the treatment, then incubated and imaged on 24th, 48th, and 72nd hours 
after the treatments. The wells contained DMEM during the imaging. The Images are 



















 Figure 3.33 Fluorescent microscopy of A375 and HaCaT in co-culture (dacarbazine-
loaded modified nano-emulsion) 
Fluorescent labelled HaCaT (CMTPX, red) and A375 (CMFDA, green) cells in co-
culture were treated with dacarbazine-loaded modified pullulan-chitosan nano-
emulsion. Two cell lines were seeded (1:5, A375: HaCaT) in wells of a 6 well plate 
incubated for 12 hours before the treatment, then incubated and imaged on 24th, 48th, 
and 72nd hours after the treatments. The wells contained DMEM during the imaging. 
The Images are a single demonstration from three independent experiments 



















 Figure 3.34 Fluorescent microscopy of A375 and HaCaT in co-culture (naïve 
doxorubicin) 
Fluorescent labelled HaCaT (CMTPX, red) and A375 (CMFDA, green) cells in co-culture were 
treated with naïve doxorubicin. Two cell lines were seeded (1:5, A375: HaCaT) in wells of a 6 
well plate incubated for 12 hours before the treatment, then incubated and imaged on 24th, 48th, 
and 72nd hours after the treatments. The wells contained DMEM during the imaging. The 





















 Figure 3.35 Fluorescent microscopy of A375 and HaCaT in co-culture (naïve 
dacarbazine) 
Fluorescent labelled HaCaT (CMTPX, red) and A375 (CMFDA, green) cells in co-culture 
were treated with naïve dacarbazine. Two cell lines were seeded (1:5, A375: HaCaT) in wells 
of a 6 well plate incubated for 12 hours before the treatment, then incubated and imaged on 
24th, 48th, and 72nd hours after the treatments. The wells contained DMEM during the 
imaging. The Images are a single demonstration from three independent experiments 





















 Figure 3.36 Fluorescent microscopy of A375 and HaCaT in co-culture (doxorubicin-
loaded modified nano-emulsion) 
Fluorescent labelled HaCaT (CMTPX, red) and A375 (CMFDA, green) cells in co-culture were 
treated with doxorubicin-loaded modified pullulan-chitosan nano-emulsion. Two cell lines 
were seeded (1:5, A375: HaCaT) in wells of a 6 well plate incubated for 12 hours before the 
treatment, then incubated and imaged on 24th, 48th, and 72nd hours after the treatments. The 
wells contained DMEM during the imaging. The Images are a single demonstration from three 







3.2.4.3 Fluorescent imaging of A375 and HaCaT cells in mono-cultures 
treated with modified and non-modified nano-emulsion  
Melanoma (A375) and keratinocyte (HaCaT) cells were treated with doxorubicin-loaded nano-
emulsion, modified doxorubicin-loaded nano-emulsion, modified dacarbazine-loaded nano-
emulsion, naïve doxorubicin, and naïve dacarbazine, in mono-culture. The images obtained 
after 72 hours of treatment and are a single demonstration from three independent experiments. 
Melanoma cells were labelled with CMFDA, and keratinocyte cells were labelled with CMTPX 
fluorescent labels for imaging before the treatment using the same procedure as the previous 
section.  
After the treatment was done (after 72 hours) the cells were fixed and stained with DAPI 
nucleus stain and were imaged with an EVOS microscope.  
The images below show the treated and the control melanoma (A375) and the keratinocyte 

















Figure 3.37 CMFDA and DAPI labelled A235 cells treated with drug-loaded nano-
emulsions 
Treatments are (A) untreated A375, (B) doxorubicin-loaded nano-emulsion, (C) 
modified doxorubicin-loaded nano-emulsion, (D) modified dacarbazine-loaded 
nano-emulsion, (E) naïve dacarbazine, and (F) naïve doxorubicin. The cells were 
imaged immediately after 72 hours of treatment. The images are a single 


















Figure 3.38 Comparison of CMTPX labelled HaCaT treated with nano-emulsions 
Treatments are (A) untreated A375, (B) doxorubicin-loaded nano-emulsion, (C) 
modified doxorubicin-loaded nano-emulsion, (D) modified dacarbazine-loaded 
nano-emulsion, (E) naïve dacarbazine, and (F) naïve doxorubicin. The cells were 
imaged immediately after 72 hours of treatment. The images are a single 













According to the images obtained from mono-cultures and DAPI staining, keratinocytes 
(HaCaT) that are treated with surface-modified nano-emulsions show an increased DAPI 
fluorescent intensity which indicates increased viability of cells. On the other hand, melanoma 
(A375) cells treated with surface-modified drug-loaded nano-emulsion indicate decreased 
fluorescent intensity of DAPI, this is an indication of lower viability. The decreased and 
apoptotic melanoma cells can be detected in the CMFDA image of the same treatment. 
Figure 3.37-B indicates A375 cells treated with doxorubicin-loaded pullulan-chitosan nano-
emulsion, compared to (A) untreated A735, the cell numbers decreased and visually seem 
apoptotic. In figure 3.37-C, folate-modified nano-emulsion also decreased the A375 cells. 
HaCaT cells treated with folate-modified dacarbazine/doxorubicin (figure 3.38 C and D) seem 
intact and healthy. Nevertheless, Figure 3.38-B indicates negatively affected HaCaT cells from 
non-modified nano-emulsion treatment. 
Although surface-modified nano-emulsion is more toxic to melanoma cells, the non-surface-
modified nano-emulsion reduces the numbers of both melanoma (A375) and keratinocytes 
(HaCaT). The scale bar for all the images obtained from EVOS fluorescent microscopy is 200 








3.2.4.4 Polymerase chain reaction and gene expression of the treated 
cells  
The effect of nano-emulsion treatment on the melanoma and HaCaT cells were investigated at 
the molecular level by monitoring the expression of four genes (excluding house-keeping gene 
GAPDH). Therefore, the expression of Caspase 9, Caspase 3, Bax, and Bcl2 were investigated 
in both treated cell lines. The band intensities obtained from the PCR are demonstrated for 
Caspase3, caspase9, Bax, and Bcl2 respectively in Figure 3.43 to Figure 3.48.  
Accordingly, the obtained bands were quantified using ImageJ (n=3), normalized using 
GAPDH band intensity, and gene expression intensities are demonstrated in Figures 3.39 to 
3.42. 
The figure indicates apoptosis gene, caspase 3, in A375 cells treated with folate-modified 
doxorubicin and dacarbazine-loaded pullulan-chitosan nano-emulsion expressed 67 and 63% 
respectively.  While cells treated with naïve doxorubicin and dacarbazine expressed 11 and 
16% caspase3, respectively.  Caspase 3 expression in control A375 cells was 16%.  
Caspase 9 was also measured. The expression of caspase 9 in control A375 cells was 23%, this 
value increased to 73 and 65% for folate-modified doxorubicin and dacarbazine-loaded nano-
emulsion treatments.  
Pro-apoptotic gene Bax was expressed 6% in A375 cells, while in cells treated with folate-
modified doxorubicin and dacarbazine-loaded pullulan-chitosan nano-emulsion this figure was 







Anti-apoptotic gene Bcl2 was expressed 17% in folate-modified doxorubicin-loaded nano-
emulsion, 19% in folate modified dacarbazine-loaded nano-emulsion, 57% in doxorubicin, and 
35% in dacarbazine treated cells, compared to 86% expression in control A375.  
Caspase 3, in HaCaT cells treated with folate-modified doxorubicin and dacarbazine-loaded 
pullulan-chitosan nano-emulsion, expressed 15 and 3% respectively.  While cells treated with 
naïve doxorubicin and dacarbazine expressed 13 and 59% caspase 3, respectively.  Caspase 3 
expression in control HaCaT cells was 17%.  
Caspase 9 was also measured. The expression of caspase 9 in control HaCaT cells was 25%, 
this value was 24 and 28% for folate-modified doxorubicin and dacarbazine-loaded nano-
emulsion treatments.  
Pre-apoptotic gene Bax was expressed 37% in HaCaT cells, while in cells treated with folate-
modified doxorubicin and dacarbazine-loaded pullulan-chitosan nano-emulsion this figure was 
41 and 31% respectively.  Naïve doxorubicin and dacarbazine-expressed Bax to 93 and 86% 
respectively.  
Pre anti-apoptotic gene Bcl2 was expressed 93% in folate-modified doxorubicin-loaded nano-
emulsion, 68% in folate modified dacarbazine-loaded nano-emulsion, 40% in doxorubicin, and 








Figure 3.39 Quantified DNA band intensities analysed with PCR and gel electrophoresis (Caspase 
3) 
The figure demonstrates the expression of the caspase 3 gene in A375 and HaCaT cell lines 
treated with drug-loaded nano-emulsions and naïve drugs compared to untreated control cells. 
The band intensities were quantified using ImageJ. The Experiment was conducted after 72 
hours of treatment. Complementary DNA was used to screen the gene expressions. The band 
intensity of each treatment was normalised to GAPDH (housekeeping gene) and is reported as 
a percentage of control (untreated cells). The data are representative of the mean values of 3 
independent experiments ±SD in the bar chart. The results were analysed with two-way 
















































































































































































































Figure 3.40 Quantified DNA band intensities analysed with PCR and gel electrophoresis (Caspase 
9) 
The figure demonstrates the expression of the caspase 9 gene in A375 and HaCaT cell lines 
treated with drug-loaded nano-emulsions and naïve drugs compared to untreated control cells. 
The band intensities were quantified using ImageJ. The Experiment was conducted after 72 
hours of treatment. Complementary DNA was used to screen the gene expressions. The band 
intensity of each treatment was normalised to GAPDH (housekeeping gene) and is reported as 
a percentage of control (untreated cells). The data are representative of the mean values of 3 
independent experiments ±SD in the bar chart. The results were analysed with two-way 








Figure 3.41 Quantified DNA band intensities analysed with PCR and gel electrophoresis (Bax) 
The figure demonstrates the expression of the Bax gene in A375 and HaCaT cell lines treated 
with drug-loaded nano-emulsions and naïve drugs compared to untreated control cells. The 
band intensities were quantified using ImageJ. The Experiment was conducted after 72 hours 
of treatment. Complementary DNA was used to screen the gene expressions. The band intensity 
of each treatment was normalised to GAPDH (housekeeping gene) and is reported as a 
percentage of control (untreated cells). The data are representative of the mean values of 3 
independent experiments ±SD in the bar chart. The results were analysed with two-way 








Figure 3.42 Quantified DNA band intensities analysed with PCR and gel electrophoresis (Bcl2) 
The figure demonstrates the expression of the Bcl2 gene in A375 and HaCaT cell lines treated 
with drug-loaded nano-emulsions and naïve drugs compared to untreated control cells. The 
band intensities were quantified using ImageJ. The Experiment was conducted after 72 hours 
of treatment. Complementary DNA was used to screen the gene expressions. The band intensity 
of each treatment was normalised to GAPDH (housekeeping gene) and is reported as a 
percentage of control (untreated cells). The data are representative of the mean values of 3 
independent experiments ±SD in the bar chart. The results were analysed with two-way 








Figure 3.43 DNA bands detected in agarose gel 
After the thermo-cycler step, the samples were collected and mixed with 3 µl of loading dye. 
The mixtures were then loaded into the wells and run on the 1% agarose gel in the tank. A 
molecular weight marker of 1Kb and 100 Kb were used alongside the cDNA samples. 
Electrophoresis was set to run for 60 minutes in the 100 V constant. After 60 minutes, the gel 
was imaged using the UV transilluminator at the wavelength of 200-280 nm and the DNA 










Figure 3.44 DNA bands detected in agarose gel 
After the thermo-cycler step, the samples were collected and mixed with 3 µl of loading dye. 
The mixtures were then loaded into the wells and run on the 1% agarose gel in the tank. A 
molecular weight marker of 1Kb and 100 Kb were used alongside the cDNA samples. 
Electrophoresis was set to run for 60 minutes in the 100 V constant. After 60 minutes, the gel 
was imaged using the UV transilluminator at the wavelength of 200-280 nm and the DNA 










Figure 3.45 DNA bands detected in agarose gel 
After the thermo-cycler step, the samples were collected and mixed with 3 µl of loading dye. 
The mixtures were then loaded into the wells and run on the 1% agarose gel in the tank. A 
molecular weight marker of 1Kb and 100 Kb were used alongside the cDNA samples. 
Electrophoresis was set to run for 60 minutes in the 100 V constant. After 60 minutes, the gel 
was imaged using the UV transilluminator at the wavelength of 200-280 nm and the DNA 










Figure 3.46 DNA bands detected in agarose gel 
After the thermo-cycler step, the samples were collected and mixed with 3 µl of loading dye. 
The mixtures were then loaded into the wells and run on the 1% agarose gel in the tank. A 
molecular weight marker of 1Kb and 100 Kb were used alongside the cDNA samples. 
Electrophoresis was set to run for 60 minutes in the 100 V constant. After 60 minutes, the gel 
was imaged using the UV transilluminator at the wavelength of 200-280 nm and the DNA 











Figure 3.47 DNA bands detected in agarose gel 
After the thermo-cycler step, the samples were collected and mixed with 3 µl of loading dye. 
The mixtures were then loaded into the wells and run on the 1% agarose gel in the tank. A 
molecular weight marker of 1Kb and 100 Kb were used alongside the cDNA samples. 
Electrophoresis was set to run for 60 minutes in the 100 V constant. After 60 minutes, the gel 
was imaged using the UV transilluminator at the wavelength of 200-280 nm and the DNA 










Figure 3.48 DNA bands detected in agarose gel 
After the thermo-cycler step, the samples were collected and mixed with 3 µl of loading dye. 
The mixtures were then loaded into the wells and run on the 1% agarose gel in the tank. A 
molecular weight marker of 1Kb and 100 Kb were used alongside the cDNA samples. 
Electrophoresis was set to run for 60 minutes in the 100 V constant. After 60 minutes, the gel 








3.2.4.5 Folate binding protein ELISA 
To confirm folate receptors' quantity on A375 cell’s surface, folate binding protein (FBP) 
ELISA was conducted. This was reported before by (Ogbodu et al., 2015), however, secondary 
confirmation was done in current research. Hence, the FBP ELISA was conducted to confirm 
and quantify the folate binding receptors on melanoma (A375) compared to keratinocytes 
(HaCaT) as negative control and epithelial breast cells (MDB-MA-231) as a positive control. 
This is to show that uptake of the folate-modified nano-emulsions in melanoma cells is via 
folate receptors. The results obtained from the colourimetric reading and using linear regression 
from the standard curve Figure 3.49. Table 3.2 is indicating the concentration of the folate 
receptors expressed in three cell lines. Accordingly, the folate concentration on the A375 
surface is 179 pg/ml, for HaCaT and MDB-MA-231 the concentrations are 21.5 and 315 pg/ml 
respectively. 
Three supernatants of three cell lines were used, A375, HaCaT, and MDB-MA-231. HaCaT 
cell line was used as negative control and MDB-MA-231 cell supernatant was used as a positive 
control. Subsequently, it was confirmed that A375 cells express folate receptors, however less 
than MDB-MA-231. HaCaT had negative amounts and on the other hand, MDB-MA-231 was 










Figure 3.49 Standard curve of different concentrations of the folate binding protein detected in 
ELISA  
The results are the mean value of three independent ELISA tests ±SD. 
 
 
Table 3.2 Folate receptor concentration  



























3.3 Evaluation of anti-inflammatory compounds encapsulated in 
nano-emulsions on melanoma cells 
3.3.1 Introduction: Encapsulation of BMS-470539-
dihydrochloride and [DTrp8]-γ-MSH in pullulan-chitosan 
nano-emulsion as a novel tool for melanoma treatment 
Previous studies have shown the expression of MC1 on A375 cells (Nagy et al., 2017), and 
multiple studies have shown these to have anti-inflammatory effects in different models of 
inflammation including gout (Getting et al., 2006), asthma (Getting et al., 2008), Rheumatoid 
Arthritis (Patel et al., 2010), Osteoarthritis (Can et al., 2020, Kaneva et al., 2012) and Stroke 
(Holloway et al., 2015). MC1 receptor is activated by the number of melanocortin peptides 
including α-Melanocyte stimulating hormone (αMSH), NDP-α-MSH, and POMC gene-derived 
peptides (Tafreshi et al., 2019). Hence, in this study, the effect of encapsulation of the anti-
inflammatory compounds in nano-emulsion was investigated. This approach seeks to find out 
any improvement in their anti-inflammatory effect and consequently a reduction in melanoma 
viability. The approach involved encapsulation of BMS-470539-dihydrochloride and [DTrp8]-
γ-MSH in pullulan-chitosan modified nano-emulsion and subsequent measurement of iNOS 
and COX-2 level in A375 cells. 
Accordingly, the compounds were encapsulated in folate-modified pullulan-chitosan nano-






limited half-life of the compounds, the encapsulation procedures were completed in less than 6 
hours.  
3.3.2 Viability of A375 cells treated with encapsulated BMS-
470539-dihydrochloride and [DTrp8]-γ-MSH in folate-
modified pullulan-chitosan nano-emulsion 
To clarify the effect of naïve BMS-470539-dihydrochloride and [DTrp8]-γ-MSH and their 
encapsulation in nano-emulsion on the melanoma cell treatment, the MTT cytotoxicity test was 
performed to assess their effects on cell viability. The A375 cells were treated with BMS-
470539-dihydrochloride (10 µg/ml) and [DTrp8]-γ-MSH] (3 µg/ml) and encapsulated BMS-
470539-dihydrochloride and [DTrp8]-γ-MSH] for 24, 48, and 72 hours and the viability of A375 
cells was measured and analysed accordingly.  
The viability of cells treated with BMS-470539-dihydrochloride ranged from 78 to 86% and 
for encapsulated BMS-470539-dihydrochloride from 75 to 12% over the 24-72-hour time 
course. The viability of cells treated with [DTrp8]-γ-MSH] ranged from 83 to 59% and for 














Figure 3.50 Viability of the A375 cells treated with encapsulated and naïve BMS-470539-
dihydrochloride 
A375 cells were treated with naïve and encapsulated BMS-470539-dihydrochloride (10µg/ml).  
Independent experiments were conducted for different time points. The test was conducted 24, 
48, and 72 hours after treatments. The viability data were obtained using the MTT method, 
results were calculated based on untreated control cells, and reported as the percentage of 
control. Bars represent the mean value of 6 biological replicates ±SD error. The data were 
analysed with two-way ANOVA Tukey’s comparison test, **** is indicating P<0.0001, *** 







Figure 3.51 Viability of the A375 cells treated with encapsulated and naïve [DTrp8]-g-MSH 
A375 cells were treated with naïve and encapsulated [DTrp8]-γ-MSH (1µg/ml). Independent 
experiments were conducted for different time points. The test was conducted 24, 48, and 72 
hours after treatments. The viability data were obtained using the MTT method, results were 
calculated based on untreated control cells, and reported as the percentage of control. Bars 
represent the mean value of 6 biological replicates ±SD error. The data were analysed with two-
way ANOVA Tukey’s comparison test, **** is indicating P<0.0001, *** P<0.001, ** P<0.01, 
and * P<0.05. 
 
 




























Figure 3.52 Viability of the A375 cells treated with LPS 
A375 cells were treated with LPS. Independent experiments were conducted for different time 
points. The test was conducted 24, 48, and 72 hours after treatments. The viability data were 
obtained using the MTT method, results were calculated based on untreated control cells, and 
reported as the percentage of control. Bars represent the mean value of 6 biological replicates 
±SD error. The data were analysed with two-way ANOVA Tukey’s comparison test, **** is 










According to Figure 3.50 and 3.51, the viability of A375 cells treated with encapsulated 
compounds decreased drastically during 72 hours, compared to untreated control cells. The 
viability of A375 cells treated with naïve BMS-470539-dihydrochloride decreases to 84% over 
72 hours, compared to untreated A375 cells. However, A375 cells treated with encapsulated 
BMS-470539-dihydrochloride were 15% viable after 72 hours. Likewise, A375 cells treated 
with naïve [DTrp8]-γ-MSH show decreased viability to 58.35% over 72 hours and to 23.29% 
for the cells treated with encapsulated [DTrp8]-γ-MSH. LPS decreased the viability of A375 
cells from 49.36% to 25.17% both compared to control viable cells. 
3.3.3 iNOS and COX-2 expression analysis  
Expression of iNOS and COX-2 are important markers of inflammation and directly affect 
melanoma proliferation and invasion (Johansson et al., 2009). Hence, the effect of encapsulated 
peptides in decreasing cell viability and proliferation of melanoma cells is of importance to 
disease progression. Since increased iNOS and COX-2 are markers for inflammation and 
particularly a marker for progression and invasion of melanoma, expression of both during the 
treatment with encapsulated BMS-470539-dihydrochloride and [DTrp8]-γ-MSH in pullulan-
chitosan modified nano-emulsion was measured.  
A western blot experiment was done to screen the expression of iNOS and COX-2 proteins in 
treated melanoma cells. Cells were treated with both encapsulated and naïve compounds, in the 
presence or absence of LPS (1.0 µg/ml).  
The figure below (Figure .3 53) is an indication of the iNOS and COX-2 expressions that were 







Figure 3.53 iNOS and COX-2 expression analysis by Western blot  
This image is a single demonstration of three independent western blots (for each time point) conducted to analyse iNOS and COX-2 expressions in 
treated A375 cells. The experiment was conducted after 24, 48, and 72 of incubation with treatments. The results are normalised to α-tubulin. The full 






According to the figure, iNOS and COX-2 expression significantly decreased using 
encapsulated compound treatments at 48 and 72hour time points compared to their expression 
in A375 cells treated with non-encapsulated compound. At the earlier time point only a 
reduction was seen with respect to COX-2 with similar levels of expression observed for iNOS. 
Accordingly, the iNOS and COX-2 expressions were zero after 72 hours. However, the proteins 
were still expressed in the cells treated with only peptides. The Intensity of the bands obtained 











Figure 3.54 iNOS and COX-2 expression over 24 hours in melanoma cells treated with 
encapsulated and naïve compounds 
Expression of iNOS and Cox-2 were evaluated by western blot. The experiment was conducted to 
analyse iNOS and COX-2 expressions in treated A375 cells. The results are reported as a mean value 
obtained from three independent western blots after 24 hours of treatment. The results are normalised 
to α-tubulin. Concentrations used  for the treatments were , 10 µg/ml BMS-470539-dihydrochloride, 3.0 






























































































































































Figure 3.55 iNOS and COX-2 expression over 48 hours in melanoma cells treated with 
encapsulated and naïve compounds 
Expression of iNOS and Cox-2 were evaluated by western blot. The experiment was conducted to 
analyse iNOS and COX-2 expressions in treated A375 cells. The results are reported as a mean value 
obtained from three independent western blots after 48 hours of treatment. The results are normalised 
to α-tubulin. Concentrations used for the treatments were, 10 µg/ml BMS-470539-dihydrochloride, 3.0 




























































































































































Figure 3.56 iNOS and COX-2 expression over 72 hours in melanoma cells treated with 
encapsulated and naïve compounds 
Expression of iNOS and Cox-2 were evaluated by western blot. The experiment was conducted to 
analyse iNOS and COX-2 expressions in treated A375 cells. The results are reported as a mean value 
obtained from three independent western blots after 72 hours of treatment. The results are normalised 
to α-tubulin. Concentrations used  for the treatments were , 10 µg/ml BMS-470539-dihydrochloride, 3.0 

























































































































































According to image 3.56, no bands are representing the expression of iNOS and COX-2 after 
72 hours of treatment with encapsulated BMS-470539-dihydrochloride and [DTrp8]-γ-MSH. 
This is an indication of no iNOS and COX-2 expression in melanoma cells, on the other hand, 
the α-tubulin band associated with the 72hour treatment of encapsulated compounds displays 
low expression. This was due to the lower population of A375 cells in the wells after 72 hours 
of treatment with encapsulated compounds. As the results are consistent with the MTT viability 
experiment for 72hour treatment of the cells with encapsulated compounds (figures 3.50, and 
3.51). The viability of A375 cells treated with encapsulated compounds was significantly lower 
compared to control and naïve compounds.  
3.3.4 Fluorescent microscopy of A375 and HaCaT cells in co-
culture, treated with encapsulated BMS-470539-
dihydrochloride and [DTrp8]-γ-MSH and non-encapsulated 
BMS-470539-dihydrochloride and [DTrp8]-γ-MSH 
To screen the effects of compounds visually, the treatments were done on co-culture of A375 
melanoma and HaCaT keratinocytes. Here the effect of treatments can be detected on 
keratinocytes as well (Curry et al., 2001).  
Figure 3.57 and Figure 3.58 were obtained from the treated co-culture plates over 24, 48, and 
72 hours. The co-culture plates were imaged with DMEM inside the wells. Therefore, the effect 
of treatments was observed during 72 hours.  
According to the images, the effect of encapsulated BMS-470539-dihydrochloride and 






A375 cells are rapidly proliferating cells under normal culture conditions. In Figure 3.57 and 
Figure 3.58 both encapsulated BMS-470539-dihydrochloride and [DTrp8]-γ-MSH have 
inhibited A375 proliferation while HaCaT cells are proliferating. The A375 cells are labelled 







Figure 3.57  Fluorescent imaging of HaCaT and A375 co-cultures treated with encapsulated and naïve BMS-470539-dihydrochloride  
The images are a single demonstration of three independent experiments. The cells labelled with CMFDA green (A375) and CMTPX red (HaCaT), 
incubated after treatments and imaged on 24th, 48th, and 72nd hours of incubation time. All images belong to a single multi-wall plate containing cells and 








Figure 3.58 Fluorescent imaging of HaCaT and A375 co-cultures treated with encapsulated and naïve [DTrp8]-g-MSH   
The images are a single demonstration of three independent experiments. The cells labelled with CMFDA green (A375) and CMTPX red (HaCaT), 
incubated after treatments and imaged on 24th, 48th, and 72nd hours of incubation time. All images belong to a single multi-wall plate containing cells and 































The development of chemo-resistance in response to cytotoxic drugs in the course of melanoma 
treatment was a major obstacle toward efficient therapy (Naves et al., 2017a). So far, 
researchers have vastly investigated approaches to defeat melanoma drug resistance, however, 
few have address flux-dependent melanoma chemo-resistance (Robey et al., 2018). This thesis 
aimed to design a drug delivery to alleviate melanoma by decreasing its resistance towards 
cytotoxic drugs. This was done by encapsulating the drug in a polymeric nano-emulsion 
providing a controlled release thereby controlled drug efflux. The nano-emulsion was also 
designed to facilitate the treatment procedure by using topical delivery administration for early-
stage melanoma. The first part of this thesis was concerned with the development of a novel 
nano-emulsion delivery system to address melanoma and the associated chemo-resistant 
(Khalid and El-Sawy, 2017). 
Efficient targeted therapy and controlled delivery of therapeutics have been successfully 
applied to provide enhanced apoptosis induction to A375 primary melanoma cells. 
Subsequently, controlled delivery of therapeutics via nano-emulsion was investigated as an 
efficient melanoma targeted therapy approach. As a consequence, the viability of A375 
decreased by 15% while treated with doxorubicin and dacarbazine-loaded nano-emulsions, 
compared to untreated A375. Furthermore, the drug-carrying nano-emulsion was able to induce 
apoptosis to A375 cells by 80% after 72 hours.  
In the second part of the study, as a novel approach, BMS470539 and [DTrp8]-γ-MSH were 






regulation of iNOS and COX-2 in A375 cells. iNOS and COX-2 are two important markers for 
melanoma progression (Hao et al., 2018) hence this feature was investigated as potential 
progress for melanoma treatment. The anti-inflammatory compound loaded nano-emulsions 
decrease melanoma viability by 10% and 12% compared to non-encapsulated compounds. This 
was done in consequence of decreased iNOS and COX-2 expressions to 0% after 72 hours of 
treatment with encapsulated anti-inflammatory compounds.  
4.2 Nano-emulsion optimisation  
4.2.1 In vitro release test 
In general, specific drug delivery systems are used as tools to retain the drug in the body or 
affected area (Sagbas and Sahiner, 2018). However, in cancer drug delivery, there are other 
aspects to be considered. For example, the patient’s lifetime, the tumour should be able to be 
eliminated at the earliest in the host body (Koushik et al., 2016). In the meantime, the drug 
release should not be too fast to prevent chemo-resistance (Cavaco et al., 2017). Hence as a 
primary step drug release pattern has been optimised based on the “cancer drug delivery” 
criteria (Iturrioz-Rodríguez et al., 2019, Sun et al., 2020).  
Nano-emulsions developed from each of the polymers (chitosan, pullulan, and alginate) 
successfully slowed down the drug release over the 21 days, however, they did not provide a 
steady release. Not all the samples presented a steady and controlled release profile to fulfill 
the criteria of this research. Minute details and fluctuations in the cumulative release trends of 






presented a lower initial burst compared to pullulan and chitosan, Yet, chitosan and pullulan 
nano-emulsions presented more fluctuations in the release profiles. However, pullulan and 
chitosan are reported to provide controlled release after further modifications (Soni et al., 2018, 
Shah et al., 2020, Mahdavinia et al., 2017).  
The release pattern measurements were done over 21 days (section .3 1.2.1). Hence, major 
fluctuations detected after 72 hours were deemed to be due to the instability of coumarin-6 
(Gupta et al., 2019). On the other hand, doxorubicin was separately encapsulated in the same 
nano-emulsions and the release profiles were screened. As was expected, more steady 
cumulative release patterns were detected assuming that blended nano-emulsions improved the 
bioavailability of doxorubicin (Khdair et al., 2016). This was due to the more stable nature of 
doxorubicin compared to coumarin-6 (Bastiat et al., 2013, Li et al., 2019a). Hence coumarin-6 
is a good option to track nano-particles but for short-term release or uptake (Chittasupho et al., 
2009). It is recommended for the release test to be conducted using other chemotherapy drugs 
such as dacarbazine.   
Not all the results obtained from the primary naïve polymeric nano-emulsions release show a 
steady and long-term controlled release profile. Hence, the best preparations from each group 
were chosen and blended to see the effect on the release profile (section 3.1.2.2). Obtained 
release profiles from blended nano-emulsions were greatly improved.  
The hypothesis of chemo-resistance prevention requires avoiding a sudden burst of the drug 
and keeping the release pattern steady whiles increasing with time. For blended nano-
emulsions, each release profile showed a different pattern, however, all increased during 21 






release profile. This may have happened through improved entrapment of the drug  
(Mohammed et al., 2017). It was noticeable that blended nano-emulsions presented a more 
controlled release. Hence, the chitosan-alginate-pullulan polymer blending seems to be 
successful. 
There were fluctuations for both doxorubicin and coumarin-6 release profiles; albeit less for 
doxorubicin. This can be the indication of the unstable nature of coumarin-6 for long-term 
release experiments. The overall pattern of each individual nano-emulsion is dependent on 
several factors, such as polymer mass ratio, water solubility, and surface charge (Rizvi and 
Saleh, 2018). In the case of chitosan and alginate nano-emulsions, however, the hypothesis did 
not match with the obtained results. This means, albeit increased mass ratio of the polymer, the 
initial burst of the drug was still high and fluctuations were occurring during the release. 
Although alginate is soluble in neutral water, its initial burst is lowest. On the other hand, 
chitosan, soluble in acidic environments, has a higher initial burst compared to alginate.  
The optimal nano-emulsion was chosen as pullulan-chitosan (1:2). According to the release 
pattern recorded for the optimal blended nano-emulsion, the release pattern was improved 
compared to previous investigations on chitosan-only nano-particles (Baghbani et al., 2017, Tai 
et al., 2020). Furthermore, this research contains the novel approach for using pullulan among 
the main components of a nano-emulsion for drug delivery. Utilisation of pullulan alone and as 
a blend led to a drug release up to 21 days. Previous investigations on drug release from pullulan 






4.2.2 Cell viability test 
MTT test was used as a primary test to screen the viability of the treated cells based on 
mitochondrial activity (A375 and HaCaT) (Rai et al., 2018b, Soe et al., 2019). HaCaT cells 
were used as a marker of non-cancerous control cells to monitor the possible toxicity of nano-
emulsions as a topical delivery system.  
Initially, a viability test was conducted on the cells treated with non-loaded blended nano-
emulsions. Three concentrations of the nano-emulsions were used as treatments.  As the result 
of increasing concentration, the overall viability of A375 treated with the non-loaded nano-
emulsions was detected as a minimum of 25% and a maximum of 107%. Consequently, with 
the increased concentration of nano-emulsion, the cell viability decreased compared to control. 
On the other hand, the same treatments were conducted on HaCaT cells. Interestingly, a few of 
the nano-emulsion samples decreased the viability of HaCaT cells drastically against 
expectations (Sahu et al., 2019b). The rationale for effective delivery to A375 is to avoid 
harming the surrounding non-cancerous cells (Liu et al., 2018). Hence in the optimisation 
process, the high viability of HaCaT is important. Decreased viability of cells treated with nano-
emulsions containing chitosan can be an indication of its cytotoxicity against cancer cell lines, 
according to previous investigations (Abedian et al., 2019, Gibot et al., 2015). Pullulan also has 
been extensively investigated for its increased uptake in cancer cells such as A375 cells (Nešić 
et al., 2020), and its anti-proliferative activity (Manitchotpisit et al., 2014, Bischoff et al., 2015). 
Hence, this can be a reason for the decrease of viability in the cells treated with pullulan-based 






The action of nano-emulsion toward A375 cells is crucial. To this end in another experiment, 
the viability of A375 cells treated with both naïve and doxorubicin-loaded nano-emulsions was 
compared to non-loaded doxorubicin.  
The cell viability was retained in the A375 cells treated with non-encapsulated doxorubicin. 
This indication may have two reasons behind it. The first, is that the drug is unable to decrease 
A375 cell viability despite its toxic nature. Secondly, the cells developed resistance to the drug. 
Out of the two, the latter is more probable, since the intrinsic resistance of melanoma cells to 
doxorubicin were previously stated and investigated (Oláh et al., 2018, Elliott and Al-Hajj, 
2009). However, encapsulated doxorubicin drastically decreases the A375 cell viability 
compared to untreated A375. This can be an indication of the effective delivery of doxorubicin 
without the development of resistance in the cells. Hence the combination of doxorubicin and 
polymeric shell confirms the hypothesis of the drug being protected from degradation or being 
lysed. More importantly, the delivery of encapsulated doxorubicin with controlled efflux 
prevented the melanoma cells to develop resistance to the drug. This can be a confirmation of 
flux-dependent resistance development in melanoma (Kalal et al., 2017).   
4.2.3 Cellular uptake and intracellular drug release studies 
To address the cellular uptake of the nano-emulsions, confocal microscopy was conducted 
(Cutrona and Simpson, 2019). The experiment was done over 72 hours to screen the uptake of 
the nano-emulsions and consequent intracellular drug release by quantifying the fluorescent 
intensity of doxorubicin and coumarin-6 during the 72 hours. Using coumarin-6 as a fluorescent 






widely used as a drug model in delivery systems because of its good stability  (Rivolta et al., 
2011, Chirio et al., 2014). This experiment can also be further investigated using alternative 
fluorescent trackers to compare its effect on release and traceability (Yuan and Liu, 2017), and 
Coumarin-6 can be further investigated as a non-toxic drug model for in vivo animal models.  
According to the quantified fluorescent intensity an increasing pattern was detected for most of 
the samples. Among drug-loaded nano-emulsions, a few samples performed a controlled 
release over 72 hours. Increased fluorescent intensity is an indication of intracellular drug 
release in the cytosol. However, in some samples, the release pattern showed a sudden increase 
or decrease. Several reasons can cause a sudden decrease or increase in fluorescent intensity 
(Pretor et al., 2015). Instability of dye and sudden degradation of nano-emulsion are among the 
causes leading to fluorescent fluctuations. 
The confocal images were obtained for both doxorubicin and coumarin-6 loaded nano-
emulsions. The treatments were applied to both cell lines (A375 and HaCaT). Among all, it was 
detected that nano-emulsions consisting of chitosan or pullulan had increased uptake in 
melanoma cells. This showed the increased affinity of these two polymers to bind to the A375 
cells. This is consistent with the previous investigations of increased polysaccharide-based 
particle uptake in cancer cells (Salatin and Yari Khosroushahi, 2017). The nano-emulsions had 
successful uptake by cells and the encapsulated molecules were able to escape endosomes in 
the cell cytosol during 72 hours. As the nano-emulsions are made of polysaccharides without 
any surface modification, they have provides successful uptake as successfully as modified or 






4.2.4 Cellular apoptosis induction ability of the nano-emulsions 
Initial optimisations based on release were performed to investigate the best delivery efflux 
from nano-emulsions. Melanoma cells are prone to develop flux-dependant drug-resistance and 
escape the apoptosis cycle, hence monitoring the effect of nano-emulsions on apoptosis 
induction is important. After the treatments over 4, 24, 48, and 72hours apoptosis induction 
ability of doxorubicin-loaded nano-emulsions were investigated. Even though the nano-
emulsions presented successful uptake, their ultimate impact was investigated through DNA 
fragmentation ELISA.  
Melanoma cells were treated with doxorubicin-loaded blended nano-emulsions. As indicated 
in Figure 3.24, all the doxorubicin-loaded blended non-emulsions were able to successfully 
induce apoptosis to melanoma cells over the time course of 72 hours. However, among them, 
pullulan-chitosan nano-emulsion (pullulan-chitosan 1:2) performed more prompt and had an 
increasing apoptosis induction pattern during the time. At the beginning of four hours, the 
apoptosis induction to melanoma cells was about 55% and increased to about 90% after 72 
hours. The pullulan-chitosan nano-emulsion showed better performance since it was able to 
induce apoptosis fast enough. Its apoptosis induction pattern was consistent with its release 
profile. This is an indication of improved delivery of the drug which was carried by the nano-
emulsion (pullulan-chitosan), without developing resistance. Sample nine consisted of chitosan 
and pullulan.  Chitosan and pullulan are both polysaccharides that have been used in cancer 
drug delivery systems in earlier investigations (Scomparin et al., 2011). Chitosan intrinsically 






(Popat et al., 2014, Adhikari and Yadav, 2018) and can act as an anti-proliferative agent for 
cancer cells. Pullulan, as well, is a non-toxic and non-immunogenic polysaccharide, it can 
increase cellular uptake (Huang et al., 2018, Tao et al., 2016). Pullulan (Tao et al., 2018) and 
chitosan (Garg et al., 2019) were separately investigated in several cancer drug delivery systems 
as anti-proliferative polymers. However, the capability of the developed pullulan-chitosan 
nano-emulsion to induce apoptosis on other melanoma cell lines and various cancer cells can 
be further investigated.  
In another aspect, nano-size nano-emulsion has provided a better uptake in A375 cells via the 
EPR effect due to the intrinsic characteristics of involved polymers. To summarise, the effect 
of pullulan-chitosan nano-emulsion was convincingly effective in inducing apoptosis to 
melanoma cells after 72 hours and consequent decrease of drug resistance. 
In this research, ELISA was used as an anti-body-based experiment to detect the early apoptosis 
state of A375 cells. However, a more detailed study of A375 cell death mode, further 
investigations can be carried out by Annexin-V flow cytometry and tunnel assays.  
4.2.5 Nano-emulsion characterisation  
So far the experiments were conducted to come up with an optimised nano-emulsion. Before 
the surface modifications, the optimised nano-emulsion was characterised. The size range of 
nano-emulsion particles is an important factor defining their fate in cancer cells (Hui et al., 
2019). Also, depending on the route of administration, the particle size and particle 






One of the disadvantages of nano-emulsions is their instability (Kale and Deore, 2017). Nano-
particles having a zeta potential between -10 and +10 mV are considered neutral (Clogston and 
Patri, 2011).  Interestingly in the results obtained and according to zeta potential (Table 3.1), 
the optimised nano-emulsion performs a neutral behaviour, due to the zeta potential of +5.  
According to previous investigations, similar nano-emulsions of chitosan are measured with 
high positive zeta potential (Baghbani et al., 2017, Li et al., 2016), on the other hand, pullulan 
nano-emulsions have low negative zeta potential (Costa et al., 2019, Niu et al., 2020). This 
accounts for the neutral zeta potential of nano-emulsion consisting of chitosan and pullulan 
blend. Furthermore, scanning electron microscopy revealed the relative morphology of the 
nano-emulsion particles.  
The encapsulation efficiency of the nano-emulsion was also investigated. This is an important 
factor for nano-emulsions to be effective in the delivery. Both dacarbazine and doxorubicin 
were encapsulated in the nano-emulsion successfully. The encapsulation efficiency of both 
drugs (doxorubicin and dacarbazine) was about 85%, which was lower compared to nano-
emulsions consisting of only one polymer type (Abhinav et al., 2016). However, the 








4.3 Modification of optimised chitosan-pullulan nano-emulsion  
According to the results obtained, the developed nano-emulsion successfully provided 
controlled release and increased uptake via passive targeting by the EPR effect. However, the 
uptake test was done for both melanoma and keratinocyte cells, and uptake of the particles was 
detected in both cell lines. Hence, the motive for further modifications was to provide active 
targeting towards melanoma.   
4.3.1 Folate-modification of nano-emulsion  
Surface modification of the nano-emulsion was performed using folate (folic acid) (Dhas et al., 
2015) to target folate receptors on A375 cells. Folate receptors are overexpressed in cancer cells 
and they exist excessively on their surfaces. According to the previous investigations and 
literature review, the A375 cell line was used as a folate receptor-negative (Ladino et al., 1997). 
Although, in comparison to non-cancerous cells, it has increased the expression of folate 
receptors (Ogbodu et al., 2015). On the same note, folate binding protein (FBP) ELISA was 
performed as a confirmation of folate receptor expression on the A375 cells (Chen et al., 2016).  
Zeta potential and size distribution were also done for the folic acid surface coated nano-
emulsion Table 3.1. According to the results, a slight increase in particle size was observed. 
This could be due to surface coating, although the size difference is not considered high. 
However, according to zeta potential, the particles demonstrate neutral behaviour. Other than 






cancer-targeting receptors (Daniels et al., 2012). RGD peptide can be used as an alternative 
modification for the nano-emulsion to target A375 cells (Gajbhiye et al., 2019).  
Modification of nano-emulsion using alternative receptors on A375 may increase or decrease 
the uptake of nano-emulsion particles depending on the concentration of receptors expressed in 
A375. Subsequently, by alterations in particle uptake, cellular viability may be affected. 
 
4.3.2 Viability of melanoma and keratinocyte cells treated with 
surface modified optimized nano-emulsion 
It is expected that after modification, the toxicity of nano-emulsions would be more on 
melanoma cells. Hence the MTT assay was performed to compare the viability of cells treated 
with drug-loaded nano-emulsion before and after modification. 
The viabilities of both HaCaT and A375 cells treated with drug-loaded nano-emulsion and 
surface coated drug-loaded nano-emulsion, doxorubicin, and dacarbazine, was investigated 
(Jangdey et al., 2019). According to the MTT test, surface coated nano-emulsion significantly 
decreased the viability of melanoma cells while keratinocyte cells remained viable.  
The results indicated an important point. The viability of melanoma treated by doxorubicin and 
dacarbazine was 93 and 53% respectively (Piotrowska et al., 2019, Andreucci et al., 2019).  
This may be due to emerging potential resistance in melanoma cells (Piotrowska et al., 2019, 
Movafegh et al., 2018). On the other hand, folate-functionalised nano-emulsion seems to have 
a protective effect on the non-cancerous control cell line (HaCaT). Figure 3.29 is an indication 






mechanism of their uptake was predicted to be via folate receptors which are confirmed in the 
toxicity tests.  
The findings of this experiment indicate a promising approach towards melanoma treatment. 
So, the encapsulated drugs in folate-modified nano-emulsion had more tendency to have uptake 
in melanoma cells and affect their viability without triggering cells to develop resistance. The 
decrease of A375 cell viability happens while the HaCaT cells remain viable (107 and 97% for 
folate-modified doxorubicin and dacarbazine loaded nano-emulsion treatments respectively). 
The outcome of this experiment can also be further investigated by Annexin-V flowcytometry 
assay to screen the state of the cells in the same treatments.  
4.3.3 Fluorescent microscopy of melanoma and keratinocyte cells 
in co-culture  
To visually monitor the melanoma and keratinocyte cells, each cell line was labelled with a 
different fluorescent marker. The A375 cells were labelled with CMFDA and the HaCaT cells 
with CMTPX. DAPI stain was also utilized for the nucleus imaging. The images were captured 
both from melanoma and keratinocyte in mono-cultures and once more in the co-culture of both 
cell lines. Both mono-culture and co-culture were conducted to monitor the effect of nano-
emulsion as a topical delivery system, on A375 and HaCaT as a monolayer model. In single-
cell treatments, the images were captured from CMFDA labelled A375 cells and CMTPX 
labelled HaCaT cells.  
In the images obtained from fluorescent microscopy, the difference between the cells treated 






detected according to the shape of the cells (apoptotic or healthy cell). Keratinocytes treated 
with surface-modified nano-emulsions, on the other hand, continue to proliferate, while many 
of the melanoma cells treated with folate-modified nano-emulsions show impeded growth and 
apoptosis.  
The co-culture of the cells provided a more realistic model compared to a mono-culture (Chung 
et al., 2018), and it is feasible and quick compared to the preparation of a 3D culture. This 
method can be used as an alternative for mono-culture to study the effect of treatments on two 
or more cell lines. However, there are limitations to monolayer cu-culture such as different 
doubling times of the cells. Furthermore, the co-culture of two adherent cell lines can be 
challenging if the time required for their detachment is similar (Gabbott et al., 2018). 
For advanced investigations, a 3D co-culture model can provide a better resemblance to the 
actual tumour (Majety et al., 2015). Hence, the 3D tumour model helps to have a better 
understanding of the tumour microenvironment and paracrine signalling in two cell lines 
(Kapałczyńska et al., 2018) before translation of the drug delivery system to the clinical stage.  
The obtained images from the co-culture can give us a better understanding of the treatment’s 
effect on the cells. However, the experiment was done for 72 hours containing DMEM in the 
wells, which had slightly affected the background noise of the images (Ettinger and Wittmann, 
2014). According to the images obtained from co-culture, the A375 cells treated with the folate-
modified nano-emulsion seem to have faded fluorescent intensity and scattered nucleolus as 






4.3.4 Polymerase chain reaction  
PCR gel electrophoresis experiment was conducted to investigate the apoptosis-associated gene 
expressions in treated A375 and HaCaT cell lines (He et al., 2018, Del Puerto et al., 2010). In 
this regard, the regulation of five genes was investigated including reference gene and caspase-
3, caspase-9, pre-apoptotic Bax, and anti-apoptotic Bcl2 genes (Lo et al., 2010). In this 
experiment, cDNA has been used instead of genomic DNA (Litwack, 2018) since the aim is to 
monitor the gene expression, upregulation, or downregulation of certain pro-apoptotic and anti-
apoptotic genes rather than detection. Accordingly, cDNA was used to provide a more accurate 
analysis.  
According to Figure 3.41 and Figure 3.42, in the A375 cells treated with doxorubicin and 
dacarbazine decreased expression of the pro-apoptotic gene (Bax) was detected. Bax and Bcl2 
genes are known as an important apoptosis-related gene and has been investigated as a marker 
of resistance in the literature (Kale et al., 2018, Wang et al., 2017). This can be an indication of 
resistance towards both naïve drugs.  
Upregulation of caspase-9 and Bax was detected in A375 cells treated with folate-modified 
nano-emulsion compared to non-modified drug-loaded nano-emulsion and naïve drug 
treatments. On the other hand, HaCaT had lower Bcl2 expressed rather than Bax.  
An increase of the pro-apoptosis genes in A375 cells treated with folate-modified drug-loaded 
nano-emulsion was detected. Although the detection of this result indicates the increase in 
initial apoptosis markers, however, more investigations on the apoptosis of A375 can be done 






Annexin-V flow cytometry (Kotawong et al., 2018). A few researchers also investigated 
expression of caspase-3, caspase-9, Bax, and Bcl2 by western blot (Wang et al., 2019a, Shang 
et al., 2019) . 
4.4 Investigation of cell viability and iNOS and COX-2 
downregulation after treating with encapsulated anti-
inflammatory compounds 
In the second part of the thesis, melanocortin peptides were used to control melanoma 
progression. Melanocortin compounds are anti-inflammatory agents that have been used for 
both chronic and acute inflammation therapies (Tsatmali et al., 2002, Wang et al., 2019b). 
Cancer cells, most particularly melanoma cells, overexpress melanocortin receptors (Zhou et 
al., 2020). So far melanocortin peptides were used to target receptors on cancer cells as a 
targeted delivery tool (Li et al., 2019, Zhou et al., 2020, Dissanayake et al., 2017).  
However, in current research using a novel approach, anti-inflammatory melanocortin 
compounds were used as potential tools to inhibit melanoma progression. Hence, this was done 
utilizing folate-modified pullulan-chitosan nano-emulsion developed and optimised according 
to section 2.2.5 and instead of the drugs, anti-inflammatory compounds were encapsulated in 






4.4.1 iNOS and COX-2 expression  
iNOS and COX-2 protein upregulations have been investigated and reported as precursors for 
melanoma progression and metastasis (Johansson et al., 2009, Paulino et al., 2016). Hence, the 
effect of melanocortin compounds on iNOS and COX-2 expressions was investigated for the 
first time as a novel approach by BMS-470539-dihydrochloride and [DTrp8]-γ-MSH loaded 
optimal nano-emulsion to ascertain whether they were effective in modulating these 
inflammatory pathways. 
The treatments were evaluated over 72 hours and their effect on cell viability and protein 
expression was confirmed by MTT and Western blot assays, subsequently imaged by 
fluorescent microscopy.  
Evaluation of the cell viability via MTT assay has demonstrated that the melanoma cells treated 
with the melanocortin compound (BMS-470539-dihydrochloride and [DTrp8]-γ-MSH) loaded 
nano-emulsions caused a decrease to 12 and 9% respectively in A375 cell viability after 72 
hours (Can et al., 2020). According to the investigations, COX-2 has been expressed in most of 
the malignant melanoma primary tumours and was confirmed in five malignant melanoma cell 
lines including MeWo, SK-Mel-13, SK-Mel-28, IGR 37, and A375 (Goulet et al., 2003, 
Denkert et al., 2001a). This leads to the progression of the melanoma cells. On the other hand, 
according to the studies conducted on benign nevi, no expression of COX-2 was detected 
(Denkert et al., 2001b, Lee et al., 2020). Inhibition of CXCL10 expression by iNOS also affects 
melanoma tumorigenesis and progression (Tanese et al., 2012). Therefore, iNOS is an 






Interestingly, the Western blot test showed a 100% knockdown of iNOS and COX-2 expression 
in A375 cells after 72 hours of encapsulated BMS470539-dihydrochloride and [DTrp8]-γ-MSH 
treatment and is a novel finding for these compounds on this cell line. According to the western 
blots, no band was detected for iNOS and COX-2 expressions in the cells treated with 
encapsulated compounds after 72 hours. Accordingly, the associated α-tubulin band was faint 
but detectable, this is most likely due to low levels of A375 cells left after treatment as can be 
seen from the data generated in the cell viability experiments (Figure 3.50 and 3.51), compared 
to untreated A375 cells. Whilst this data provides evidence of proof of concept it would be 
interesting to see if increasing the cell density would enable a higher number of cells for 
extraction to demonstrate this more clearly. 
This is a promising point in melanoma treatment and prognosis. While the compounds used in 
this study decreased melanoma viability, according to the previous investigations they increase 
the viability of cells such as chondrocytes (Can et al., 2020). This happens following TNF-α 
stimulation, whereby the loss of chondrocytes within the cartilage leads to the development of 
osteoarthritis (Can et al., 2020). This indicates the potential of the current treatment procedure 
for targeted delivery applications. 
There are certain problems with the delivery of small molecules and peptides. Most peptides 
have a very limited half-life starting from a few minutes to a few hours, thence they lack 
stability (Wei et al., 2016). Moreover, they are prone to oxidation and hydrolysis (Fosgerau and 
Hoffmann, 2015) which decreases their ability to function (Lau and Dunn, 2018). The 
administration route for them is usually the in-situ or subcutaneous injection. However, the 






In this study, the MC1 agonist BMS470539-dihydrochloride and MC3 agonist, [DTrp8]-γ-MSH 
(Tao et al., 2006) were encapsulated in the pullulan-chitosan optimised nano-emulsion, to 
ensure that the compounds would be protected against early degradation and therefore reach 
the target more efficiently (Bentz et al., 2017).  
Although the approach is promising, there are certain challenges to address in further 
investigations. These include the sterilisation of the nano-emulsion after encapsulation of the 
compounds. In this study, short periods of UV light exposure were used to sterilise the nano-
emulsion compound. The obtained results can be further confirmed by q-PCR or Annexin-V 
assays to detect the state of the cells (apoptotic/ necrotic).  
4.4.2 Toxicity induced by encapsulated compounds on A375 cells 
Measurement of the effect on cell viability induced by the naïve and encapsulated compounds 
on melanoma was used to ascertain their effects on the mitochondrial activity and subsequent 
viability of the melanoma (A375) cells. The viability of the melanoma cells treated with 
encapsulated BMS-470539-dihydrochloride and [DTrp8]-γ-MSH for 72 hours, caused a 
significant decrease in cell viability compared to naïve compounds. Which is consistent with 
the bands on the 72hour western blot.  
As iNOS and COX-2 are known to have a substantial effect on melanoma progression and 
invasion (Kim et al., 2016), they also have an impact on melanoma viability (Herraiz et al.). In 
this study, the ultimate impact of the encapsulated compounds on iNOS and COX-2 expression 






downregulate the expression of both iNOS and COX-2 and decrease the A375 cell viability 
after 72 hours. However, the effect of the compounds on HaCaT cells is yet to be investigated.  
4.4.3 Fluorescent microscopy of melanoma-keratinocyte co-
culture treated with encapsulated compounds 
The effect of encapsulated peptides on melanoma cells was investigated using Western blot and 
MTT. In further investigations, encapsulated BMS-470539-dihydrochloride, [DTrp8]-γ-MSH, 
and naïve BMS-470539-dihydrochloride, [DTrp8]-γ-MSH treatments were applied to the co-
culture of pre-labelled A375 and HaCaT cells to visually screen their effectivity (Chung et al., 
2018). Accordingly, the images were obtained, and the melanoma (green labelled) growth was 
monitored. Under normal conditions (without treatment) A375 cells proliferate rapidly and it 
was expected to grow within 72 hours. However, decreased numbers of A375 cells in the well 
(Figure 3.57 and 3.58) were detected while treated with encapsulated compounds. On the 
contrary, HaCaT cells (red labelled) continue to proliferate over the 72hours. This study 
suggests that BMS-470539-dihydrochloride and [DTrp8]-γ-MSH in both naïve and 
encapsulated form, do not affect effects on HaCaT cells.  The results obtained from the 













The aim of this thesis was achieved through two main phases. Firstly, development and 
optimisation of an appropriate drug-delivery platform for melanoma; secondly, investigation of 
inflammation control as a tool to control melanoma progression. 
From the findings of the first part of the experimental work, polysaccharide-based nano-
emulsions presented the promising potential for melanoma drug delivery. Alginate, chitosan, 
and pullulan each tested for their features in drug release. However, the blended alginate-
pullulan, pullulan-chitosan, and chitosan-alginate demonstrated improved release profiles. The 
optimisation procedure of the blended nano-emulsions led to the optimal nano-emulsion 
“pullulan-chitosan”. The synthesized and folate-modified pullulan-chitosan nano-emulsion was 
found to have enhanced uptake in A375 cells. Furthermore, doxorubicin/dacarbazine loaded 
nano-emulsion substantially decreased the melanoma viability. In the meantime, the control 
cell line (HaCaT) was minimally affected by the drug-loaded folate-modified nano-emulsion. 
Hence the first part of the investigation showed that the drug-loaded pullulan-chitosan nano-
emulsion can be used as melanoma targeted treatment. 
The second part of the investigations pointed out that the nano-emulsion has the potential to be 
used as a highly efficient multi-propose delivery platform. Upregulation of the inflammation 
markers is reported to affect melanoma progression. Hence the delivery of anti-inflammatory 
compounds using the developed nano-emulsion was investigated. This novel approach led to a 






efficient delivery of the anti-inflammatory compounds using the pullulan-chitosan nano-
emulsion. 
In conclusion, the developed formulation can be considered as an important tool toward the 
elimination of melanoma drug resistance. Moreover, the delivery of anti-inflammatory 























6 Future work 
 
In the results of the experimental part of this thesis, a novel folate modified pullulan-chitosan 
nano-emulsion was developed. This delivery platform had two unique features. First, targeted 
uptake in melanoma cells, and an ability to provide intracellular controlled release. Second, the 
potential to be used as a delivery platform for small molecules/compounds. This novel approach 
was used to deliver a-MSH-peptides into skin melanoma cells to downregulate iNOS and COX-
2 and then using the same system, doxorubicin/dacarbazine was delivered into the A375 cells 
to induce apoptosis.  
Although the obtained results depicted success in reducing A375 viability and inducing 
apoptosis, other features need to be investigated further. In this project, nano-emulsions were 
applied to mono-layer cell cultures on two cell lines. To get closer to a real-life system, the 
formulation can be tested in a 3D tumour model and a flow system. Furthermore, as the rout of 
the delivery was aimed to be topical, the detailed study on nano-emulsion particle permeation 
through skin layers is crucial. This can be done via using a skin model or ex vivo flow tumour 
models. In such a system, the effects of the drug-loaded nano-emulsions on the tumour 
microenvironment, and the resulting interstitial fluid pressure on the uptake of the immobilised 
drugs can be investigated.  
Investigation of the hepatotoxicity or any accumulations in distant organs can also be conducted 
before the translation of the nano-emulsion to clinical trial. Further research can be carried out 







As chemotherapy drugs have severe side effects, the developed nano-emulsion can be a tool to 
decrease the damages caused to healthy tissues during the course of treatment. The nano-
emulsion can also be investigated as a tool to study the severe side effect of other cytotoxic 
drugs along with doxorubicin and dacarbazine. 
Furthermore, effect of nano-emulsion can be investigated on the range of skin cancer cell lines 
such as SK-MEL-28, MeWo, and B16 F1. Ability of skin cancer to metastasis can also be 
investigated as the further effects of the optimal nano-emulsion.  
Moreover, to use the nano-emulsion as a topical delivery formulation, the size of nano-emulsion 
particles can be further reduced to a range of 50-75 nm. Therefore, there will be a potential for 
the drug-loaded nano-emulsion particles to penetrate the skin. 
Furthermore, the combined therapy of a-MSH-peptides-doxorubicin-dacarbazine loaded nano-
emulsion can be investigated in melanoma treatments. The downregulation of inflammation 
modulators can significantly affect the progression of melanoma. Hence a combined therapy of 
anti-inflammatory compounds and chemotherapeutics can be a potential therapy for melanoma.  
Also, additional anti-inflammatory compounds such as NSAIDs (diclofenac) or COX-2 
inhibitors (celecoxib) can be encapsulated in the nano-emulsion for investigation of cancer 










Appendix A. Evaluation of doxorubicin quantity 
To evaluate encapsulation efficiency for doxorubicin-loaded nano-emulsion, HPLC was performed. The calibration curve was plotted based on various 
doxorubicin concentrations. Doxorubicin peak was detected at 2 minutes. 
 
Figure 7.1 HPLC peak detected at 2 minutes for doxorubicin 
UHPLC (Ultimate 3000 Thermo-scientific) was performed using a C18 column (4.6 mm x 100 mm, 2.7 µm, Thermo-Scientific 071973). 
UV detection for doxorubicin was done at 233 nm. The mobile phase contained water and acetonitrile (25:75 v/v, adjusted to pH 3.0 using 







Appendix B. SEM imaging. 
 
 
Figure 7.2 SEM image of the optimal pullulan-chitosan nano-emulsion 
Scanning electron microscopy (SEM) was performed using FEI Quanta FEGSEM operating at 













Appendix C. Western blots 
                                                    B 
  
 
Figure 7.3 iNOS and COX-2 expression analysis by Western blot  
This image is a single demonstration of three independent western blots (for each 
time point) conducted to analyse iNOS and COX-2 expressions in treated A375 
cells. The experiment was conducted after 24, 48, and 72 of incubation with 
treatments. The results are normalised to α-tubulin. Blots demonstrated in the figure 
are the full demonstrations of figure 3.53. Figure 7.3A is indicating the a-tubulin 
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